{"meta":{"query_hash":"caafb69b4be7","filters":{"venue":"Dermatology and Therapy"},"cohort_total":183,"direct_labels_cover":0,"predictions_cover":183,"exported":183,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/caafb69b4be7","api":"https://metacan.xera.ac/api/v1/cohort?venue=Dermatology+and+Therapy"},"results":[{"id":"W1762442364","doi":"10.1007/s13555-015-0077-2","title":"Perceptions on the Psychological Impact of Facial Erythema Associated with Rosacea: Results of International Survey","year":2015,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Rosacea; Erythema; Psychology; Perception; Clinical psychology; Medicine; Dermatology","score_opus":0.07179059397305979,"score_gpt":0.3655215687370648,"score_spread":0.293730974764005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1762442364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99689496,0.00020380589,0.00013888377,0.00010004796,0.000008106664,0.00007396214,0.00067306345,0.0000057960087,0.0019014189],"genre_scores_gemma":[0.9989856,0.00015803026,0.00013110906,0.000047434223,0.000006711308,0.000031229403,0.00033178992,0.0000018853092,0.0003063365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992582,0.00025774952,0.000112012814,0.00007044927,0.0001922164,0.0001093275],"domain_scores_gemma":[0.9969799,0.0006741513,0.0013792654,0.00015083475,0.0004417544,0.0003740944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016949082,0.00020150539,0.00022089492,0.00062196015,0.00022361435,0.0003667935,0.00017713741,0.0003227705,0.0021414054],"category_scores_gemma":[0.0030105738,0.00013132926,0.00044879684,0.00053382,0.0002491598,0.0005461393,0.0005874956,0.0005591177,0.00026782247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000087552115,0.0001491583,0.99020517,0.00006969553,0.00005212632,0.000042455133,0.0012074693,0.00006375003,0.00031325553,0.000020948559,0.00038875773,0.007399793],"study_design_scores_gemma":[0.000004028707,0.00014717627,0.9979838,0.000012954828,0.000009401094,0.00008119044,0.0011965306,0.000051995787,0.00006402146,0.000007757519,0.0004374386,0.0000035788073],"about_ca_topic_score_codex":0.0016291001,"about_ca_topic_score_gemma":0.001328197,"teacher_disagreement_score":0.0021414054,"about_ca_system_score_codex":0.00018690727,"about_ca_system_score_gemma":0.00015221203,"threshold_uncertainty_score":0.008963585},"labels":[],"label_agreement":null},{"id":"W1977644637","doi":"10.1007/s13555-013-0033-y","title":"Triple-Blind, Prospective, Internally Controlled Comparative Study Between AbobotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Facial Rhytids","year":2013,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; ABO blood group system; Adverse effect; Botulinum toxin; Surgery; Internal medicine","score_opus":0.044182538008597894,"score_gpt":0.3278096531584924,"score_spread":0.2836271151498945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977644637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99599814,0.0010583594,0.0003458564,0.000036861242,0.000110168934,0.0016612065,0.00021160436,0.000023516257,0.00055426045],"genre_scores_gemma":[0.9943123,0.00068715774,0.0011705316,0.00019591447,0.00025109824,0.0023999102,0.00037454424,0.000007458528,0.0006012268],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980209,0.00078492024,0.00022764364,0.00044314805,0.0002980321,0.00022540517],"domain_scores_gemma":[0.9972801,0.0008894467,0.00068320654,0.0002692697,0.00024334053,0.0006345073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032243486,0.0011513842,0.0037815953,0.00054358516,0.0006164211,0.0007279748,0.0008571119,0.0011580769,0.0045418455],"category_scores_gemma":[0.0027760034,0.00056976476,0.0013759382,0.0004901512,0.0016176177,0.0009274627,0.00036887123,0.0013522853,0.0007669061],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.933272,0.035359163,0.0031872147,0.0004842353,0.00077334396,0.000063750274,0.0001579825,0.00019568458,0.0092371665,0.00007269396,0.0002512496,0.016945558],"study_design_scores_gemma":[0.3732424,0.6078535,0.015943782,0.000030085414,0.00053770945,0.00008891709,0.00006894216,0.00033719215,0.0013434612,0.0000509756,0.00047779965,0.000025341757],"about_ca_topic_score_codex":0.00083666574,"about_ca_topic_score_gemma":0.0011195223,"teacher_disagreement_score":0.0045418455,"about_ca_system_score_codex":0.0006935556,"about_ca_system_score_gemma":0.0013058055,"threshold_uncertainty_score":0.017052174},"labels":[],"label_agreement":null},{"id":"W2003027167","doi":"10.1007/s13555-014-0043-4","title":"Health-Related Quality of Life Worsens Disproportionately to Objective Signs of Psoriasis After Withdrawal of Adalimumab Therapy","year":2014,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre de Recherche Dermatologique du Québec Métropolitain","funders":"AbbVie","keywords":"Medicine; Discontinuation; Psoriasis; Dermatology Life Quality Index; Adalimumab; Psoriasis Area and Severity Index; Internal medicine; Quality of life (healthcare); Randomized controlled trial; Placebo; Severity of illness; Physical therapy; Disease; Dermatology","score_opus":0.020566537768950222,"score_gpt":0.26867663484768733,"score_spread":0.2481100970787371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003027167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99848455,0.0008199499,0.00007250223,0.000046632107,0.000009712013,0.000041140138,0.00011133927,0.000004687196,0.00040950312],"genre_scores_gemma":[0.9993886,0.00012405426,0.000044862427,0.000064892614,0.000021332946,0.000029232266,0.00015131311,0.0000016601371,0.00017404395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985776,0.00058061955,0.00014336845,0.00017751216,0.00030357097,0.00021739145],"domain_scores_gemma":[0.9958461,0.0011906406,0.0019532398,0.00029939023,0.00024721152,0.00046353444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030185548,0.00030158664,0.001512975,0.00026414718,0.00027961584,0.00061587885,0.00020815067,0.00040225586,0.0021218401],"category_scores_gemma":[0.0037089195,0.00020930814,0.0010025497,0.0003267322,0.00029651745,0.00033948233,0.00028648265,0.0010263964,0.00020923093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23762164,0.0035031503,0.667154,0.000418335,0.0028258453,0.00031000294,0.00020223782,0.000543155,0.021315577,0.000048516995,0.0007560042,0.06530153],"study_design_scores_gemma":[0.0032021445,0.024613807,0.96930736,0.000022770748,0.00047455353,0.00044723874,0.000040051855,0.00023707193,0.0011117338,0.00004329742,0.00048741524,0.000012490519],"about_ca_topic_score_codex":0.0003363039,"about_ca_topic_score_gemma":0.00061141694,"teacher_disagreement_score":0.0030185548,"about_ca_system_score_codex":0.00035475934,"about_ca_system_score_gemma":0.00043932226,"threshold_uncertainty_score":0.015963852},"labels":[],"label_agreement":null},{"id":"W2051956976","doi":"10.1007/s13555-015-0070-9","title":"Primary Care Review of Actinic Keratosis and Its Therapeutic Options: A Global Perspective","year":2015,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Actinic keratosis; Medicine; Incidence (geometry); Dermatology; Population; Skin cancer; Perspective (graphical); Intensive care medicine; Family medicine; Basal cell; Cancer; Environmental health; Pathology; Internal medicine","score_opus":0.047600690083379846,"score_gpt":0.34899121349477036,"score_spread":0.3013905234113905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051956976","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013572426,0.9974685,0.00002288107,0.0010525553,0.0002819418,0.0000058536525,0.000016252023,0.0000022697,0.0010141386],"genre_scores_gemma":[0.001487436,0.9967327,0.00010442958,0.00089565903,0.0005690124,0.000008895165,0.000027150398,8.692063e-7,0.00017384501],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99915147,0.00027870986,0.0002077138,0.00008049228,0.00022951054,0.000052052306],"domain_scores_gemma":[0.9955265,0.002098422,0.000877608,0.00006109732,0.0011568351,0.00027946115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011708969,0.00041925305,0.0012739459,0.0051843342,0.000510597,0.0015131235,0.0007068712,0.0013096674,0.00765135],"category_scores_gemma":[0.0040986617,0.00030175401,0.0006829632,0.0071721813,0.00048401905,0.0017743077,0.00055270304,0.0011157284,0.0008898294],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012226339,0.00013232337,0.0018528503,0.109282844,0.00033653824,0.0015384675,0.00050529145,0.00020126054,0.0006270823,0.0031973098,0.15705737,0.7251464],"study_design_scores_gemma":[0.000057668498,0.0002518148,0.010522436,0.07401005,0.00074708555,0.010261314,0.00074043445,0.0000843914,0.00013835999,0.0010478019,0.9021041,0.000034700355],"about_ca_topic_score_codex":0.004481261,"about_ca_topic_score_gemma":0.01016925,"teacher_disagreement_score":0.00765135,"about_ca_system_score_codex":0.0014433002,"about_ca_system_score_gemma":0.0037939693,"threshold_uncertainty_score":0.02559632},"labels":[],"label_agreement":null},{"id":"W2104297249","doi":"10.1007/s13555-015-0076-3","title":"Influence of Psoriasis on Household Chores and Time Spent on Skin Care at Home: A Questionnaire Study","year":2015,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Varsinais-Suomen Sairaanhoitopiiri","keywords":"Psoriasis; Medicine; Quarter (Canadian coin); Quality of life (healthcare); Physical therapy; Nursing; Dermatology","score_opus":0.017903952037004626,"score_gpt":0.2444107126873785,"score_spread":0.22650676065037387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104297249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99912125,0.0000911732,0.000054757864,0.000023183904,0.0000024371375,0.000027853788,0.00026306818,0.0000023256814,0.0004139812],"genre_scores_gemma":[0.99938464,0.00008000285,0.000112405076,0.000029210387,0.000004820295,0.000030010853,0.00019528707,0.000001259928,0.00016232999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991942,0.00027804697,0.00012445301,0.00009423836,0.00016958005,0.00013938424],"domain_scores_gemma":[0.9966492,0.00094113726,0.0013666996,0.000100219426,0.00034067195,0.0006021274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093250093,0.00023269083,0.00035538746,0.00077818794,0.00032624815,0.00043280597,0.0001890255,0.00033698892,0.0025996605],"category_scores_gemma":[0.0029816024,0.00020824297,0.00064880966,0.001101736,0.00021871619,0.00045530917,0.0003423641,0.00040918463,0.0004974268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017007464,0.0002657322,0.99436015,0.00005900429,0.0000785485,0.0001502543,0.0005527481,0.00007337812,0.0003157635,0.000008925518,0.00016398133,0.003801563],"study_design_scores_gemma":[0.000012930453,0.0005639544,0.9980154,0.000008881674,0.000022159964,0.0003473304,0.000542248,0.00008484565,0.000044452274,0.0000045121105,0.00034729068,0.0000058788096],"about_ca_topic_score_codex":0.0021137795,"about_ca_topic_score_gemma":0.0023640615,"teacher_disagreement_score":0.0025996605,"about_ca_system_score_codex":0.00025328336,"about_ca_system_score_gemma":0.00021968971,"threshold_uncertainty_score":0.008696735},"labels":[],"label_agreement":null},{"id":"W2288009363","doi":"10.1007/s13555-016-0098-5","title":"New Patient-Oriented Tools for Assessing Atrophic Acne Scarring","year":2016,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatologic Treatments and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Galderma","keywords":"Acne scars; Medicine; Acne; Scars; Quality of life (healthcare); Dermatology; Patient-reported outcome; Surgery; Nursing","score_opus":0.045077258011468294,"score_gpt":0.3425518277291313,"score_spread":0.297474569717663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2288009363","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8695575,0.0071433694,0.07182993,0.0016256248,0.0004949896,0.0108364085,0.008939079,0.0012937284,0.02827943],"genre_scores_gemma":[0.7826983,0.0017060738,0.20126593,0.0004752248,0.00013103515,0.008098137,0.003216227,0.000057339377,0.0023517606],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9954703,0.002292229,0.000732208,0.00021169297,0.001111477,0.00018221635],"domain_scores_gemma":[0.9851415,0.008890942,0.0026895716,0.0004458552,0.002458362,0.00037374278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063130935,0.0007751217,0.0005209069,0.0033162565,0.00023650941,0.00094221905,0.00064219045,0.0007645295,0.003329794],"category_scores_gemma":[0.017081082,0.00020993174,0.0010408593,0.0012134636,0.00039383964,0.0016355951,0.0010134967,0.00094402034,0.0006437454],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019679193,0.001137326,0.27441767,0.0026818875,0.0004194804,0.00057650916,0.0034130537,0.0025689916,0.012078593,0.0030250954,0.012600603,0.6851129],"study_design_scores_gemma":[0.0012503351,0.0077936817,0.8586991,0.001907008,0.00059678836,0.008599323,0.0054292097,0.014538598,0.01446205,0.007830419,0.07848579,0.00040765252],"about_ca_topic_score_codex":0.0002892229,"about_ca_topic_score_gemma":0.0005905818,"teacher_disagreement_score":0.0063130935,"about_ca_system_score_codex":0.000481683,"about_ca_system_score_gemma":0.00058212795,"threshold_uncertainty_score":0.033387244},"labels":[],"label_agreement":null},{"id":"W2303711714","doi":"10.1007/s13555-016-0107-8","title":"Erratum to: New Patient-Oriented Tools for Assessing Atrophic Acne Scarring","year":2016,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Galderma","keywords":"Section (typography); Engineering; Operations research; Computer science; Business; Advertising","score_opus":0.02408999880148773,"score_gpt":0.30663720799473193,"score_spread":0.2825472091932442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2303711714","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012505513,0.0071944706,0.002975365,0.17600334,0.79853463,0.00012793909,0.0014536716,0.00034566902,0.0121142715],"genre_scores_gemma":[0.027774373,0.02978481,0.025020016,0.42192575,0.22943605,0.0005989711,0.0046037035,0.0013824697,0.25947383],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99611855,0.00079800916,0.001128461,0.00023996393,0.0014969617,0.00021816295],"domain_scores_gemma":[0.97587425,0.008599519,0.0016186766,0.00071038236,0.012577901,0.0006192231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003874285,0.0013754658,0.0009393928,0.0019243612,0.001570461,0.0022890314,0.0014115935,0.0043104845,0.015479875],"category_scores_gemma":[0.041215725,0.0006386452,0.000980295,0.001289561,0.0013214918,0.002124585,0.0011066872,0.0070177913,0.015095539],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003721826,0.000020428435,0.0005699258,0.00012136811,0.000006092226,0.00023396792,0.000065026274,0.00003960159,0.00007818766,0.00065184006,0.97826356,0.019912738],"study_design_scores_gemma":[0.00005764256,0.00006431369,0.0026518386,0.0011118023,0.00004110004,0.0023616347,0.00035779443,0.0003304461,0.0006083027,0.0011124465,0.9912582,0.00004454386],"about_ca_topic_score_codex":0.011894672,"about_ca_topic_score_gemma":0.015671967,"teacher_disagreement_score":0.015479875,"about_ca_system_score_codex":0.0014431408,"about_ca_system_score_gemma":0.003229504,"threshold_uncertainty_score":0.05178529},"labels":[],"label_agreement":null},{"id":"W2339075395","doi":"10.1007/s13555-016-0113-x","title":"How People with Facial Acne Scars are Perceived in Society: an Online Survey","year":2016,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatologic Treatments and Research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Clinical Research; Western University","funders":"","keywords":"Scars; Acne; Medicine; Dermatology; Acne scars; Population; Surgery","score_opus":0.06653179374572875,"score_gpt":0.32415352177674506,"score_spread":0.2576217280310163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339075395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988323,0.00007765125,0.000034108587,0.00016170366,0.0000053163017,0.000014485743,0.00016682921,0.0000019318136,0.00070561864],"genre_scores_gemma":[0.9991904,0.00019141221,0.000070458336,0.00013219533,0.000007681904,0.000019356576,0.000105796,0.000001187796,0.0002815295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99933785,0.00023947385,0.00007587379,0.00006173892,0.00016872068,0.00011631212],"domain_scores_gemma":[0.9983203,0.00030014754,0.00073946884,0.00006025221,0.00024332733,0.00033641755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093562785,0.000143676,0.00023653984,0.00070758676,0.00044436214,0.0007637954,0.00015793831,0.00049680227,0.0021866143],"category_scores_gemma":[0.0025833861,0.00018241617,0.00035047284,0.00057988026,0.00028177604,0.0008662352,0.0006123042,0.0005113637,0.00042205863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042363146,0.00017683442,0.9804238,0.00007515133,0.000036772268,0.00020263552,0.008780656,0.00004114075,0.0005003814,0.00003179014,0.00056542724,0.009123153],"study_design_scores_gemma":[0.000005895172,0.00026118613,0.9680206,0.0000389832,0.000017236787,0.00047856165,0.029238407,0.00013236317,0.00009086965,0.000027743137,0.0016743616,0.000013762733],"about_ca_topic_score_codex":0.0034520568,"about_ca_topic_score_gemma":0.0041093244,"teacher_disagreement_score":0.0034520568,"about_ca_system_score_codex":0.000240508,"about_ca_system_score_gemma":0.00018706129,"threshold_uncertainty_score":0.00731498},"labels":[],"label_agreement":null},{"id":"W2521785556","doi":"10.1007/s13555-016-0145-2","title":"Use of Lesion Response Rate in Actinic Keratosis Trials","year":2016,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Galderma","keywords":"Actinic keratosis; Medicine; Context (archaeology); Keratosis; Dermatology; Clinical trial; Perspective (graphical); Medical physics; Lesion; Clinical Practice; Confounding; Intensive care medicine; Surgery; Pathology; Physical therapy; Computer science; Artificial intelligence","score_opus":0.16506689133309646,"score_gpt":0.3763824648101496,"score_spread":0.21131557347705313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521785556","genre_codex":"review","genre_gemma":"commentary","domain_codex":"methods","domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22538513,0.3438312,0.24536946,0.03326696,0.011404968,0.048004605,0.014724631,0.0018601718,0.07615297],"genre_scores_gemma":[0.83992016,0.011655926,0.07720309,0.009247037,0.0022160527,0.050423253,0.003284726,0.00047644967,0.005573191],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.2578665,0.68615013,0.02571565,0.010340681,0.018772902,0.0011541629],"domain_scores_gemma":[0.37411425,0.4893012,0.07448969,0.04526062,0.013547893,0.0032863128],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.49538103,0.0014733135,0.007776852,0.0033071311,0.0010756832,0.0048642843,0.0033162914,0.005528843,0.0050358125],"category_scores_gemma":[0.47022527,0.0008866823,0.008309925,0.004056131,0.0031423206,0.005950928,0.0034342094,0.0055322074,0.0012825032],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18484966,0.0013902903,0.1316867,0.051999986,0.09365533,0.001070109,0.004203812,0.012171944,0.004500646,0.05503732,0.03019648,0.42923772],"study_design_scores_gemma":[0.071244925,0.08176746,0.2927619,0.03085708,0.051035147,0.0035686379,0.0012888999,0.0486477,0.010674127,0.12897803,0.2776336,0.0015425096],"about_ca_topic_score_codex":0.00039555936,"about_ca_topic_score_gemma":0.00038750307,"teacher_disagreement_score":0.49538103,"about_ca_system_score_codex":0.0021269154,"about_ca_system_score_gemma":0.0021133802,"threshold_uncertainty_score":0.622285},"labels":[],"label_agreement":null},{"id":"W2584044598","doi":"10.1007/s13555-016-0168-8","title":"Acne and Rosacea","year":2017,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Windsor; Western University","funders":"","keywords":"Rosacea; Acne; Dermatology; Medicine; Propionibacterium acnes; Erythema; Disease; Population; Rhinophyma; Pathology","score_opus":0.11968321473126704,"score_gpt":0.42119099341698174,"score_spread":0.3015077786857147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584044598","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013805768,0.89213765,0.0030965568,0.01055286,0.005306878,0.00019149003,0.0005883244,0.0002867667,0.074033685],"genre_scores_gemma":[0.21580476,0.6769296,0.006296579,0.019927947,0.012138077,0.00025178242,0.0016676111,0.00016686824,0.06681675],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99812084,0.0004325295,0.00024486452,0.00030754777,0.0006208632,0.00027326256],"domain_scores_gemma":[0.9985335,0.0004024615,0.00041253679,0.00009885777,0.0003552659,0.00019725515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008250574,0.00097317056,0.0012409549,0.0016697438,0.0012489555,0.0026977255,0.0006704515,0.0020940218,0.014960431],"category_scores_gemma":[0.002950159,0.00023523672,0.0009040422,0.0016121285,0.0018938393,0.0019487842,0.0025117632,0.0029833608,0.0051563103],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049253786,0.00028165392,0.0116236275,0.009793482,0.00029659065,0.008695867,0.0014755492,0.00035909965,0.009171707,0.053027604,0.1344071,0.7703752],"study_design_scores_gemma":[0.000038567778,0.00012499918,0.008193961,0.0020278143,0.00008797618,0.034682352,0.0006462409,0.00010418068,0.0009994572,0.010490392,0.94256234,0.000041700325],"about_ca_topic_score_codex":0.0018759586,"about_ca_topic_score_gemma":0.0020463997,"teacher_disagreement_score":0.014960431,"about_ca_system_score_codex":0.00091277243,"about_ca_system_score_gemma":0.0011838322,"threshold_uncertainty_score":0.050047636},"labels":[],"label_agreement":null},{"id":"W2743134732","doi":"10.1007/s13555-017-0196-z","title":"Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy","year":2017,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"LEO Pharma","keywords":"Betamethasone dipropionate; Psoriasis; Calcipotriol; Medicine; Combination therapy; Pharmacology; Fixed-dose combination; Corticosteroid; Dosing; Dermatology; Internal medicine","score_opus":0.029347536833552235,"score_gpt":0.2818068940366248,"score_spread":0.25245935720307255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743134732","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8207316,0.13804483,0.026633374,0.0007387922,0.00028124437,0.00066252565,0.00038210588,0.0002625241,0.012263029],"genre_scores_gemma":[0.96324956,0.01777742,0.016125416,0.00025785388,0.000107818945,0.0001989474,0.00021257768,0.00003593446,0.0020345515],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996244,0.00007406682,0.00002921742,0.000070210706,0.00015503464,0.000047056263],"domain_scores_gemma":[0.99991345,0.000023545272,0.00002326344,0.0000060226735,0.0000192603,0.000014386198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031060574,0.00028588783,0.0005006586,0.0005733368,0.00013083166,0.00044427745,0.00036922848,0.0003003671,0.0017303227],"category_scores_gemma":[0.00030279814,0.00012176844,0.00034364217,0.00035352484,0.00013943689,0.00031022105,0.00017353272,0.00049675157,0.00035981194],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023307202,0.0012744247,0.002843603,0.0015429764,0.00021146286,0.0003467817,0.00007963438,0.0034649195,0.586051,0.0005877278,0.0018306337,0.39943618],"study_design_scores_gemma":[0.0025318789,0.035211995,0.043287627,0.00050696504,0.0016902259,0.0058474294,0.00035654925,0.021530902,0.73297405,0.0014758899,0.15442659,0.00015995123],"about_ca_topic_score_codex":0.0005512386,"about_ca_topic_score_gemma":0.0010585679,"teacher_disagreement_score":0.0017303227,"about_ca_system_score_codex":0.00028431026,"about_ca_system_score_gemma":0.00029661867,"threshold_uncertainty_score":0.005788505},"labels":[],"label_agreement":null},{"id":"W2766193813","doi":"10.1007/s13555-017-0204-3","title":"Patients’ Perspectives on the Impact of Genital Psoriasis: A Qualitative Study","year":2017,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre","funders":"LEO Pharma; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Sex organ; Itching; Psoriasis; Psychosocial; Quality of life (healthcare); Sexual desire; Dermatology; Psychiatry; Human sexuality","score_opus":0.03300738132252601,"score_gpt":0.32895274583850254,"score_spread":0.29594536451597653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766193813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886367,0.0009928528,0.0007069733,0.0048127235,0.000095057934,0.0001542957,0.00023634941,0.000017212642,0.0043477546],"genre_scores_gemma":[0.99631196,0.00070593186,0.0002929541,0.0015486248,0.000021491873,0.00016362894,0.00005741517,0.000015501646,0.0008824018],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.98518825,0.011474714,0.00037725657,0.00048684215,0.0007789671,0.0016940157],"domain_scores_gemma":[0.9741911,0.019440472,0.0016107919,0.00042418888,0.0015586638,0.002774827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014362517,0.00062170025,0.0010222504,0.0013294321,0.008567026,0.0048062983,0.0017930765,0.0023067873,0.0047425115],"category_scores_gemma":[0.021604758,0.0009203943,0.0007174166,0.0014311505,0.007105334,0.004877396,0.005905991,0.004728443,0.00046704995],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040258834,0.000042339954,0.003089385,0.00013259664,0.000007652571,0.00038013892,0.9930426,0.000022928381,0.00029572868,0.0003990364,0.00045039025,0.0020969065],"study_design_scores_gemma":[0.00000733391,0.000050876464,0.0010148496,0.00012204536,0.0000045851784,0.00014583631,0.9954796,0.000044622862,0.00006559442,0.00012124952,0.0029288374,0.00001463209],"about_ca_topic_score_codex":0.010569591,"about_ca_topic_score_gemma":0.014803659,"teacher_disagreement_score":0.014362517,"about_ca_system_score_codex":0.0053388127,"about_ca_system_score_gemma":0.004157823,"threshold_uncertainty_score":0.07595712},"labels":[],"label_agreement":null},{"id":"W2773144918","doi":"10.1007/s13555-017-0211-4","title":"Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies","year":2017,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Centre de Recherche Dermatologique du Québec Métropolitain; Dalhousie University; Dermatrials Research; Université Laval","funders":"Novartis Pharma","keywords":"Secukinumab; Medicine; Psoriasis Area and Severity Index; Psoriasis; Plaque psoriasis; Internal medicine; Dermatology; Psoriatic arthritis","score_opus":0.03147621493430002,"score_gpt":0.30312334748383063,"score_spread":0.2716471325495306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773144918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71263707,0.27508298,0.004135987,0.0008133956,0.00034005576,0.0012643109,0.002766566,0.00015525156,0.0028043797],"genre_scores_gemma":[0.9779959,0.017799638,0.0012988336,0.00044383816,0.00026030434,0.00062427664,0.0013028606,0.000026709544,0.00024762968],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9893583,0.007358097,0.0013352132,0.000797112,0.0009238808,0.00022742533],"domain_scores_gemma":[0.9871329,0.007203545,0.0035581933,0.0010146272,0.0008131719,0.00027758026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019830862,0.0015386282,0.0054479726,0.001549832,0.00037363815,0.0018640388,0.00056274777,0.0010014824,0.0018639482],"category_scores_gemma":[0.01613434,0.0006416439,0.012450731,0.0015309892,0.0004484682,0.00063589413,0.00076616794,0.0006270524,0.00016954537],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1875168,0.000454171,0.14845985,0.0123979,0.5566364,0.0002140245,0.00027969564,0.0017392081,0.0052653765,0.00013758012,0.0016003767,0.0852987],"study_design_scores_gemma":[0.033980343,0.013298236,0.34998462,0.001639313,0.5906595,0.0007695908,0.00025437595,0.0015771666,0.0015282328,0.00073321915,0.005428734,0.00014673237],"about_ca_topic_score_codex":0.00069992786,"about_ca_topic_score_gemma":0.00199179,"teacher_disagreement_score":0.019830862,"about_ca_system_score_codex":0.00044652558,"about_ca_system_score_gemma":0.0011398542,"threshold_uncertainty_score":0.104876935},"labels":[],"label_agreement":null},{"id":"W2791688326","doi":"10.1007/s13555-018-0225-6","title":"Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States","year":2018,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Medicaid; Medical prescription; Angioedema; Cohort; Pediatrics; Health care; Incidence (geometry); Pharmacy; Diagnosis code; Internal medicine; Population; Family medicine; Environmental health","score_opus":0.017023850962813374,"score_gpt":0.2748602357602909,"score_spread":0.2578363847974775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791688326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984486,0.00014162286,0.000010784723,0.00006360751,0.0000019237832,0.000004294549,0.0011395339,0.0000016191663,0.00018795703],"genre_scores_gemma":[0.99863905,0.00013701551,0.000029832405,0.000035323188,0.0000046589425,0.000009639984,0.0010920877,8.889051e-7,0.00005155069],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996094,0.00006976029,0.000059503425,0.00007146631,0.0000940331,0.00009590219],"domain_scores_gemma":[0.9987312,0.00010780715,0.0008829229,0.000031908334,0.0000796115,0.00016646636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003925289,0.00017564556,0.00020515668,0.00097357016,0.00035411635,0.0005388406,0.0002516703,0.0003270251,0.0012625037],"category_scores_gemma":[0.0012342834,0.00018013275,0.00043566525,0.001482371,0.00023745591,0.00041032306,0.00042091435,0.00040738238,0.0001207956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017441052,0.000016993314,0.9994636,0.000003312144,0.000017070046,0.000018383498,0.000022352036,0.000022272987,0.000022429103,0.000008820523,0.00010262853,0.00028464242],"study_design_scores_gemma":[0.00000235314,0.000017626988,0.99958986,0.000005802849,0.0000075895555,0.00008061342,0.00011678788,0.00009094417,0.0000140897055,0.0000048736624,0.000068315065,0.0000012003807],"about_ca_topic_score_codex":0.026059426,"about_ca_topic_score_gemma":0.03444346,"teacher_disagreement_score":0.026059426,"about_ca_system_score_codex":0.0007877414,"about_ca_system_score_gemma":0.0005663427,"threshold_uncertainty_score":0.05181545},"labels":[],"label_agreement":null},{"id":"W2806716877","doi":"10.1007/s13555-018-0242-5","title":"Building a Citizen Pscientist: Advancing Patient-Centered Psoriasis Research by Empowering Patients as Contributors and Analysts","year":2018,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Mental Health and Patient Involvement","field":"Health Professions","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; National Institutes of Health; LEO Pharma; Mallinckrodt Pharmaceuticals; Dermira; Regeneron Pharmaceuticals; University of Pennsylvania; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases; Celgene; Coherus Biosciences; National Psoriasis Foundation; Valeant Pharmaceuticals International; Sanofi; Patient-Centered Outcomes Research Institute; Ortho Dermatologics; Eli Lilly and Company; Pfizer; Amgen","keywords":"Crowdsourcing; Cloud computing; Big data; Medicine; Citizen science; The Internet; Data science; Disease; Computer science; Medical education; World Wide Web; Pathology; Data mining","score_opus":0.10161376234067283,"score_gpt":0.4637016269208175,"score_spread":0.3620878645801447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806716877","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16728356,0.0042720498,0.35311046,0.30138308,0.007239181,0.007151825,0.0039696954,0.0122765,0.14331359],"genre_scores_gemma":[0.48840934,0.0033799098,0.4136094,0.05113967,0.003562652,0.007055087,0.002538819,0.0017601423,0.02854508],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.9638443,0.026387151,0.0010821366,0.0024065468,0.0044053826,0.0018744547],"domain_scores_gemma":[0.9335037,0.02632336,0.0049289693,0.008641244,0.007917965,0.018684845],"candidate_categories":["open_science"],"consensus_categories":[],"category_scores_codex":[0.031064132,0.0006758702,0.00050109735,0.0017821242,0.006341295,0.008731061,0.0021756017,0.003336151,0.014614399],"category_scores_gemma":[0.05022278,0.00076142274,0.0012589049,0.0015089579,0.003774549,0.009207325,0.020403806,0.005009153,0.0076584965],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010175996,0.0016022782,0.03404464,0.0016541256,0.00014641239,0.0013185827,0.064543575,0.0007910776,0.010692451,0.024873378,0.31410286,0.5452131],"study_design_scores_gemma":[0.0003413091,0.0007121617,0.0061664856,0.0010613794,0.000087250926,0.0010306868,0.027096465,0.0031706481,0.0042265127,0.034860596,0.9210695,0.00017706594],"about_ca_topic_score_codex":0.0011191943,"about_ca_topic_score_gemma":0.0026632117,"teacher_disagreement_score":0.9978244,"about_ca_system_score_codex":0.0020693257,"about_ca_system_score_gemma":0.014712713,"threshold_uncertainty_score":0.16428483},"labels":[],"label_agreement":null},{"id":"W2905794790","doi":"10.1007/s13555-018-0279-5","title":"Clinical Goals and Barriers to Effective Psoriasis Care","year":2018,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Université de Sherbrooke; Dermatrials Research; Probity Medical Research","funders":"Cilag; Allergan; Medac; Astellas Pharma; Glenmark Pharmaceuticals; National Psoriasis Foundation; Pfizer; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; University of Connecticut; Eli Lilly and Company; Cardiff University; Celgene; LEO Pharma; Ortho Dermatologics; Gilead Sciences; Sanofi; GlaxoSmithKline; Galderma; Bristol-Myers Squibb; Meiji Seika Pharma; Coherus Biosciences; UCB Pharma; Valeant Pharmaceuticals International; Amgen","keywords":"Psoriasis; Pace; Medicine; Disease; Intensive care medicine; Alternative medicine; Business; Family medicine; Dermatology; Pathology","score_opus":0.013536864592358354,"score_gpt":0.2924971744397164,"score_spread":0.27896030984735803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905794790","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013800348,0.010578855,0.0025734764,0.9532832,0.0014378311,0.00010144558,0.0000845392,0.000056201177,0.018084092],"genre_scores_gemma":[0.7792931,0.022417339,0.018612439,0.17068048,0.002590201,0.0006873942,0.000301398,0.00015709247,0.005260509],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.94845206,0.03133646,0.0037516903,0.0022819205,0.007411053,0.00676679],"domain_scores_gemma":[0.9282511,0.026864225,0.004789774,0.0018098815,0.0114222225,0.026862783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.050284907,0.0003766862,0.0006313692,0.0008930949,0.0041935192,0.012177808,0.0022573026,0.0060913432,0.0072773453],"category_scores_gemma":[0.08571006,0.0004602188,0.0005707779,0.0007384282,0.0071026734,0.006333821,0.010197295,0.013058636,0.0019195043],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002453919,0.000869444,0.03167305,0.00369497,0.00014271539,0.0013600918,0.028187925,0.0013740711,0.002343502,0.24387129,0.35466573,0.3315718],"study_design_scores_gemma":[0.00017108407,0.00047591978,0.028700035,0.00897081,0.000086905,0.0018617098,0.09318558,0.0014941208,0.0014386013,0.25894985,0.6044448,0.00022044379],"about_ca_topic_score_codex":0.0071626566,"about_ca_topic_score_gemma":0.0066253273,"teacher_disagreement_score":0.050284907,"about_ca_system_score_codex":0.0069006705,"about_ca_system_score_gemma":0.03328898,"threshold_uncertainty_score":0.26593518},"labels":[],"label_agreement":null},{"id":"W2942826343","doi":"10.1007/s13555-019-0298-x","title":"The Scar Bane, Without the Pain: A New Approach in the Treatment of Elevated Scars: Thermomechanical Delivery of Topical Triamcinolone Acetonide and 5-Fluorouracil","year":2019,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatologic Treatments and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Triamcinolone acetonide; Medicine; Keloid; Visual analogue scale; Scars; Surgery; Adverse effect; Transdermal; Refractory (planetary science); Corticosteroid; Anesthesia; Internal medicine; Pharmacology","score_opus":0.037352579461313526,"score_gpt":0.2999429815741568,"score_spread":0.26259040211284324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942826343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9089254,0.050215155,0.034178175,0.001399794,0.00024516537,0.00021486322,0.000032685035,0.00016497703,0.0046237363],"genre_scores_gemma":[0.9649475,0.012169013,0.019774672,0.000657121,0.00018223157,0.000071668524,0.000034184504,0.000017216644,0.0021463335],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998735,0.000030374338,0.000008192406,0.00002103686,0.000046205438,0.000020565227],"domain_scores_gemma":[0.99990535,0.00003116362,0.000028933999,0.000012888875,0.0000075546395,0.000014096398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028533698,0.00022771175,0.00029002313,0.0003884214,0.00019750548,0.00035644864,0.00031971617,0.00035744996,0.00075266435],"category_scores_gemma":[0.000244535,0.00016121357,0.00037628887,0.00013878851,0.00033412725,0.00044848293,0.0002504376,0.00082894205,0.000148245],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072245917,0.0009473065,0.0025238798,0.00049395213,0.000050467606,0.0022365188,0.0002569327,0.00047067433,0.69562864,0.0007609884,0.00054894167,0.29535913],"study_design_scores_gemma":[0.0017942698,0.05512327,0.09656542,0.00045179427,0.0007658494,0.17079955,0.00097024,0.019155003,0.56985474,0.0013917809,0.082868606,0.00025938003],"about_ca_topic_score_codex":0.00040856216,"about_ca_topic_score_gemma":0.0012714838,"teacher_disagreement_score":0.00075266435,"about_ca_system_score_codex":0.00013678151,"about_ca_system_score_gemma":0.0002132394,"threshold_uncertainty_score":0.002517879},"labels":[],"label_agreement":null},{"id":"W2956154159","doi":"10.1007/s13555-019-0312-3","title":"Emerging Methods to Objectively Assess Pruritus in Atopic Dermatitis","year":2019,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; National Institutes of Health; LEO Pharma; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; National Institute of Allergy and Infectious Diseases; Celgene; National Psoriasis Foundation; Valeant Pharmaceuticals International; Sanofi; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer; Amgen","keywords":"Atopic dermatitis; Medicine; Dermatology; MEDLINE; Web of science; Pathology; Meta-analysis","score_opus":0.07293752344279375,"score_gpt":0.43408377549210075,"score_spread":0.361146252049307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956154159","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008127876,0.99380577,0.0020895463,0.0006060363,0.0002676852,0.00022823666,0.0004285167,0.000016490245,0.0017448153],"genre_scores_gemma":[0.0144591415,0.97183496,0.010428323,0.0010747022,0.00035997073,0.0008003962,0.00050408224,0.000013916741,0.00052445655],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9882234,0.0051947255,0.0024760563,0.00081245933,0.0031418833,0.00015151795],"domain_scores_gemma":[0.97768205,0.01623059,0.0028036952,0.00037195653,0.0027959095,0.00011574595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010525287,0.0015338463,0.003175744,0.0122634815,0.00029941017,0.0035752621,0.0014525232,0.0017744403,0.0041299574],"category_scores_gemma":[0.026483245,0.00043217128,0.0028806452,0.009683875,0.0011050333,0.0034164835,0.0014339117,0.0013088831,0.0010010302],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023600609,0.00007555116,0.002860733,0.2709443,0.0016889443,0.00017636754,0.0005502933,0.0002975453,0.00060014654,0.004384606,0.0069681415,0.71121734],"study_design_scores_gemma":[0.00030890232,0.0010603218,0.02981163,0.46391496,0.014207732,0.004193716,0.002386679,0.0012254011,0.002270859,0.011204845,0.469101,0.00031387398],"about_ca_topic_score_codex":0.0018917181,"about_ca_topic_score_gemma":0.0033844586,"teacher_disagreement_score":0.0122634815,"about_ca_system_score_codex":0.0016167993,"about_ca_system_score_gemma":0.0033974936,"threshold_uncertainty_score":0.055663705},"labels":[],"label_agreement":null},{"id":"W2981554886","doi":"10.1007/s13555-019-00333-2","title":"Responder Threshold for Patient-Oriented Eczema Measure (POEM) and Children’s Dermatology Life Quality Index (CDLQI) in Adolescents with Atopic Dermatitis","year":2019,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; LEO Pharma; Incyte; Regeneron Pharmaceuticals; Sanofi; Valeant Pharmaceuticals International; Pfizer; Eli Lilly and Company","keywords":"Dermatology Life Quality Index; Eczema Area and Severity Index; Atopic dermatitis; Medicine; Quality of life (healthcare); Placebo; Dermatology; Psoriasis; Pathology","score_opus":0.013267611128179596,"score_gpt":0.2682726440320314,"score_spread":0.2550050329038518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981554886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99368626,0.0030698676,0.00089395506,0.0001441982,0.000033284377,0.00053422304,0.0005680709,0.000023793353,0.0010463425],"genre_scores_gemma":[0.99753547,0.00031157152,0.0011892196,0.00008648869,0.000013467522,0.0005057406,0.00025904365,0.0000033903048,0.00009557871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980908,0.0010839674,0.00018177749,0.00019713423,0.00036640413,0.000079859434],"domain_scores_gemma":[0.9960521,0.0020825756,0.0011874099,0.000118404845,0.00028650108,0.00027310918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047212006,0.0002642716,0.00077052,0.0002973472,0.00012884877,0.0004023036,0.00028632645,0.00046859644,0.0016362531],"category_scores_gemma":[0.0058994694,0.00014476228,0.00063002994,0.00028118805,0.00023581611,0.00027373523,0.00031115793,0.0010182991,0.00015708868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11972942,0.0088527035,0.680105,0.0024303773,0.002009719,0.00026146875,0.00079359853,0.0041610724,0.017486162,0.0006219508,0.0034096413,0.16013895],"study_design_scores_gemma":[0.018450053,0.06354898,0.90310836,0.00023563804,0.00094417564,0.0005939349,0.00019600282,0.0035958898,0.006390803,0.00029415824,0.0026071502,0.00003476523],"about_ca_topic_score_codex":0.00040999716,"about_ca_topic_score_gemma":0.00053421373,"teacher_disagreement_score":0.0047212006,"about_ca_system_score_codex":0.00035083937,"about_ca_system_score_gemma":0.00039746196,"threshold_uncertainty_score":0.024968386},"labels":[],"label_agreement":null},{"id":"W2991027094","doi":"10.1007/s13555-019-00338-x","title":"Pathogenesis, Clinical Signs and Treatment Recommendations in Brittle Nails: A Review","year":2019,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Fragility; Nail (fastener); Medicine; Dermatology; Brittleness; Population; Dentistry; Nail plate; Chemistry; Materials science; Environmental health","score_opus":0.20369369014775887,"score_gpt":0.47578422243440116,"score_spread":0.27209053228664226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991027094","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000087544904,0.9992083,0.000052227268,0.00014560926,0.00013212825,0.000004413739,0.000015412988,0.00000364583,0.00035077592],"genre_scores_gemma":[0.0006848041,0.99865985,0.00012493785,0.00014347096,0.00015177808,0.0000050367294,0.000029622835,9.415769e-7,0.0001995422],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99975485,0.000040555,0.00007683521,0.000044054384,0.00006278203,0.000020923484],"domain_scores_gemma":[0.9994438,0.00031518322,0.000098689576,0.000011108498,0.00010317616,0.000028015269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042813888,0.0010247417,0.001489538,0.0038555139,0.00033546652,0.0009534886,0.0009396547,0.0011606152,0.0038225586],"category_scores_gemma":[0.0013238103,0.00030327163,0.0009987174,0.0024988654,0.00043937864,0.0013451608,0.00052546785,0.0012587539,0.0010637864],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012409071,0.00010893967,0.00059223734,0.056963596,0.00020266787,0.00086347474,0.00010324189,0.0004379177,0.0008215602,0.0015362143,0.03766732,0.90057874],"study_design_scores_gemma":[0.00006529922,0.00021202514,0.0045414823,0.04628333,0.0009854563,0.019988421,0.0003073545,0.00028698082,0.0005743622,0.0031788354,0.92351043,0.00006600471],"about_ca_topic_score_codex":0.0017326255,"about_ca_topic_score_gemma":0.002535098,"teacher_disagreement_score":0.0038555139,"about_ca_system_score_codex":0.00061651133,"about_ca_system_score_gemma":0.0011376402,"threshold_uncertainty_score":0.012787759},"labels":[],"label_agreement":null},{"id":"W2991496398","doi":"10.1007/s13555-019-00340-3","title":"Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure","year":2019,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Cilag; Sanofi Genzyme; Genentech; Medac; Mitsubishi Tanabe Pharma Corporation; Sanofi; Kyowa Hakko Kirin; LEO Fondet; Astellas Pharma; Regeneron Pharmaceuticals; Mylan; Eli Lilly and Company; Purdue Pharma; Sun Pharma; Dermira; Purdue University; Coherus Biosciences; UCB Pharma; Valeant Pharmaceuticals International; Baxalta; Celgene; Pfizer; Biogen; GlaxoSmithKline; Amgen; Meiji Seika Pharma; Galderma; LEO Pharma; Ortho Dermatologics; Allergan; AstraZeneca; Samsung; Bristol-Myers Squibb","keywords":"Ixekizumab; Psoriasis; Medicine; Dermatology; Psoriatic arthritis","score_opus":0.009983924242019151,"score_gpt":0.21147808006893778,"score_spread":0.20149415582691863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991496398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9374637,0.05464844,0.0015319383,0.0002525719,0.000037988986,0.0002484338,0.0032549282,0.00004815457,0.0025137605],"genre_scores_gemma":[0.991454,0.005445201,0.00053454813,0.0001479457,0.00009378985,0.00010419629,0.0019975377,0.000007748163,0.00021495795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99538076,0.001677662,0.0008765479,0.00074214675,0.0011585538,0.00016429528],"domain_scores_gemma":[0.98907405,0.0032688626,0.0054113707,0.0008492359,0.001018373,0.00037821237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010483564,0.0004368138,0.0011694094,0.00087068474,0.00022898869,0.0011052492,0.0003335585,0.0005784169,0.0015661473],"category_scores_gemma":[0.006324719,0.00027079784,0.0030444565,0.0013451114,0.00027337114,0.0007344997,0.0005638795,0.0007476738,0.00022479093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01691503,0.00050243834,0.8711049,0.0016716839,0.01445626,0.00019245283,0.00022318833,0.0012515355,0.0033211655,0.00007368798,0.0009804808,0.089307114],"study_design_scores_gemma":[0.0014946142,0.010020423,0.973708,0.00033271487,0.007418324,0.0011676261,0.00010384774,0.0005647997,0.0014531744,0.0001286977,0.0035752554,0.000032545402],"about_ca_topic_score_codex":0.000565398,"about_ca_topic_score_gemma":0.0008174902,"teacher_disagreement_score":0.010483564,"about_ca_system_score_codex":0.0003991058,"about_ca_system_score_gemma":0.00050506694,"threshold_uncertainty_score":0.05544305},"labels":[],"label_agreement":null},{"id":"W3000932825","doi":"10.1007/s13555-019-00348-9","title":"Correction to: Pathogenesis, Clinical Signs and Treatment Recommendations in Brittle Nails: A Review","year":2020,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Medicine; Psychology","score_opus":0.12100159015021543,"score_gpt":0.4491822011076449,"score_spread":0.32818061095742945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000932825","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002355056,0.31622282,0.00081500335,0.034152202,0.643484,0.000045419965,0.00077012106,0.00017373088,0.00410114],"genre_scores_gemma":[0.005718445,0.7119053,0.0027921204,0.031624787,0.20259559,0.000105319574,0.0021382465,0.0003586065,0.04276155],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99825794,0.00030210908,0.0004411719,0.00021295372,0.0006233375,0.00016247825],"domain_scores_gemma":[0.9923029,0.002089742,0.00068415294,0.00025132412,0.0042896736,0.0003821866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025330947,0.001503437,0.001958695,0.004074143,0.0009455299,0.0024267375,0.0021598726,0.002590521,0.036208514],"category_scores_gemma":[0.017523475,0.00047204265,0.0015675969,0.003026121,0.0012740653,0.0028208792,0.0016975591,0.0040756813,0.020929618],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006117275,0.000011386652,0.00007468671,0.005680183,0.0000347337,0.0003517638,0.000054394477,0.00006689544,0.00022231953,0.0010270055,0.90877306,0.08364252],"study_design_scores_gemma":[0.000028709992,0.000025612044,0.00033890494,0.0025404734,0.00007340167,0.0020262168,0.00005387566,0.000053123516,0.00020366813,0.0007134116,0.99391794,0.000024660125],"about_ca_topic_score_codex":0.0033358592,"about_ca_topic_score_gemma":0.004570676,"teacher_disagreement_score":0.036208514,"about_ca_system_score_codex":0.0012377129,"about_ca_system_score_gemma":0.0038434493,"threshold_uncertainty_score":0.12112951},"labels":[],"label_agreement":null},{"id":"W3003496094","doi":"10.1007/s13555-020-00356-0","title":"Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study","year":2020,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Medicine; Anxiety; Embarrassment; Disease; Atopic dermatitis; Depression (economics); Population; Cross-sectional study; Sleep disorder; Quality of life (healthcare); Psychiatry; Clinical psychology; Psychology; Immunology; Pathology; Environmental health; Cognition","score_opus":0.029160031735762943,"score_gpt":0.4033856263678835,"score_spread":0.3742255946321206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003496094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999121,0.00004778461,0.00029716454,0.000087081644,0.0000027085923,0.00009051372,0.00014324799,0.0000024826727,0.00020791736],"genre_scores_gemma":[0.9988601,0.000078306286,0.0005471707,0.00008429882,0.0000028869745,0.00020962786,0.00011800263,0.000001892878,0.000097724675],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9962727,0.0025064936,0.00037488167,0.00025025397,0.00030180893,0.00029384939],"domain_scores_gemma":[0.9904558,0.005287236,0.0019718546,0.00031397885,0.0013417194,0.0006293303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071016354,0.00025056774,0.00047905833,0.0013490545,0.0009567122,0.0012092827,0.00043982198,0.00044529076,0.0012698954],"category_scores_gemma":[0.013298342,0.00031089463,0.00055102195,0.0010820796,0.0011967409,0.0009796139,0.0018090474,0.0006915537,0.00020049539],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028072266,0.0004857433,0.4750528,0.00051540235,0.00006805511,0.00088091654,0.5052385,0.00019464543,0.0023198393,0.00022168014,0.0006102579,0.014131429],"study_design_scores_gemma":[0.000044785127,0.0010268919,0.42138857,0.00021377184,0.000043606433,0.0011614832,0.571032,0.00096603355,0.0009922611,0.000247882,0.0028161118,0.000066529166],"about_ca_topic_score_codex":0.0030010242,"about_ca_topic_score_gemma":0.004026563,"teacher_disagreement_score":0.0071016354,"about_ca_system_score_codex":0.0013122889,"about_ca_system_score_gemma":0.000987926,"threshold_uncertainty_score":0.037557483},"labels":[],"label_agreement":null},{"id":"W3012894524","doi":"10.1007/s13555-020-00367-x","title":"Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials","year":2020,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Guenther Dermatology Research Centre","funders":"Cilag; LEO Pharma; Mitsubishi Tanabe Pharma Corporation; Sanofi; Kyowa Hakko Kirin; Biogen; Pfizer; Incyte; Fresenius Medical Care North America; Sun Pharma; Dermira; Samsung; UCB Pharma; Valeant Pharmaceuticals International; Medac; Baxalta; Hexal AG; Celgene; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Amgen; Galderma; Eli Lilly and Company; GlaxoSmithKline","keywords":"Ixekizumab; Medicine; Dosing; Dermatology Life Quality Index; Psoriasis; Psoriasis Area and Severity Index; Imputation (statistics); Internal medicine; Randomized controlled trial; Quality of life (healthcare); Tolerability; Adverse effect; Dermatology; Secukinumab; Psoriatic arthritis","score_opus":0.03507305455433154,"score_gpt":0.2892764760050546,"score_spread":0.25420342145072305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012894524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8875131,0.09318783,0.0023116022,0.0018129807,0.00071149267,0.004636954,0.0059229434,0.0001966984,0.003706342],"genre_scores_gemma":[0.9578102,0.021672053,0.0031301582,0.0024948134,0.0010450779,0.006046674,0.0057290755,0.000040996078,0.0020309535],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955159,0.0024410265,0.0006412419,0.00055642583,0.00054763025,0.0002977712],"domain_scores_gemma":[0.9924765,0.0030427016,0.0025123374,0.00055103534,0.00068969734,0.0007277331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010175919,0.0009043929,0.0031632564,0.0003910409,0.00060517783,0.0017330783,0.0007713281,0.0018692521,0.0030058858],"category_scores_gemma":[0.008021933,0.0004484126,0.005292985,0.00068545766,0.0007037011,0.00096909807,0.00041014512,0.0022463559,0.00053261116],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.915887,0.0044951686,0.0073997965,0.00461523,0.010469805,0.00009385047,0.00010169801,0.00040758966,0.0021082258,0.00016364346,0.0030187697,0.051239308],"study_design_scores_gemma":[0.8069855,0.123776376,0.043739416,0.0013062003,0.015711987,0.00029411013,0.000077108525,0.00066974375,0.0015737724,0.00055802555,0.0052268994,0.00008083209],"about_ca_topic_score_codex":0.00047743067,"about_ca_topic_score_gemma":0.0010857627,"teacher_disagreement_score":0.010175919,"about_ca_system_score_codex":0.0006855874,"about_ca_system_score_gemma":0.0016911501,"threshold_uncertainty_score":0.05381602},"labels":[],"label_agreement":null},{"id":"W3015065138","doi":"10.1007/s13555-020-00373-z","title":"Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence","year":2020,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Sanofi Genzyme; AstraZeneca; Allergan; Ortho Dermatologics; LEO Pharma; National Psoriasis Foundation; Pfizer; Biogen; Incyte; Regeneron Pharmaceuticals; Mylan; Castle Biosciences; Novartis Pharmaceuticals Corporation; Dermira; Sun Pharma; Celgene; Sanofi; Galderma; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; Genentech; Valeant Pharmaceuticals International; Amgen","keywords":"Secukinumab; Medicine; Disease; Intensive care medicine; Psoriasis; Psoriatic arthritis; Clinical trial; Immunology; Dermatology; Internal medicine","score_opus":0.04918913432521317,"score_gpt":0.2794191380912929,"score_spread":0.23023000376607972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015065138","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000069181595,0.9994735,0.000036059188,0.000078610574,0.00005926282,0.0000044527596,0.000010445547,0.000002532723,0.00026605438],"genre_scores_gemma":[0.00044953992,0.99921596,0.00008778796,0.00009972851,0.00004651316,0.0000052398264,0.000013915383,7.3435035e-7,0.00008059833],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9996512,0.000073765266,0.00008908012,0.00005397219,0.00011087723,0.000021154792],"domain_scores_gemma":[0.9993175,0.00047024793,0.00009322642,0.0000115958055,0.00008484898,0.00002253196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071045704,0.00082411733,0.0017580161,0.0023263565,0.0002903244,0.001010867,0.0008207005,0.0010083412,0.0035237349],"category_scores_gemma":[0.0015015068,0.0003219739,0.0010842398,0.0021563352,0.00028817283,0.00096770213,0.0005247589,0.0012404947,0.00089360913],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000118549906,0.000059827053,0.00018840874,0.08291352,0.0002990075,0.00021146347,0.00007432742,0.00027024184,0.00057323795,0.0010391924,0.014946692,0.89930546],"study_design_scores_gemma":[0.00009644269,0.00026088842,0.0019113945,0.08232598,0.0015345193,0.0040464494,0.00017887916,0.00020286778,0.00048481967,0.0017051304,0.907211,0.000041599516],"about_ca_topic_score_codex":0.0009884858,"about_ca_topic_score_gemma":0.002055074,"teacher_disagreement_score":0.0035237349,"about_ca_system_score_codex":0.0004978435,"about_ca_system_score_gemma":0.0009859772,"threshold_uncertainty_score":0.01178807},"labels":[],"label_agreement":null},{"id":"W3025530165","doi":"10.1007/s13555-020-00383-x","title":"Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)","year":2020,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Medicine; Psoriasis; Ixekizumab; Dermatology; Nail (fastener); Psoriasis Area and Severity Index; Ustekinumab; Plaque psoriasis; Internal medicine; Secukinumab; Psoriatic arthritis; Disease; Adalimumab","score_opus":0.029726125524352883,"score_gpt":0.266550465056885,"score_spread":0.23682433953253212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025530165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99688345,0.0015701007,0.00014678606,0.00010435079,0.000025003976,0.0004040819,0.00021638053,0.00003126421,0.00061854225],"genre_scores_gemma":[0.9964295,0.0010221038,0.00050323515,0.00030857007,0.00009471324,0.0003330061,0.00040706008,0.000009692597,0.0008922276],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992823,0.0004071926,0.00004776061,0.000073442505,0.000081931976,0.000107352185],"domain_scores_gemma":[0.9991497,0.00018790057,0.00018181042,0.00007975142,0.000056114593,0.00034484713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023758996,0.0007044137,0.0015454796,0.0002269449,0.00027179962,0.00059794396,0.00041556387,0.00063867867,0.0030320885],"category_scores_gemma":[0.0010319606,0.0003656423,0.0015188282,0.0002745528,0.00053332746,0.00046483203,0.00027560713,0.0015500003,0.00046879303],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8113439,0.040022615,0.012992677,0.0009535122,0.0022790455,0.00013534116,0.0002956585,0.0008145996,0.02972844,0.00008068222,0.0020648374,0.09928873],"study_design_scores_gemma":[0.48793137,0.4431097,0.06293894,0.00006139858,0.00096338574,0.00032684885,0.00007392422,0.00048493012,0.0027347505,0.00007904309,0.0012631394,0.000032630007],"about_ca_topic_score_codex":0.000847443,"about_ca_topic_score_gemma":0.0017831721,"teacher_disagreement_score":0.0030320885,"about_ca_system_score_codex":0.00040178752,"about_ca_system_score_gemma":0.00079169037,"threshold_uncertainty_score":0.012565136},"labels":[],"label_agreement":null},{"id":"W3035233083","doi":"10.1007/s13555-020-00411-w","title":"Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics","year":2020,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Medicine; Secukinumab; Ixekizumab; Psoriasis; Ustekinumab; Immunology; Dermatology; Disease; Internal medicine; Adalimumab; Psoriatic arthritis","score_opus":0.02435962657866465,"score_gpt":0.27158581235565776,"score_spread":0.24722618577699312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035233083","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016532723,0.99657416,0.00014322187,0.00036531116,0.00012499027,0.000008664377,0.000024684396,0.000007892256,0.0010978876],"genre_scores_gemma":[0.012079809,0.98588645,0.00028486922,0.0006822213,0.00024613392,0.000015263318,0.0000660818,0.000003505388,0.0007355721],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9997334,0.00007766574,0.000058944053,0.000039515126,0.00006784761,0.000022620823],"domain_scores_gemma":[0.9997496,0.00013723907,0.00005197535,0.00000448198,0.000044371267,0.000012356864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046958777,0.00024079709,0.0007605872,0.0006280342,0.00011856131,0.00058072316,0.00028576684,0.000441985,0.0013578617],"category_scores_gemma":[0.00069524505,0.00011187007,0.00056980416,0.0004902691,0.00014540528,0.00039026758,0.0001995873,0.000702312,0.0004434828],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038027592,0.000062728395,0.00047685642,0.029717855,0.00029204242,0.00041650148,0.00013027432,0.00015252677,0.004680321,0.00076394994,0.013597532,0.9493292],"study_design_scores_gemma":[0.0003404768,0.001169215,0.01055538,0.015462905,0.0015159565,0.008284491,0.00022634598,0.00027484703,0.004575244,0.0012699619,0.95627666,0.000048508897],"about_ca_topic_score_codex":0.00040858594,"about_ca_topic_score_gemma":0.0010148899,"teacher_disagreement_score":0.0013578617,"about_ca_system_score_codex":0.00022387611,"about_ca_system_score_gemma":0.00031724735,"threshold_uncertainty_score":0.00454247},"labels":[],"label_agreement":null},{"id":"W3113634853","doi":"10.1007/s13555-020-00472-x","title":"Two-Year US Pharmacovigilance Report on Brodalumab","year":2020,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Medicine; Pharmacovigilance; Adverse effect; Adverse Event Reporting System; Internal medicine","score_opus":0.023034592902739248,"score_gpt":0.27007475149976373,"score_spread":0.2470401585970245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113634853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7525738,0.038256,0.0064923624,0.009572793,0.0008428421,0.000967892,0.13840155,0.0023562827,0.050536394],"genre_scores_gemma":[0.91374105,0.0066546537,0.0021910276,0.0061170924,0.0007288135,0.00033830426,0.06616165,0.00017790664,0.0038895605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.991682,0.0012159467,0.0020672504,0.0011517876,0.0033497505,0.00053329964],"domain_scores_gemma":[0.97447443,0.0054126466,0.013940686,0.0009714405,0.004558957,0.00064189103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005078249,0.0005261264,0.0006568484,0.003359678,0.0006161181,0.0021361988,0.0005725182,0.0008198137,0.0036216166],"category_scores_gemma":[0.013733903,0.0003635868,0.0014894089,0.005143841,0.00029872786,0.0009101948,0.00093011797,0.0011608779,0.0010480493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019600815,0.00021361673,0.86434513,0.0012617862,0.0014249559,0.0025426894,0.0007227688,0.0012708023,0.0018832395,0.0007371651,0.056876864,0.06676091],"study_design_scores_gemma":[0.00021145045,0.00057348865,0.8980554,0.0008040463,0.0013059139,0.006452067,0.0006280366,0.0018108501,0.002795059,0.00043226237,0.086825,0.000106408355],"about_ca_topic_score_codex":0.022560598,"about_ca_topic_score_gemma":0.014160026,"teacher_disagreement_score":0.022560598,"about_ca_system_score_codex":0.0025592952,"about_ca_system_score_gemma":0.002582541,"threshold_uncertainty_score":0.044858575},"labels":[],"label_agreement":null},{"id":"W3114387357","doi":"10.1007/s13555-020-00474-9","title":"Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD","year":2020,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Pfizer","keywords":"Content validity; Convergent validity; Atopic dermatitis; Medicine; Quality of life (healthcare); Clinical psychology; Physical therapy; External validity; Psychometrics; Psychology; Internal consistency; Dermatology","score_opus":0.02147847622244787,"score_gpt":0.2661775843120621,"score_spread":0.24469910808961426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114387357","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821875,0.0005917255,0.0060658315,0.0002751063,0.00006264125,0.0064313794,0.00090563146,0.000032891563,0.0034473792],"genre_scores_gemma":[0.9588793,0.0006668158,0.027190574,0.00020276368,0.000028231188,0.0109946625,0.0014460027,0.000019446452,0.00057212554],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99094075,0.004402045,0.0015097824,0.0006371351,0.0022013048,0.00030886594],"domain_scores_gemma":[0.9800427,0.0068869595,0.00308138,0.001286213,0.0082691135,0.0004335731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020889832,0.00029736108,0.00047718515,0.0012646291,0.00055136,0.0007732346,0.00057738664,0.00037997216,0.00081940525],"category_scores_gemma":[0.030712375,0.00027576167,0.00095813157,0.0009430625,0.0006490533,0.00070183753,0.0013801208,0.0008406134,0.00025331453],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005176697,0.0012365319,0.7434768,0.0014921566,0.00022517845,0.00017746072,0.025830286,0.00058482034,0.0073503293,0.00095885515,0.002170594,0.21597923],"study_design_scores_gemma":[0.00015346476,0.0013285194,0.9755932,0.00071690296,0.00012278081,0.00041459795,0.0077382564,0.0015446196,0.0027583672,0.00046587258,0.009128056,0.00003535285],"about_ca_topic_score_codex":0.001280132,"about_ca_topic_score_gemma":0.002787049,"teacher_disagreement_score":0.020889832,"about_ca_system_score_codex":0.0009411967,"about_ca_system_score_gemma":0.0030229837,"threshold_uncertainty_score":0.11047733},"labels":[],"label_agreement":null},{"id":"W3122132687","doi":"10.1007/s13555-021-00490-3","title":"Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Adverse effect; Internal medicine; Ustekinumab; Plaque psoriasis; Open label; Randomized controlled trial; Clinical trial; Dermatology; Gastroenterology; Disease; Adalimumab","score_opus":0.023874858612425512,"score_gpt":0.2783510814867329,"score_spread":0.2544762228743074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122132687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924172,0.003265416,0.0003052123,0.0003309669,0.00008378615,0.0012600692,0.00087313383,0.000042624626,0.0014216295],"genre_scores_gemma":[0.9920284,0.0017249861,0.00090381724,0.0008378976,0.0002515838,0.0015356374,0.0017403524,0.000009966914,0.00096752145],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99896824,0.00060146226,0.0000843698,0.00012358454,0.00011697177,0.00010550018],"domain_scores_gemma":[0.998276,0.00044296405,0.00047018586,0.00014682648,0.0001638824,0.0005001777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003969456,0.00083469495,0.0014527888,0.00018328565,0.0002995198,0.0008897141,0.00039928444,0.00095458387,0.0023699088],"category_scores_gemma":[0.0020068276,0.0002998475,0.0013115429,0.00025334375,0.00052079617,0.00063425757,0.00034922562,0.0018106385,0.0006042614],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8684694,0.026151212,0.016842755,0.0011584377,0.001999384,0.00017606464,0.00026496276,0.000600769,0.010177646,0.00012348358,0.0029147326,0.07112115],"study_design_scores_gemma":[0.72532237,0.22656243,0.042202156,0.000112247464,0.00091032375,0.00032457788,0.00005346095,0.0006395427,0.0011009495,0.00016243728,0.002573225,0.000036311565],"about_ca_topic_score_codex":0.00028412812,"about_ca_topic_score_gemma":0.00066364324,"teacher_disagreement_score":0.003969456,"about_ca_system_score_codex":0.00034912775,"about_ca_system_score_gemma":0.0009649437,"threshold_uncertainty_score":0.020992756},"labels":[],"label_agreement":null},{"id":"W3123676674","doi":"10.1007/s13555-021-00483-2","title":"Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities","year":2021,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Janssen Biotech; Sun Pharma; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer; National Psoriasis Foundation; Amgen","keywords":"Psoriasis; Medicine; Inflammation; Interleukin 17; Immunology; Interleukin 23; Immune system; Disease; Interleukin; Cytokine; Internal medicine","score_opus":0.04843329614868765,"score_gpt":0.32176808786269695,"score_spread":0.2733347917140093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123676674","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008048132,0.9990859,0.000045419412,0.00015708698,0.00013848898,0.000002880182,0.0000144345695,0.0000029183573,0.0004725154],"genre_scores_gemma":[0.0004466354,0.9989073,0.00009200257,0.00012988728,0.00016343087,0.000004078268,0.000019752057,6.9205396e-7,0.00023615905],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998307,0.000033050906,0.000033604727,0.000027614013,0.000058328158,0.000016708924],"domain_scores_gemma":[0.9996774,0.00017503202,0.000055153112,0.000006576592,0.00006163815,0.000024239254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039698576,0.0006929761,0.0011207515,0.0020933521,0.00025742236,0.0010646867,0.0005014598,0.00077027554,0.003893613],"category_scores_gemma":[0.0007536268,0.00022963717,0.00048795613,0.0021946619,0.0002695655,0.0010981733,0.00054951455,0.0013049049,0.0012711901],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012891498,0.00008212492,0.00028130456,0.044756703,0.00015359499,0.00037723966,0.00014884253,0.00030708322,0.0017256036,0.003698943,0.04345554,0.90488416],"study_design_scores_gemma":[0.000017624465,0.00012508653,0.0010806101,0.011629775,0.00024305219,0.002383559,0.00010750697,0.00007619504,0.00030059027,0.0017523296,0.9822605,0.000023163897],"about_ca_topic_score_codex":0.0008146449,"about_ca_topic_score_gemma":0.0014173195,"teacher_disagreement_score":0.003893613,"about_ca_system_score_codex":0.0004303144,"about_ca_system_score_gemma":0.0011330384,"threshold_uncertainty_score":0.013025463},"labels":[],"label_agreement":null},{"id":"W3125588754","doi":"10.1007/s13555-021-00487-y","title":"Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Clinical Research","funders":"Sanofi Genzyme; LEO Pharma; Astellas Pharma; Kyowa Hakko Kirin; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Genentech; Valeant Pharmaceuticals International; Sanofi; GlaxoSmithKline; Australian Wool Innovation; Amgen; Pfizer; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; Astellas Pharma US","keywords":"Atopic dermatitis; Dupilumab; Medicine; Placebo; Disease; Clinical trial; Randomized controlled trial; Dermatology; Internal medicine; Pediatrics; Alternative medicine; Pathology","score_opus":0.015582128925932661,"score_gpt":0.2849635979488684,"score_spread":0.26938146902293575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125588754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897968,0.008391836,0.0001831847,0.00014014082,0.00006007761,0.00015067199,0.0004939854,0.0000148677,0.00076842966],"genre_scores_gemma":[0.9976241,0.0010900781,0.00020699654,0.0002000124,0.00006569826,0.00009336233,0.00048254113,0.0000037879345,0.00023344335],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99890876,0.0005939564,0.0001096026,0.00012625943,0.00013328748,0.00012826166],"domain_scores_gemma":[0.9983944,0.0005734783,0.0005403206,0.0001152989,0.000074321615,0.0003022213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030442262,0.00056964206,0.001584071,0.00023928817,0.0002558571,0.0009006226,0.00031380038,0.0006975968,0.0013351744],"category_scores_gemma":[0.0021865312,0.00015815563,0.0017254591,0.00033461562,0.00044952042,0.0007249888,0.0003030335,0.0011804405,0.00014980968],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8567112,0.0035751353,0.039647218,0.0013627866,0.007416628,0.00014606399,0.00016818903,0.0008729731,0.0073931515,0.00022598618,0.001066665,0.08141392],"study_design_scores_gemma":[0.424109,0.27792832,0.27584407,0.00026246937,0.010067374,0.0006542267,0.00020912674,0.0023985957,0.0033099877,0.00046879056,0.0046480102,0.000100174504],"about_ca_topic_score_codex":0.00046875104,"about_ca_topic_score_gemma":0.0012096715,"teacher_disagreement_score":0.0030442262,"about_ca_system_score_codex":0.00039144332,"about_ca_system_score_gemma":0.0003246308,"threshold_uncertainty_score":0.016099632},"labels":[],"label_agreement":null},{"id":"W3133150537","doi":"10.1007/s13555-021-00500-4","title":"Tolerability of and Adherence to Topical Treatments in Atopic Dermatitis: A Narrative Review","year":2021,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Pfizer Foundation; LEO Pharma; Eli Lilly and Company; Galderma; Regeneron Pharmaceuticals; Sun Pharma; Mylan; Celgene; Samsung; National Psoriasis Foundation; Valeant Pharmaceuticals International; Sanofi; Pfizer","keywords":"Atopic dermatitis; Medicine; Tolerability; Narrative review; Behavior management; Intensive care medicine; Alternative medicine; Psychotherapist; Psychology; Dermatology","score_opus":0.057337207521575846,"score_gpt":0.3946786122003193,"score_spread":0.33734140467874346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133150537","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017172784,0.9995671,0.000010870201,0.000055435983,0.000025233705,0.0000040349328,0.000016073252,7.3316875e-7,0.0001488731],"genre_scores_gemma":[0.0021311268,0.9976355,0.000045116947,0.00008001094,0.00004179481,0.000007762715,0.00002060644,4.0923385e-7,0.000037749214],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99933016,0.00017788803,0.00022761081,0.00008329283,0.00015237759,0.000028687038],"domain_scores_gemma":[0.9969523,0.0022838162,0.0004982125,0.000031013766,0.00019519914,0.000039526767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011555039,0.00058133405,0.0016201255,0.0024702603,0.00028269767,0.0011946275,0.0006859141,0.00077893323,0.0024731383],"category_scores_gemma":[0.004376673,0.00026666367,0.0012663093,0.0033066894,0.00034717732,0.0009481587,0.00047575723,0.0006949615,0.0002406041],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020768365,0.00007145999,0.0010474564,0.43597576,0.0012557656,0.00029650488,0.00030946234,0.00017729681,0.00036889614,0.0010514667,0.01070283,0.54853547],"study_design_scores_gemma":[0.00013560959,0.0005245143,0.014646241,0.5594676,0.013177373,0.006695368,0.00088799687,0.0002212319,0.0005678474,0.0012878784,0.4023048,0.000083587285],"about_ca_topic_score_codex":0.0017143699,"about_ca_topic_score_gemma":0.00364381,"teacher_disagreement_score":0.0024731383,"about_ca_system_score_codex":0.0005507827,"about_ca_system_score_gemma":0.00149717,"threshold_uncertainty_score":0.008273482},"labels":[],"label_agreement":null},{"id":"W3133897407","doi":"10.1007/s13555-021-00506-y","title":"Relationship Among Treatment, Pruritus, Investigator’s Static Global Assessment, and Quality of Life in Patients with Atopic Dermatitis","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Bausch Health; Sanofi Genzyme; Incyte; Mylan; Dermira; Argenx; Vanda Pharmaceuticals; Sun Pharma; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; Les Laboratories Pierre Fabre; Celgene; Valeant Pharmaceuticals International; Sanofi; Symrise; Pfizer; Galderma; Eli Lilly and Company","keywords":"Atopic dermatitis; Medicine; Dermatology Life Quality Index; Quality of life (healthcare); Post-hoc analysis; Eczema Area and Severity Index; Longitudinal study; Post hoc; Dermatology; Internal medicine; Disease; Physical therapy; Pathology","score_opus":0.03164830281985107,"score_gpt":0.31869525946197613,"score_spread":0.28704695664212504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133897407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974049,0.001817407,0.000096772776,0.00006580539,0.0000061763135,0.000027872606,0.00023961911,0.000004203245,0.000337284],"genre_scores_gemma":[0.9994605,0.00016720883,0.00008853005,0.000024117679,0.000009128643,0.000022881613,0.00017262918,5.314065e-7,0.00005446205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984433,0.00091939885,0.0001330546,0.00018763526,0.00022821788,0.000088460445],"domain_scores_gemma":[0.9956245,0.0017495519,0.0020402882,0.00017718867,0.00020112931,0.0002074331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026963262,0.00019097498,0.0006330171,0.00042459226,0.0002400773,0.0003972741,0.00022175866,0.0003296143,0.0014149083],"category_scores_gemma":[0.0050160545,0.00016325816,0.00082158507,0.0006547481,0.00018452521,0.0003243137,0.00025610262,0.00055275916,0.00010922971],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003162907,0.00024782072,0.98753476,0.00006957947,0.0005037886,0.000026876849,0.00004649052,0.00009360853,0.00018104016,0.000011206566,0.00010143246,0.008020441],"study_design_scores_gemma":[0.00018219468,0.0021573333,0.9968472,0.000010065637,0.00021464382,0.00012109439,0.00004152133,0.00019651568,0.000056787794,0.000020234222,0.00014781629,0.0000046167993],"about_ca_topic_score_codex":0.0006022617,"about_ca_topic_score_gemma":0.00087205926,"teacher_disagreement_score":0.0026963262,"about_ca_system_score_codex":0.0003116484,"about_ca_system_score_gemma":0.000273392,"threshold_uncertainty_score":0.014259696},"labels":[],"label_agreement":null},{"id":"W3134953187","doi":"10.1007/s13555-021-00504-0","title":"Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Boehringer Ingelheim","keywords":"Palmoplantar pustulosis; Medicine; Placebo; Clinical endpoint; Internal medicine; Gastroenterology; Psoriasis Area and Severity Index; Multicenter trial; Placebo-controlled study; Intention-to-treat analysis; Randomized controlled trial; Surgery; Double blind; Immunology; Multicenter study; Psoriasis; Pathology","score_opus":0.0211709192181169,"score_gpt":0.2831314459354729,"score_spread":0.261960526717356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134953187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99042374,0.0056117605,0.00080393144,0.0003359153,0.00014590751,0.001650204,0.00033421806,0.00006184751,0.00063242763],"genre_scores_gemma":[0.99343383,0.0025606945,0.0012095479,0.00042988366,0.00026271548,0.0012126148,0.00045502037,0.000011164506,0.00042452643],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987935,0.00073701906,0.00011241639,0.00014104182,0.00011187918,0.00010405417],"domain_scores_gemma":[0.99808913,0.0006566297,0.000525812,0.00014628541,0.00017145937,0.0004107299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043071294,0.0012803723,0.0022660692,0.0003448519,0.00033428878,0.0007939579,0.0006017086,0.0012571005,0.0023422719],"category_scores_gemma":[0.0024609342,0.00057928805,0.0021917839,0.00038442563,0.00090258167,0.00092549506,0.00027003107,0.001832867,0.0004245931],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8832483,0.029995102,0.0040689907,0.0013233715,0.002128768,0.00017482044,0.0001801864,0.0007989857,0.021979319,0.000084895466,0.000793605,0.055223525],"study_design_scores_gemma":[0.64604896,0.3433552,0.0071798027,0.000043598233,0.0008883896,0.00014926096,0.00003152887,0.00042728658,0.0013080138,0.000069845744,0.00048095125,0.000017163773],"about_ca_topic_score_codex":0.00024410663,"about_ca_topic_score_gemma":0.00034989862,"teacher_disagreement_score":0.0043071294,"about_ca_system_score_codex":0.00034919198,"about_ca_system_score_gemma":0.001020339,"threshold_uncertainty_score":0.02277857},"labels":[],"label_agreement":null},{"id":"W3138117345","doi":"10.1007/s13555-020-00362-2","title":"Correction to: Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study","year":2020,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Atopic dermatitis; Perception; Cross-sectional study; Natural language processing; Medicine; Computer science; Psychology; Dermatology; Pathology","score_opus":0.01997208787336325,"score_gpt":0.3886952547406255,"score_spread":0.36872316686726225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138117345","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003944787,0.00047547062,0.0009975395,0.0726909,0.9188812,0.00011399823,0.0031366667,0.00045260965,0.0028570408],"genre_scores_gemma":[0.044647146,0.009217513,0.02344919,0.20396174,0.30927438,0.002961308,0.012783484,0.0066747125,0.3870305],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.991621,0.0019259616,0.0020951643,0.0006930011,0.0031557991,0.0005090878],"domain_scores_gemma":[0.875997,0.030073894,0.004717539,0.005331132,0.08083321,0.003047252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008532407,0.001762295,0.0016235312,0.0038992136,0.0035673752,0.0034548268,0.0030225525,0.0039834557,0.083096616],"category_scores_gemma":[0.18100126,0.0008831687,0.0012824105,0.002687846,0.0023468996,0.0024759455,0.0025408862,0.00812748,0.035510756],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019666615,0.0000048233924,0.00008829782,0.00011485848,0.0000034424515,0.0001183371,0.00008497691,0.00001149987,0.000020983274,0.00023285396,0.99605006,0.0032501966],"study_design_scores_gemma":[0.00008502828,0.00003312361,0.0020107788,0.0017653195,0.000043680033,0.0011483544,0.0008827578,0.00026117623,0.00041682008,0.0016857218,0.9915876,0.0000796052],"about_ca_topic_score_codex":0.029558262,"about_ca_topic_score_gemma":0.028525757,"teacher_disagreement_score":0.083096616,"about_ca_system_score_codex":0.004227097,"about_ca_system_score_gemma":0.009937657,"threshold_uncertainty_score":0.27798587},"labels":[],"label_agreement":null},{"id":"W3152655764","doi":"10.1007/s13555-021-00518-8","title":"Psoriasis Prevalence and Severity by Expert Elicitation","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec; Université Laval; BC Children's Hospital; McMaster University; SKiN Health; Probity Medical Research; University of British Columbia; Dermatrials Research; Ottawa Hospital; Lynde Centre for Dermatology; University of Alberta; University of Ottawa; Centre de Recherche Dermatologique du Québec Métropolitain; Innovaderm (Canada)","funders":"Janssen Canada; Novartis Pharmaceuticals Canada; LEO Pharma; AbbVie","keywords":"Psoriasis; Medicine; Population; Confidence interval; Credible interval; Expert elicitation; Estimation; Body surface area; Epidemiology; Disease; Demography; Statistics; Internal medicine; Dermatology; Environmental health; Mathematics","score_opus":0.014126296446566627,"score_gpt":0.24875321946604367,"score_spread":0.23462692301947705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152655764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7199165,0.000943773,0.22629279,0.0010564908,0.00012626349,0.0065850257,0.008133691,0.00056450465,0.03638092],"genre_scores_gemma":[0.8981033,0.0004781955,0.09068116,0.00046589354,0.000084579086,0.0032557324,0.0039620614,0.000055376247,0.0029136613],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9761052,0.014749981,0.0016542866,0.0023748926,0.0043980014,0.00071767304],"domain_scores_gemma":[0.9272904,0.050788555,0.005470872,0.0043432424,0.011621888,0.00048499476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.029659431,0.00092115975,0.00070671196,0.0030065905,0.00063958595,0.0013877512,0.0010538383,0.00089374575,0.005438976],"category_scores_gemma":[0.07683743,0.00042165085,0.001387109,0.0015856752,0.000521339,0.0008810036,0.0025888644,0.00088301685,0.000980288],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006083528,0.0011631442,0.29668462,0.0048010093,0.0009946015,0.0011261029,0.019329477,0.052307885,0.028416231,0.008776269,0.025846766,0.5544703],"study_design_scores_gemma":[0.0010466086,0.0028750696,0.5861447,0.0019934094,0.0013945643,0.002419669,0.012697486,0.24748819,0.033331648,0.025487935,0.084474444,0.00064625125],"about_ca_topic_score_codex":0.006912458,"about_ca_topic_score_gemma":0.009906918,"teacher_disagreement_score":0.029659431,"about_ca_system_score_codex":0.001869309,"about_ca_system_score_gemma":0.0014831235,"threshold_uncertainty_score":0.15685594},"labels":[],"label_agreement":null},{"id":"W3153306807","doi":"10.1007/s13555-021-00529-5","title":"A New Era for Truncal Acne: Emerging from a Legacy of Neglect","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Windsor Clinical Research","funders":"Galderma","keywords":"Neglect; Acne; Medicine; History; Dermatology; Psychiatry","score_opus":0.014564188394622,"score_gpt":0.2928310622675647,"score_spread":0.27826687387294274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153306807","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015503509,0.3200502,0.0036171754,0.6329142,0.007208043,0.000026087546,0.00013644854,0.000090880116,0.020453395],"genre_scores_gemma":[0.2602063,0.44815996,0.0061377273,0.24346702,0.03537345,0.00011905495,0.00020154055,0.00019055179,0.006144497],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958189,0.001819251,0.0003393187,0.00035688057,0.001218642,0.00044707325],"domain_scores_gemma":[0.9769693,0.012687967,0.0022327374,0.0011663837,0.0035589782,0.0033846518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012235136,0.000429677,0.0013919253,0.0014311281,0.0035107825,0.0063861026,0.0010854614,0.0038001142,0.0071867243],"category_scores_gemma":[0.018431015,0.0002464205,0.0006451864,0.0013074434,0.01131106,0.014041747,0.006366152,0.009327855,0.0012635502],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006288712,0.00022056485,0.011302758,0.0029676696,0.0001558958,0.0023970066,0.01204365,0.00019481755,0.0012501184,0.13891433,0.14588138,0.684043],"study_design_scores_gemma":[0.00012320807,0.00047216384,0.009495547,0.012495858,0.00014787352,0.007795055,0.015950115,0.00030652,0.00035199727,0.12422045,0.8285182,0.0001229951],"about_ca_topic_score_codex":0.0030196428,"about_ca_topic_score_gemma":0.007801706,"teacher_disagreement_score":0.012235136,"about_ca_system_score_codex":0.0034849558,"about_ca_system_score_gemma":0.0074498006,"threshold_uncertainty_score":0.064706326},"labels":[],"label_agreement":null},{"id":"W3161437439","doi":"10.1007/s13555-021-00550-8","title":"Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"AbbVie","keywords":"Psoriasis; Plaque psoriasis; Medicine; Quality of life (healthcare); Dermatology; Nursing","score_opus":0.01540259117287134,"score_gpt":0.23959682154864953,"score_spread":0.22419423037577818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161437439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94309866,0.0020849844,0.048801906,0.002048252,0.00009889357,0.00027557157,0.0012567663,0.00026348038,0.0020714696],"genre_scores_gemma":[0.9928799,0.0003282347,0.004864061,0.00013987381,0.000039429222,0.00013982806,0.00084205286,0.000010476499,0.00075606775],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99920255,0.0004225546,0.00004065517,0.0001663051,0.00009400622,0.000073987634],"domain_scores_gemma":[0.9960037,0.0032102105,0.00033009867,0.00009978346,0.00025065494,0.00010556677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005125178,0.0008250229,0.0012600212,0.0008572658,0.00030703386,0.0011406449,0.00090263406,0.00068888435,0.0015311599],"category_scores_gemma":[0.006449086,0.0003096608,0.0012933606,0.00051105936,0.00030778474,0.00041704378,0.00040809292,0.0018451405,0.000337776],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003319693,0.0015700072,0.26177576,0.00023277303,0.0010593688,0.00047122317,0.0002650522,0.5876466,0.0008969307,0.0010135355,0.004276532,0.1374725],"study_design_scores_gemma":[0.00005056566,0.00028287063,0.013933276,0.00003410225,0.00010674117,0.000048432517,0.000016014512,0.98444194,0.00011934055,0.0007137389,0.00024179729,0.000011203434],"about_ca_topic_score_codex":0.006800455,"about_ca_topic_score_gemma":0.00400334,"teacher_disagreement_score":0.006800455,"about_ca_system_score_codex":0.00096856366,"about_ca_system_score_gemma":0.0009981614,"threshold_uncertainty_score":0.027104855},"labels":[],"label_agreement":null},{"id":"W3164736687","doi":"10.1007/s13555-021-00548-2","title":"Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis","year":2021,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Psoriasis; Medicine; Clinical trial; Computer science; Dermatology; Psoriatic arthritis; Internal medicine; Secukinumab","score_opus":0.06649211576710885,"score_gpt":0.4084196808102532,"score_spread":0.34192756504314437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164736687","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030050513,0.97255987,0.009499511,0.0017448021,0.00076226686,0.000113544775,0.000559973,0.00038978143,0.011365301],"genre_scores_gemma":[0.059771806,0.91424626,0.01766145,0.0010609283,0.0008997055,0.00021618657,0.0006615593,0.00007953227,0.0054025236],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995414,0.0002438374,0.00004042226,0.00004062306,0.0001174936,0.000016267031],"domain_scores_gemma":[0.99886984,0.0008507408,0.000112453934,0.000029443467,0.000115915114,0.000021714557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012122084,0.0009035871,0.00068663625,0.0022499207,0.00009690494,0.0011439017,0.00085763546,0.00088661973,0.0066140704],"category_scores_gemma":[0.0031294536,0.00029060713,0.00095921935,0.0012081353,0.00037588784,0.00093649956,0.00061333476,0.00088107033,0.0007436809],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043739873,0.0000728035,0.0005944477,0.03780728,0.00055637525,0.00032748628,0.00050040666,0.007060302,0.006409938,0.019159883,0.060236055,0.8668376],"study_design_scores_gemma":[0.00025396014,0.00031144317,0.003966266,0.016260544,0.0012132907,0.0026512414,0.00021288384,0.0073128245,0.0065881046,0.012867179,0.9482354,0.00012686648],"about_ca_topic_score_codex":0.0013418518,"about_ca_topic_score_gemma":0.001361927,"teacher_disagreement_score":0.0066140704,"about_ca_system_score_codex":0.0007129775,"about_ca_system_score_gemma":0.00056461984,"threshold_uncertainty_score":0.022126257},"labels":[],"label_agreement":null},{"id":"W3167102770","doi":"10.1007/s13555-021-00560-6","title":"Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits","year":2021,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Tazarotene; Psoriasis; Lotion; Tolerability; Medicine; Pharmacology; Dermatology; Clobetasol propionate; Active ingredient; Clinical trial; Adverse effect; Internal medicine","score_opus":0.050980535848023374,"score_gpt":0.3138735115390394,"score_spread":0.26289297569101605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167102770","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007418726,0.9993476,0.00004529711,0.00009758681,0.00007896824,0.0000041665335,0.000012285532,0.0000035083922,0.00033626537],"genre_scores_gemma":[0.00037888146,0.9991485,0.00011112733,0.00009034389,0.00008312629,0.000005663255,0.000019313924,8.319742e-7,0.00016216851],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997999,0.000036628797,0.000041918218,0.000035576344,0.00007039301,0.00001552254],"domain_scores_gemma":[0.9996183,0.00021339078,0.00006997606,0.000007699146,0.00006754865,0.000023028279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053644716,0.00076719775,0.0014429649,0.0027457713,0.00023880842,0.00094324123,0.0007229683,0.00080463086,0.0037550586],"category_scores_gemma":[0.0008216528,0.00027835587,0.00073192356,0.002386937,0.00028814867,0.0010266438,0.0005168269,0.0011765081,0.0011313058],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012212906,0.000090912894,0.00015119073,0.07096258,0.00023731848,0.0002465099,0.00009753604,0.000339968,0.0016135796,0.002489148,0.024691781,0.89895743],"study_design_scores_gemma":[0.000048952807,0.00022491292,0.0012681073,0.021293093,0.0006908501,0.002384027,0.00010512834,0.00014500918,0.000503947,0.0017007694,0.9716054,0.000029667515],"about_ca_topic_score_codex":0.0009127202,"about_ca_topic_score_gemma":0.0016451081,"teacher_disagreement_score":0.0037550586,"about_ca_system_score_codex":0.0004746307,"about_ca_system_score_gemma":0.0011725092,"threshold_uncertainty_score":0.012561917},"labels":[],"label_agreement":null},{"id":"W3170263128","doi":"10.1007/s13555-021-00558-0","title":"Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Atopic dermatitis; Dupilumab; Medicine; Dermatology","score_opus":0.02739593576320092,"score_gpt":0.29707965991119445,"score_spread":0.2696837241479935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170263128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95798576,0.03793585,0.00052501814,0.000373298,0.00013721907,0.0013786759,0.0006941044,0.000027366923,0.00094278035],"genre_scores_gemma":[0.9916155,0.005500616,0.0006443632,0.00040597678,0.00013489812,0.00069161894,0.0007219464,0.0000072057555,0.00027791766],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99676275,0.0021164676,0.00033255693,0.00033896082,0.00024022447,0.0002089548],"domain_scores_gemma":[0.99607337,0.0019926764,0.0010545184,0.00025837822,0.00021517191,0.00040586392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007078181,0.0010152865,0.0031006413,0.00042136558,0.00031377823,0.0010310109,0.0005558287,0.0010743298,0.0017212788],"category_scores_gemma":[0.004694015,0.00047660084,0.0061524147,0.00060363114,0.0005972608,0.0006802084,0.00047992903,0.0013980344,0.00017677649],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91036505,0.0023261595,0.01710876,0.002876821,0.024878375,0.00014747425,0.00013971266,0.0006638592,0.0042925193,0.00012596087,0.00066221075,0.036413096],"study_design_scores_gemma":[0.6605516,0.19212624,0.0981126,0.0004495733,0.040670227,0.00063565915,0.00014108277,0.001376697,0.0015413071,0.00042479648,0.0038851378,0.00008502446],"about_ca_topic_score_codex":0.0006794957,"about_ca_topic_score_gemma":0.0023889372,"teacher_disagreement_score":0.007078181,"about_ca_system_score_codex":0.0007378349,"about_ca_system_score_gemma":0.0009487963,"threshold_uncertainty_score":0.037433445},"labels":[],"label_agreement":null},{"id":"W3179238984","doi":"10.1007/s13555-021-00572-2","title":"The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score","year":2021,"lang":"en","type":"letter","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Sanofi","keywords":"Psoriasis Area and Severity Index; Body surface area; Psoriasis; Plaque psoriasis; Medicine; Severity of illness; Measure (data warehouse); Dermatology; Internal medicine; Computer science; Data mining","score_opus":0.019194619574046435,"score_gpt":0.25204580214016575,"score_spread":0.2328511825661193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179238984","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016219925,0.006223997,0.013735753,0.8853128,0.04104681,0.0004936785,0.00022669253,0.0006500486,0.036090333],"genre_scores_gemma":[0.14399752,0.012660201,0.0348771,0.6324274,0.09116217,0.00076972484,0.00032362447,0.00022646514,0.08355587],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99803275,0.0007706239,0.00023858476,0.00024829223,0.00052041234,0.00018934094],"domain_scores_gemma":[0.99732345,0.0010905523,0.00019146662,0.00018432911,0.0010104097,0.00019988178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015835651,0.0006936679,0.0007622845,0.0006383239,0.001108781,0.0015878108,0.0007598082,0.011025658,0.003031617],"category_scores_gemma":[0.009218538,0.0003165398,0.00074855814,0.00041786252,0.0018335503,0.0013785261,0.0003922939,0.011216434,0.0054967874],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042568706,0.00034284437,0.011173586,0.0005350521,0.000032747823,0.055446118,0.00054611155,0.0006562072,0.010971957,0.010023438,0.7580119,0.15183434],"study_design_scores_gemma":[0.0002489014,0.0006608367,0.0073792357,0.00040404074,0.000050734663,0.16478783,0.0003864421,0.0056071677,0.0062730587,0.009021019,0.80504715,0.00013349147],"about_ca_topic_score_codex":0.0021312858,"about_ca_topic_score_gemma":0.0033380874,"teacher_disagreement_score":0.011025658,"about_ca_system_score_codex":0.0024844878,"about_ca_system_score_gemma":0.0012039625,"threshold_uncertainty_score":0.018026292},"labels":[],"label_agreement":null},{"id":"W3189146888","doi":"10.1007/s13555-021-00585-x","title":"Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"UCB Pharma; Janssen Pharmaceuticals; Manchester Biomedical Research Centre; Sanofi Genzyme; Allergan; Ortho Dermatologics; Gilead Sciences; LEO Pharma; Bausch Health; Astellas Pharma; National Institute for Health and Care Research; Inozyme Pharma; Pfizer; Incyte; Castle Biosciences; Dermira; Vertex Pharmaceuticals; Regeneron Pharmaceuticals; Celgene; Medac; AbbVie; Sanofi; Amgen; Meiji Seika Pharma; EMD Serono; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Plaque psoriasis; Betamethasone dipropionate; Medicine; Term (time); Psoriasis; Dermatology; Anesthesia; Physics","score_opus":0.014687963623217636,"score_gpt":0.24568417798942385,"score_spread":0.2309962143662062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189146888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923469,0.0057331794,0.0004129147,0.00014754623,0.000024605863,0.00011660608,0.00023479426,0.000056443507,0.0009271374],"genre_scores_gemma":[0.9973538,0.0013450645,0.00039985863,0.0001259564,0.000050630355,0.00007484523,0.00027381213,0.000004090175,0.00037207652],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997242,0.000119473414,0.000015580747,0.000035923986,0.00007859326,0.000026228714],"domain_scores_gemma":[0.99945503,0.00022450449,0.0001705097,0.000043063937,0.000029098499,0.00007785648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011991896,0.00027018663,0.00061792874,0.0001282232,0.00009267928,0.00025836582,0.00023284528,0.0002499183,0.0019861308],"category_scores_gemma":[0.00072099676,0.00010289156,0.00046331916,0.00014875647,0.0001692117,0.00018394797,0.00014035052,0.00056425104,0.00024653564],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25165844,0.010419789,0.04418169,0.0019476403,0.0028268737,0.000115412855,0.00015482273,0.0015863026,0.086477,0.00015549021,0.0022447293,0.59823185],"study_design_scores_gemma":[0.08023526,0.38460594,0.5048066,0.00031314942,0.0039018374,0.00069740065,0.00010058001,0.0034053973,0.016126797,0.0003688852,0.005394193,0.00004402316],"about_ca_topic_score_codex":0.00021962688,"about_ca_topic_score_gemma":0.0006395494,"teacher_disagreement_score":0.0019861308,"about_ca_system_score_codex":0.00010858698,"about_ca_system_score_gemma":0.00025243763,"threshold_uncertainty_score":0.006644249},"labels":[],"label_agreement":null},{"id":"W3201393437","doi":"10.1007/s13555-021-00586-w","title":"Practical Management of Patients with Atopic Dermatitis on Dupilumab","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Women's College Hospital; McGill University Health Centre; University of Ottawa; McGill University; Ottawa Hospital; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; SKiN Health; Hospital for Sick Children; Innovaderm (Canada); Probity Medical Research","funders":"Sanofi Genzyme; Sanofi","keywords":"Dupilumab; Atopic dermatitis; Medicine; Statement (logic); Adverse effect; Dermatology; MEDLINE; Family medicine; Intensive care medicine; Internal medicine","score_opus":0.013332968362758216,"score_gpt":0.2797698717500938,"score_spread":0.2664369033873356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201393437","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22185303,0.07166912,0.04829754,0.5088607,0.009112608,0.0026998452,0.00084042596,0.0005065955,0.13616024],"genre_scores_gemma":[0.83926356,0.029605217,0.07548307,0.043878715,0.004693912,0.0006898426,0.0006699537,0.00006256249,0.0056531494],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9764691,0.015410281,0.0035143998,0.00054017693,0.0033459244,0.0007201239],"domain_scores_gemma":[0.953201,0.026213912,0.007288913,0.0009114144,0.010169453,0.0022152767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026299175,0.00047105877,0.0005313192,0.0010012754,0.0021360859,0.0017500777,0.0009420831,0.001877856,0.003114138],"category_scores_gemma":[0.063041255,0.00024747083,0.0008348922,0.00052405335,0.0012434466,0.0016467292,0.002758143,0.0035563058,0.0010004172],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003353671,0.00031638774,0.0585041,0.005250095,0.00021285252,0.011551245,0.016277729,0.0020058586,0.0040047546,0.005766866,0.2096241,0.6861506],"study_design_scores_gemma":[0.00021742287,0.0012666651,0.05154599,0.02740377,0.00044784578,0.040325306,0.03528897,0.0045334552,0.0054185083,0.0271903,0.80596,0.00040184206],"about_ca_topic_score_codex":0.0008095125,"about_ca_topic_score_gemma":0.0019040303,"teacher_disagreement_score":0.026299175,"about_ca_system_score_codex":0.0012943039,"about_ca_system_score_gemma":0.0048484937,"threshold_uncertainty_score":0.139085},"labels":[],"label_agreement":null},{"id":"W3208098493","doi":"10.1007/s13555-021-00631-8","title":"Perception and Experience of Biologic Therapy in Atopic Dermatitis: A Qualitative Focus Group Study of Physicians and Patients in Europe and Canada","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Department of Medicine, University of Toronto; LEO Pharma Research Foundation; Sorbonne Université; Medizinische Fakultät, Heinrich-Heine-Universität Düsseldorf; Royal Free London NHS Foundation Trust; LEO Pharma; University of Toronto","keywords":"Medicine; Dupilumab; Atopic dermatitis; Quality of life (healthcare); Tolerability; Psychosocial; Adverse effect; Focus group; Specialty; Intensive care medicine; Family medicine; Dermatology; Psychiatry; Internal medicine; Nursing","score_opus":0.016814737691487294,"score_gpt":0.29568854526150573,"score_spread":0.27887380757001845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208098493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953505,0.0009017243,0.00010567092,0.0017120013,0.000029494475,0.00008581937,0.00009387512,0.000004156269,0.0017167156],"genre_scores_gemma":[0.9969657,0.00059725385,0.000108164895,0.0014853759,0.000010645073,0.00007170348,0.000046597423,0.0000068617637,0.00070763705],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9922954,0.003638395,0.00026359275,0.0005568913,0.0008099101,0.00243583],"domain_scores_gemma":[0.98729205,0.0055456734,0.0011459325,0.00018674748,0.0020397073,0.0037897637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069745868,0.00047408268,0.00094559876,0.001518511,0.01350464,0.004925309,0.0020765471,0.0023576757,0.0030681533],"category_scores_gemma":[0.010654626,0.0005821746,0.000547958,0.0021225186,0.0074050045,0.002186473,0.0048079956,0.0029375623,0.00022271705],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006390375,0.00009372519,0.016668733,0.00011396378,0.00000896852,0.00059655495,0.97907263,0.000024516408,0.00032524668,0.0002297537,0.00059199834,0.0022100538],"study_design_scores_gemma":[0.000006856547,0.000045977595,0.0090691615,0.000105752646,0.0000035536914,0.0000935257,0.98846453,0.000035151526,0.000041478826,0.000024932871,0.0020952278,0.000013927828],"about_ca_topic_score_codex":0.6715686,"about_ca_topic_score_gemma":0.7519228,"teacher_disagreement_score":0.32843143,"about_ca_system_score_codex":0.025425842,"about_ca_system_score_gemma":0.0245954,"threshold_uncertainty_score":0.6607312},"labels":[],"label_agreement":null},{"id":"W3208931909","doi":"10.1007/s13555-021-00635-4","title":"Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Amgen","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Population; Dermatology; Dactylitis; Disease; Physical therapy; Family medicine; Internal medicine; Enthesitis; Environmental health","score_opus":0.04574691052094136,"score_gpt":0.2830449940988742,"score_spread":0.2372980835779328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208931909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99599504,0.00019569507,0.00008111957,0.00040432074,0.000008585402,0.000060170263,0.0019428813,0.0000075060807,0.0013046401],"genre_scores_gemma":[0.99763095,0.00017948382,0.00017454915,0.00031024683,0.00001622082,0.000078328536,0.0013707714,0.000004928916,0.00023449636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750215,0.0010126535,0.00034362968,0.0002528651,0.00056870136,0.00031994793],"domain_scores_gemma":[0.99229383,0.0017052877,0.0033732932,0.0002638068,0.0012413854,0.0011224783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033905166,0.0001698324,0.00041925104,0.000762315,0.00047995395,0.0008604529,0.0003760859,0.0007970933,0.0014839917],"category_scores_gemma":[0.00981369,0.00023760853,0.00083832,0.001071521,0.00032191034,0.0009871155,0.0013015053,0.0013307147,0.00049372856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015369491,0.00019277091,0.9904855,0.00006124229,0.00008525611,0.000046683275,0.0015350003,0.000079321835,0.00010966956,0.0000315241,0.0015823307,0.0056369696],"study_design_scores_gemma":[0.000010352757,0.00011380983,0.9976592,0.000017160164,0.000015571906,0.00007751466,0.0012964956,0.00013208002,0.000024866256,0.000019371384,0.0006239319,0.000009692552],"about_ca_topic_score_codex":0.006962417,"about_ca_topic_score_gemma":0.006375461,"teacher_disagreement_score":0.006962417,"about_ca_system_score_codex":0.00066193996,"about_ca_system_score_gemma":0.00054237904,"threshold_uncertainty_score":0.017930984},"labels":[],"label_agreement":null},{"id":"W3211156244","doi":"10.1007/s13555-021-00632-7","title":"A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Palmoplantar pustulosis; Medicine; Double blind; Placebo; Dermatology; Randomized controlled trial; Internal medicine; Psoriasis; Alternative medicine; Pathology","score_opus":0.02480674125765737,"score_gpt":0.29438390573820644,"score_spread":0.2695771644805491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211156244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980229,0.0035785846,0.0011802317,0.00055001245,0.00040810087,0.01084066,0.0012440196,0.00019328606,0.0017761844],"genre_scores_gemma":[0.97322243,0.0026897052,0.0033695512,0.0017027115,0.00058283895,0.013855204,0.0014092482,0.000029614082,0.0031387536],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99925643,0.00039008795,0.000050543924,0.00013420162,0.00007204494,0.00009665599],"domain_scores_gemma":[0.9989008,0.00028519388,0.0002630661,0.000092997376,0.00011933062,0.0003386806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023337223,0.0014296563,0.0029076666,0.00053053076,0.0005801404,0.0007299105,0.0009279776,0.0017641003,0.0074135535],"category_scores_gemma":[0.0015599991,0.0007696607,0.0011643126,0.0003989622,0.0009663766,0.0008041901,0.00029056642,0.0020096104,0.0012510896],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93886566,0.030503588,0.0010425532,0.00082278246,0.00079627347,0.00009485646,0.00008650488,0.00019272628,0.010505549,0.00010685014,0.0009827049,0.015999971],"study_design_scores_gemma":[0.85358834,0.14311029,0.0020391452,0.000018552884,0.00020310424,0.000041207055,0.0000144207115,0.00016470847,0.0003440861,0.000045145356,0.00042273937,0.000008251894],"about_ca_topic_score_codex":0.00044979606,"about_ca_topic_score_gemma":0.00096635043,"teacher_disagreement_score":0.0074135535,"about_ca_system_score_codex":0.00038279974,"about_ca_system_score_gemma":0.0013312098,"threshold_uncertainty_score":0.024800837},"labels":[],"label_agreement":null},{"id":"W3213457292","doi":"10.1007/s13555-021-00621-w","title":"Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"Sanofi Genzyme; Regeneron Pharmaceuticals; Sanofi","keywords":"Dupilumab; Atopic dermatitis; Medicine; Dermatology Life Quality Index; Placebo; Quality of life (healthcare); Eczema Area and Severity Index; Internal medicine; Dermatology; Disease; Clinical trial; Alternative medicine; Pathology","score_opus":0.011400116157297142,"score_gpt":0.27204845747962947,"score_spread":0.26064834132233233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213457292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8825674,0.095072605,0.00054934894,0.006414803,0.00016240824,0.000113673916,0.0009675552,0.00002659865,0.014125549],"genre_scores_gemma":[0.99216896,0.0057247714,0.00033677113,0.001139931,0.00020918234,0.000027275977,0.0001761287,0.0000027499962,0.00021420568],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969195,0.0022284768,0.00024104647,0.00012761375,0.0003811471,0.000102245634],"domain_scores_gemma":[0.9939268,0.004022229,0.0012855186,0.000091171474,0.0004250801,0.0002491122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048961183,0.000201246,0.00082352426,0.00027943464,0.00024215548,0.000804627,0.00017312203,0.000402809,0.0020275754],"category_scores_gemma":[0.006366312,0.00007126539,0.0007573056,0.00034436863,0.0002833615,0.00058652606,0.0002685914,0.0006950516,0.00021398139],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02608121,0.0013346664,0.3701217,0.0064548193,0.004470788,0.0013293965,0.0017387489,0.001328228,0.007197555,0.0013721756,0.009268318,0.56930244],"study_design_scores_gemma":[0.007879881,0.058354218,0.84972936,0.0029026447,0.008613939,0.011841327,0.0025945497,0.0031644609,0.007105789,0.001906913,0.04573625,0.0001705891],"about_ca_topic_score_codex":0.00022537356,"about_ca_topic_score_gemma":0.0005532275,"teacher_disagreement_score":0.0048961183,"about_ca_system_score_codex":0.0002777014,"about_ca_system_score_gemma":0.0002589483,"threshold_uncertainty_score":0.02589345},"labels":[],"label_agreement":null},{"id":"W3217600324","doi":"10.1007/s13555-021-00567-z","title":"Correction to: Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Atopic dermatitis; Dermatology; Medicine; Content (measure theory); Mathematics","score_opus":0.014611556947680158,"score_gpt":0.2674827593194101,"score_spread":0.25287120237172994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217600324","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00049729383,0.0010678126,0.0016411293,0.05821454,0.93380994,0.00008687552,0.0026118145,0.00044910068,0.0016216004],"genre_scores_gemma":[0.051249698,0.015409897,0.030534042,0.18857186,0.41555336,0.0025148855,0.014385438,0.006202414,0.27557832],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98736376,0.0030375444,0.0029047725,0.0014881288,0.0043595214,0.0008463134],"domain_scores_gemma":[0.8627226,0.031799395,0.005390126,0.006882344,0.08999223,0.0032133283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01226079,0.0016940065,0.0019161655,0.005137627,0.0026753817,0.004306107,0.0032064235,0.004839619,0.05882967],"category_scores_gemma":[0.19691142,0.0013140768,0.0013912614,0.003471916,0.0023753513,0.0025123642,0.0031848412,0.007909061,0.025676563],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045169512,0.0000075602625,0.0002344914,0.0002441154,0.000014729837,0.00010909471,0.00012421221,0.000033942768,0.00008662516,0.00044399477,0.9906784,0.007977522],"study_design_scores_gemma":[0.00014016019,0.00003450885,0.0037457324,0.0015080827,0.00007610545,0.0008386191,0.0004430065,0.0004886765,0.0005299389,0.0013026964,0.9908054,0.00008707411],"about_ca_topic_score_codex":0.022913171,"about_ca_topic_score_gemma":0.02949951,"teacher_disagreement_score":0.05882967,"about_ca_system_score_codex":0.0045878976,"about_ca_system_score_gemma":0.010634535,"threshold_uncertainty_score":0.19680482},"labels":[],"label_agreement":null},{"id":"W4200154151","doi":"10.1007/s13555-021-00642-5","title":"Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Dermatrials Research; Ottawa Hospital; Innovaderm (Canada); University of British Columbia; Probity Medical Research; Centre de Recherche Dermatologique du Québec Métropolitain; University of Alberta; Lynde Centre for Dermatology; McMaster University; SKiN Health; University of Ottawa","funders":"Janssen Canada; AbbVie; LEO Pharma; Novartis","keywords":"Psoriasis; Inference; Computer science; Medicine; Management science; Intensive care medicine; Dermatology; Engineering; Artificial intelligence","score_opus":0.6304445897635514,"score_gpt":0.5953265520917284,"score_spread":0.03511803767182309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200154151","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025654933,0.0077894167,0.9223912,0.045516532,0.0006566961,0.0068219653,0.0022808057,0.00066314114,0.011314727],"genre_scores_gemma":[0.014873491,0.0018594569,0.97742724,0.001650099,0.00011577892,0.0030544947,0.0005254253,0.000044414162,0.0004497026],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.86981094,0.103066646,0.011561229,0.0036534278,0.01112296,0.00078480167],"domain_scores_gemma":[0.74896395,0.19793935,0.013383991,0.009642362,0.027873445,0.0021969972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.10784157,0.00274577,0.0028262835,0.009476766,0.0020073615,0.008696964,0.008334147,0.006873979,0.009014808],"category_scores_gemma":[0.29240924,0.0017957644,0.0040577897,0.007788027,0.0037727884,0.0051162653,0.005838917,0.007857673,0.0036697795],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003051314,0.00058855483,0.004241175,0.01924126,0.0015823714,0.001025035,0.006105562,0.056392472,0.0013269545,0.33995944,0.08817903,0.4810531],"study_design_scores_gemma":[0.0007359901,0.0002844703,0.0013698491,0.026186505,0.001279444,0.00034836153,0.0020969256,0.09100141,0.0014239457,0.72927964,0.14572796,0.00026562094],"about_ca_topic_score_codex":0.007447551,"about_ca_topic_score_gemma":0.014566546,"teacher_disagreement_score":0.10784157,"about_ca_system_score_codex":0.007397389,"about_ca_system_score_gemma":0.023162553,"threshold_uncertainty_score":0.5703276},"labels":[],"label_agreement":null},{"id":"W4200232143","doi":"10.1007/s13555-021-00661-2","title":"Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front Line","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; SKiN Health; University of Calgary","funders":"LEO Pharma; Bausch Health; Eisai; Sanofi Genzyme; Incyte; Dermira; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Amgen; Boehringer Ingelheim; Celgene; Sanofi; Meiji Seika Pharma; Pfizer; Galderma; Ortho Dermatologics; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Referral; Medicine; Health care; Clinical Practice; Multidisciplinary approach; Front line; Family medicine","score_opus":0.021628210300348567,"score_gpt":0.31553662836221386,"score_spread":0.2939084180618653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200232143","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18091102,0.036854062,0.000632989,0.76584786,0.0019263979,0.000066096174,0.00022827975,0.0000539629,0.013479313],"genre_scores_gemma":[0.9176109,0.023745194,0.001970812,0.054234818,0.0008978895,0.00009615937,0.00015954605,0.00003154657,0.0012531251],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.98662764,0.00664547,0.00093802926,0.00058965344,0.0019386241,0.0032606358],"domain_scores_gemma":[0.954353,0.015281167,0.0057227593,0.00051317853,0.0053772167,0.018752743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013647512,0.00029627018,0.00060552225,0.0012367,0.0032695618,0.005138019,0.0010978004,0.0037256216,0.0067911386],"category_scores_gemma":[0.02956148,0.0004096596,0.000569698,0.0014708717,0.0027956793,0.006009899,0.0066167344,0.004808331,0.0005491367],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003164376,0.0008137939,0.14409594,0.009597122,0.00016152699,0.0050926725,0.22142912,0.0006433193,0.0017132219,0.012423058,0.10063208,0.50308174],"study_design_scores_gemma":[0.00012503107,0.0008279996,0.14590663,0.016773848,0.00012461098,0.0039445153,0.6422156,0.0009948208,0.00041162182,0.0102972835,0.17819457,0.00018346227],"about_ca_topic_score_codex":0.009202842,"about_ca_topic_score_gemma":0.010676832,"teacher_disagreement_score":0.013647512,"about_ca_system_score_codex":0.0041232714,"about_ca_system_score_gemma":0.016806947,"threshold_uncertainty_score":0.0721758},"labels":[],"label_agreement":null},{"id":"W4205675137","doi":"10.1007/s13555-021-00649-y","title":"Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Probity Medical Research","funders":"LEO Pharma; Kyowa Hakko Kirin; Sanofi Genzyme; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Genentech; Valeant Pharmaceuticals International; Sanofi; Celgene; Biogen; GlaxoSmithKline; Amgen; Meiji Seika Pharma; Pfizer; Galderma; Ortho Dermatologics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriasis; Quality of life (healthcare); Clinical trial; Medicine; Phase (matter); Quality (philosophy); Intensive care medicine; Internal medicine; Dermatology; Nursing; Philosophy; Physics","score_opus":0.08333823224810268,"score_gpt":0.36791601861026796,"score_spread":0.2845777863621653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205675137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870768,0.004785774,0.00057488953,0.00047791167,0.00012823885,0.003449084,0.0011008292,0.00011335316,0.0022931818],"genre_scores_gemma":[0.9877615,0.0023545846,0.0012743454,0.00084932713,0.0002069632,0.003513933,0.0020068535,0.00001784753,0.00201457],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991978,0.00041769046,0.000043117074,0.00011297185,0.00009030166,0.00013814606],"domain_scores_gemma":[0.99934465,0.0001121065,0.0001468308,0.000046930167,0.000058848804,0.0002905604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025044456,0.0010357408,0.001731838,0.0003173,0.00033218408,0.00091587775,0.00054354116,0.0012467982,0.002398631],"category_scores_gemma":[0.001136418,0.0003109975,0.0014318048,0.00028305233,0.00045570996,0.00062289124,0.00031819363,0.0020451595,0.00038625833],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85914636,0.030805312,0.004361241,0.0013379509,0.0018768762,0.00030918498,0.00014004186,0.0014241205,0.02268324,0.000306535,0.0038106847,0.07379836],"study_design_scores_gemma":[0.74163437,0.23355283,0.016641123,0.00007231373,0.0006510427,0.00044337512,0.000033391556,0.0012843054,0.0022169317,0.00029141043,0.0031408132,0.000037972248],"about_ca_topic_score_codex":0.0003512671,"about_ca_topic_score_gemma":0.0011132631,"teacher_disagreement_score":0.0025044456,"about_ca_system_score_codex":0.00059557165,"about_ca_system_score_gemma":0.00094187714,"threshold_uncertainty_score":0.0132449865},"labels":[],"label_agreement":null},{"id":"W4206112747","doi":"10.1007/s13555-021-00679-6","title":"Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"Celgene; Eli Lilly and Company; AbbVie; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Psoriasis Area and Severity Index; Secukinumab; Internal medicine; Body mass index; Psoriasis; Disease; Dermatology","score_opus":0.012722383655553214,"score_gpt":0.23173519781918517,"score_spread":0.21901281416363194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206112747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849908,0.010869272,0.00058602175,0.00027773465,0.00018714435,0.0005484029,0.0015630317,0.00003337063,0.00094423565],"genre_scores_gemma":[0.9948114,0.0013892598,0.000402085,0.00036644365,0.00018792124,0.000572364,0.0018998187,0.000016972872,0.00035372144],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972946,0.0012626108,0.00050793495,0.00035625426,0.0002821807,0.00029640048],"domain_scores_gemma":[0.9976776,0.0010632934,0.00048019036,0.00037784647,0.0001737604,0.00022725805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004463048,0.0011855825,0.005335006,0.0006317797,0.00026508138,0.0012053497,0.0006754449,0.0010508437,0.001651228],"category_scores_gemma":[0.0049692215,0.00041959592,0.010528634,0.00072086963,0.00031558852,0.00061781274,0.000619937,0.0014161047,0.00022693862],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78983617,0.0011120599,0.08391018,0.0021830369,0.073363766,0.0004919831,0.00032672417,0.0021742056,0.0065544713,0.00021597148,0.0025192536,0.037312225],"study_design_scores_gemma":[0.24808699,0.09279692,0.49313366,0.0007925794,0.13923891,0.0015000963,0.001074319,0.008342691,0.0036892511,0.0021645455,0.00885151,0.0003286189],"about_ca_topic_score_codex":0.0008635543,"about_ca_topic_score_gemma":0.0023756847,"teacher_disagreement_score":0.005335006,"about_ca_system_score_codex":0.0004482135,"about_ca_system_score_gemma":0.00069136225,"threshold_uncertainty_score":0.023603141},"labels":[],"label_agreement":null},{"id":"W4206401696","doi":"10.1007/s13555-021-00656-z","title":"Correction to: Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey","year":2022,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Mental Health and Psychiatry","field":"Arts and Humanities","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Disease; Perception; Psoriasis; Medicine; Dermatology; Psychology; Pathology; Neuroscience","score_opus":0.05836838919314624,"score_gpt":0.2798845869733298,"score_spread":0.22151619778018355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206401696","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025440342,0.0004378443,0.00032247536,0.10110885,0.8914949,0.000040052048,0.0028188832,0.00017790074,0.0033446345],"genre_scores_gemma":[0.028019432,0.0063209706,0.005190524,0.27798548,0.29849648,0.000968624,0.007991612,0.002895141,0.37213174],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.994679,0.0010262157,0.00089813286,0.00059310166,0.002233717,0.0005699632],"domain_scores_gemma":[0.9454063,0.016330816,0.0023429608,0.0026844635,0.03053968,0.0026957747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004862627,0.0017264549,0.0014709724,0.0031849681,0.0035594467,0.003927124,0.0029908647,0.0057291705,0.078281514],"category_scores_gemma":[0.11311395,0.00088067754,0.001316889,0.0025299184,0.001933511,0.0021076198,0.002086825,0.010064709,0.03424479],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014227707,0.000004200679,0.00009837671,0.000040218387,0.0000026386742,0.00005778411,0.0000272091,0.000009952661,0.000005782477,0.00013094977,0.9980222,0.0015864874],"study_design_scores_gemma":[0.00011409967,0.00002799388,0.0035081953,0.00089510897,0.00003764801,0.00054904,0.0007245123,0.00023364849,0.00021454107,0.0011398547,0.99249685,0.000058496968],"about_ca_topic_score_codex":0.062209755,"about_ca_topic_score_gemma":0.060936555,"teacher_disagreement_score":0.078281514,"about_ca_system_score_codex":0.005439373,"about_ca_system_score_gemma":0.009760989,"threshold_uncertainty_score":0.26187778},"labels":[],"label_agreement":null},{"id":"W4213031527","doi":"10.1007/s13555-022-00690-5","title":"Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Manchester Biomedical Research Centre; National Institute for Health and Care Research; Dermira; Castle Biosciences; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Sanofi Genzyme; Incyte; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Sanofi; Amgen; Pfizer","keywords":"Psoriasis Area and Severity Index; Medicine; Psoriasis; Internal medicine; Placebo; Clinical trial; Randomized controlled trial; Ixekizumab; Gastroenterology; Dermatology","score_opus":0.0738873349008602,"score_gpt":0.3023967785833831,"score_spread":0.2285094436825229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213031527","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0641125,0.9216702,0.006365907,0.0013877896,0.00070430234,0.00068009057,0.003467921,0.00021379764,0.0013974756],"genre_scores_gemma":[0.8653383,0.12194657,0.006032473,0.0014967389,0.00046457985,0.0012007324,0.0026969938,0.0001223199,0.00070111983],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9724769,0.020525992,0.0025496536,0.0025546202,0.0015060196,0.00038689],"domain_scores_gemma":[0.9605961,0.031393073,0.0043559577,0.0018935541,0.0012899822,0.00047134896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03179814,0.0027645798,0.013066536,0.0042875484,0.0004652093,0.00315198,0.002321904,0.0019461411,0.003564683],"category_scores_gemma":[0.043180034,0.0013855017,0.051365174,0.0043136124,0.00065276364,0.001571146,0.0015506861,0.0024435937,0.00033166067],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059924605,0.000022552862,0.0057387375,0.019378288,0.9622147,0.000049921888,0.000023696222,0.0020373072,0.00013246876,0.000096552554,0.0003022816,0.004011128],"study_design_scores_gemma":[0.001677928,0.0002817788,0.0043848623,0.0015222175,0.989688,0.00004923051,0.000013627747,0.0013111908,0.000073769676,0.00033963416,0.0006378416,0.000019989735],"about_ca_topic_score_codex":0.006963159,"about_ca_topic_score_gemma":0.0080779735,"teacher_disagreement_score":0.03179814,"about_ca_system_score_codex":0.0020681797,"about_ca_system_score_gemma":0.0015789624,"threshold_uncertainty_score":0.16816664},"labels":[],"label_agreement":null},{"id":"W4213328363","doi":"10.1007/s13555-022-00687-0","title":"A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma; National Institute for Health and Care Research; Manchester Biomedical Research Centre; UCB","keywords":"Psoriasis; Medicine; Dermatology; Antifungal; Interleukin 17; Disease; Invasive candidiasis; Incidence (geometry); Intensive care medicine; Immunology; Immune system; Internal medicine; Fluconazole","score_opus":0.01712598439463311,"score_gpt":0.2629888597760026,"score_spread":0.2458628753813695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213328363","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011680998,0.2485341,0.07599228,0.23482306,0.014465479,0.004006789,0.005969079,0.00752346,0.39700466],"genre_scores_gemma":[0.037402067,0.31800646,0.19202255,0.14988765,0.0136038745,0.00565328,0.0061993254,0.0009796183,0.2762452],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996007,0.00012258333,0.00007239718,0.00003534999,0.00013247355,0.000036437592],"domain_scores_gemma":[0.99930274,0.00023783404,0.00008039015,0.000018483262,0.00021757402,0.00014300786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055472757,0.0008208155,0.00097396545,0.0012065162,0.0005900285,0.00094716187,0.0008947802,0.0027416237,0.03899442],"category_scores_gemma":[0.0025194485,0.00034414133,0.00059326214,0.0007228243,0.00036050324,0.001452196,0.00079468347,0.0032275978,0.028477006],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000089981906,0.0003642087,0.00096634554,0.0008746988,0.000015601641,0.0021370968,0.00027289538,0.0002474494,0.0014085827,0.0013183499,0.6425618,0.34974295],"study_design_scores_gemma":[0.00009876904,0.00022309694,0.0029206683,0.0014978084,0.000019282395,0.007899195,0.00029076188,0.00031391878,0.00025770988,0.0028635326,0.98358005,0.00003514877],"about_ca_topic_score_codex":0.0016472576,"about_ca_topic_score_gemma":0.004970601,"teacher_disagreement_score":0.03899442,"about_ca_system_score_codex":0.00036490214,"about_ca_system_score_gemma":0.0009899319,"threshold_uncertainty_score":0.13044935},"labels":[],"label_agreement":null},{"id":"W4220793238","doi":"10.1007/s13555-022-00704-2","title":"Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre; Western University","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Psoriasis; Psoriatic arthritis; Dermatology; Medicine; Nail (fastener); Secukinumab","score_opus":0.03272359154223959,"score_gpt":0.2870244712254104,"score_spread":0.25430087968317083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220793238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94535536,0.043274302,0.0011360204,0.00051489467,0.00024130916,0.002883099,0.0014234307,0.0001325669,0.0050390344],"genre_scores_gemma":[0.9889169,0.005630233,0.0013679658,0.0004836569,0.00021790563,0.0012121119,0.0007055855,0.000020058822,0.0014456551],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99664754,0.0022887348,0.00033138925,0.00022409302,0.00027773742,0.00023049583],"domain_scores_gemma":[0.9972554,0.0010914636,0.0008136049,0.00022219529,0.00023607719,0.00038125992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066331527,0.0006212412,0.0020863446,0.000462256,0.00036316155,0.0011177672,0.00036301304,0.00061535044,0.003054921],"category_scores_gemma":[0.0032367983,0.00032062945,0.002463873,0.0005655756,0.0005560576,0.00061423366,0.0004110693,0.0011915733,0.00031849928],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7415906,0.006236322,0.016851086,0.00682248,0.016401172,0.00014573392,0.00032040037,0.0016132806,0.01884176,0.00041848863,0.0037394015,0.18701936],"study_design_scores_gemma":[0.47058132,0.41680747,0.06644365,0.0011141796,0.017785275,0.0008110342,0.0002437986,0.0010055263,0.011990939,0.0009611569,0.012167491,0.0000882227],"about_ca_topic_score_codex":0.0005738452,"about_ca_topic_score_gemma":0.002965753,"teacher_disagreement_score":0.0066331527,"about_ca_system_score_codex":0.0004283791,"about_ca_system_score_gemma":0.0010422921,"threshold_uncertainty_score":0.035079837},"labels":[],"label_agreement":null},{"id":"W4220927294","doi":"10.1007/s13555-022-00707-z","title":"Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Ustekinumab; Discontinuation; Medicine; Psoriasis; Dermatology; Plaque psoriasis; Internal medicine; Disease; Infliximab","score_opus":0.02282714459850081,"score_gpt":0.23854891269022555,"score_spread":0.21572176809172475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220927294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955245,0.0015308288,0.00009257343,0.00023419166,0.000013942442,0.000017003482,0.0017875794,0.0000068610448,0.00079253566],"genre_scores_gemma":[0.9981664,0.00039023472,0.000054172557,0.000083721054,0.000029314955,0.000017435616,0.0010999852,0.000002078221,0.00015671042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990526,0.00034748882,0.00012095915,0.00016713244,0.00020233118,0.0001093927],"domain_scores_gemma":[0.99574775,0.0009550752,0.0025547075,0.00017433599,0.00023420888,0.00033396095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011170912,0.0001449591,0.00037255618,0.00075237284,0.00034696652,0.00052822434,0.00028994985,0.0005085156,0.0014299483],"category_scores_gemma":[0.004031597,0.00017504151,0.0011109435,0.001281944,0.00013597176,0.00025876716,0.00031962688,0.0007238183,0.0001628977],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005451043,0.000034306962,0.9953461,0.000020855608,0.0001413322,0.000038325034,0.000032594096,0.000074620235,0.00004094771,0.000015428508,0.00045661375,0.0032538166],"study_design_scores_gemma":[0.00005900972,0.00015373203,0.99819714,0.00003347759,0.00011391474,0.00025649476,0.000060221628,0.00058041414,0.000043038413,0.00004118792,0.00045612114,0.0000053307454],"about_ca_topic_score_codex":0.006653137,"about_ca_topic_score_gemma":0.0062222746,"teacher_disagreement_score":0.006653137,"about_ca_system_score_codex":0.00044790914,"about_ca_system_score_gemma":0.00045643793,"threshold_uncertainty_score":0.013228834},"labels":[],"label_agreement":null},{"id":"W4220987608","doi":"10.1007/s13555-022-00703-3","title":"Enhanced Effectiveness of Adalimumab Compared to Topical/Traditional Systemic Agents in the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Canadian Observational Epidemiologic Study (COMPLETE-PS)","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dermatrials Research; TransCanada (Canada); Memorial University of Newfoundland; Barrie Urology Group; Lynde Centre for Dermatology","funders":"AbbVie","keywords":"Plaque psoriasis; Adalimumab; Psoriasis; Observational study; Medicine; Dermatology; Internal medicine; Tumor necrosis factor alpha","score_opus":0.11494625202222078,"score_gpt":0.2949359315501205,"score_spread":0.1799896795278997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220987608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.972737,0.013610289,0.00037929887,0.0006146092,0.000063774416,0.00035221694,0.009960891,0.000019384062,0.0022625017],"genre_scores_gemma":[0.9943123,0.0022521657,0.0005012938,0.00019556856,0.000033768712,0.000058327132,0.0023673153,0.0000054468296,0.0002738658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962863,0.0011181423,0.0003051765,0.00049943215,0.0014682403,0.0003227573],"domain_scores_gemma":[0.9933037,0.0012780577,0.0025173083,0.00041014707,0.0018861457,0.00060463353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058281072,0.00035467756,0.0006046183,0.000578865,0.0009499762,0.0010554042,0.0008391329,0.00045658913,0.0022012054],"category_scores_gemma":[0.0116391955,0.00025881946,0.0018205539,0.0023238023,0.00054394285,0.00025476242,0.0004183444,0.00076169154,0.00012635608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009367171,0.00034768658,0.9638497,0.0011654824,0.0040491577,0.000043551045,0.00025315033,0.00025350545,0.0003124243,0.00014666846,0.0023180973,0.01789337],"study_design_scores_gemma":[0.0008566418,0.0005056436,0.995174,0.00012466442,0.0016589909,0.000048863396,0.000097300726,0.0002785471,0.00007838947,0.000029797557,0.0011315558,0.000015657468],"about_ca_topic_score_codex":0.84348464,"about_ca_topic_score_gemma":0.8441386,"teacher_disagreement_score":0.15651536,"about_ca_system_score_codex":0.00733139,"about_ca_system_score_gemma":0.015284616,"threshold_uncertainty_score":0.31487417},"labels":[],"label_agreement":null},{"id":"W4223967404","doi":"10.1007/s13555-022-00721-1","title":"Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"Janssen Pharmaceuticals; Sanofi Genzyme; LEO Pharma; Bausch Health; Kyowa Hakko Kirin; Lundbeckfonden; Glenmark Pharmaceuticals; Dermira; UCB Pharma; Regeneron Pharmaceuticals; Celgene; Genentech; Valeant Pharmaceuticals International; Kiniksa Pharmaceuticals; AbbVie; Sanofi; Amgen; Pfizer; Galderma; Ortho Dermatologics; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Eczema Area and Severity Index; Atopic dermatitis; Medicine; Clinical endpoint; Placebo; Internal medicine; Meta-analysis; Randomized controlled trial; Dermatology; Alternative medicine","score_opus":0.050273596870138305,"score_gpt":0.3224130559871784,"score_spread":0.2721394591170401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223967404","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007219339,0.9878128,0.0019002819,0.00037152154,0.00022174422,0.0006332742,0.0012819815,0.00005139956,0.00050766155],"genre_scores_gemma":[0.39628783,0.5879386,0.0075207986,0.0015356671,0.00039698128,0.003472162,0.0021912877,0.00007484219,0.00058194064],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.976785,0.015293685,0.0040383837,0.0018923372,0.0016434335,0.00034708437],"domain_scores_gemma":[0.96276224,0.030496065,0.0039029683,0.0010899545,0.001494792,0.00025398855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02785229,0.0027297528,0.016565446,0.00707664,0.00046585052,0.0031024683,0.002179008,0.001814583,0.004007247],"category_scores_gemma":[0.058035787,0.0013386455,0.037645895,0.0064955363,0.000761316,0.0019227262,0.0015063924,0.0015852132,0.00031536925],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019730325,0.000017169114,0.0030912557,0.16389003,0.8219301,0.000055085548,0.000044503657,0.00084091735,0.00010890464,0.00016908775,0.0004199735,0.00745989],"study_design_scores_gemma":[0.00075650495,0.00015320892,0.0022002715,0.0127920285,0.98212725,0.00005109777,0.000022712198,0.0003447467,0.000064396874,0.00037928068,0.0010910676,0.000017458993],"about_ca_topic_score_codex":0.006432584,"about_ca_topic_score_gemma":0.011622089,"teacher_disagreement_score":0.02785229,"about_ca_system_score_codex":0.0027675012,"about_ca_system_score_gemma":0.003116562,"threshold_uncertainty_score":0.1472987},"labels":[],"label_agreement":null},{"id":"W4224236679","doi":"10.1007/s13555-022-00722-0","title":"Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lynde Centre for Dermatology; University of Alberta; BC Children's Hospital; Toronto General Hospital; McMaster University; SKiN Health; Probity Medical Research; University of British Columbia; University Health Network; Ottawa Hospital; Dermatrials Research; University of Ottawa; Centre de Recherche Dermatologique du Québec Métropolitain; Innovaderm (Canada)","funders":"Janssen Canada; Sanofi Genzyme; Novartis Pharmaceuticals Canada; Gilead Sciences; LEO Pharma; Bausch Health; Astellas Pharma; Sanofi; Kyowa Hakko Kirin; Genentech; Coherus Biosciences; Pfizer; Incyte; Sun Pharma; Dermira; BC Children's Hospital; Regeneron Pharmaceuticals; Baxalta; Celgene; ViiV Healthcare; Amgen; Amgen Canada; Meiji Seika Pharma; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Psoriasis; Medicine; Population; Intensive care medicine; Life expectancy; Viral load; Immunology; Human immunodeficiency virus (HIV)","score_opus":0.04170993901513721,"score_gpt":0.26177482557682524,"score_spread":0.22006488656168804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224236679","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.056116756,0.032261543,0.66481596,0.16787238,0.0010488653,0.020930259,0.0072710724,0.0012030313,0.048480123],"genre_scores_gemma":[0.30505136,0.0070819594,0.6621687,0.014589519,0.0006471475,0.006270422,0.0029543857,0.00012442187,0.0011121607],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.8379116,0.13414441,0.014855439,0.0047864844,0.0068678996,0.0014341307],"domain_scores_gemma":[0.5730991,0.38396245,0.011653688,0.006652913,0.021214727,0.0034171324],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.22339745,0.0017643354,0.0030829005,0.0057439497,0.0016626391,0.004450228,0.00423254,0.0049293893,0.0048659416],"category_scores_gemma":[0.30052504,0.0013641618,0.006391818,0.0020813707,0.0015789361,0.0030948308,0.0059726364,0.0063631153,0.001313735],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036912954,0.0011393463,0.048661668,0.026762936,0.0071483757,0.0023312345,0.013784841,0.124305524,0.0036955397,0.030707335,0.10695219,0.6308198],"study_design_scores_gemma":[0.005409401,0.0020632641,0.0297837,0.06494269,0.013144424,0.0016094437,0.0059616105,0.37288848,0.0064798575,0.22356758,0.27275985,0.0013897578],"about_ca_topic_score_codex":0.0076928767,"about_ca_topic_score_gemma":0.011755292,"teacher_disagreement_score":0.22339745,"about_ca_system_score_codex":0.0052297963,"about_ca_system_score_gemma":0.0159357,"threshold_uncertainty_score":0.9576892},"labels":[],"label_agreement":null},{"id":"W4280532101","doi":"10.1007/s13555-022-00742-w","title":"Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE)","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"Janssen Biotech; LEO Pharma; Glenmark Pharmaceuticals; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; Biogen; GlaxoSmithKline","keywords":"Dupilumab; Demographics; Atopic dermatitis; Medicine; Baseline (sea); Internal medicine; Dermatology; Demography","score_opus":0.013280773016405872,"score_gpt":0.27087603749648986,"score_spread":0.25759526448008396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280532101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99583864,0.00015626852,0.000052925312,0.000045326615,0.000002912,0.000021486008,0.003285205,0.0000053168014,0.0005919439],"genre_scores_gemma":[0.99682343,0.00009494316,0.00007761994,0.000040449206,0.000009204924,0.00002506569,0.0028402742,0.0000015304947,0.00008752265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99937385,0.00012740634,0.000104004575,0.00017424383,0.000119306096,0.00010130998],"domain_scores_gemma":[0.99755484,0.0002435859,0.0015199226,0.00013261318,0.0002460587,0.0003030094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009342866,0.00018317104,0.00024108219,0.00086190406,0.0003700474,0.0006309159,0.00026078644,0.0003019644,0.0017262044],"category_scores_gemma":[0.0022330552,0.00017065623,0.00030492072,0.0012805478,0.0002686649,0.00082818925,0.0004400631,0.00039500842,0.00022734122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084870706,0.000019975396,0.99908257,0.0000067647306,0.000023777495,0.00003244851,0.000029338364,0.000028077562,0.000042704498,0.000010171948,0.00017898293,0.00046026014],"study_design_scores_gemma":[0.000008601305,0.000084520485,0.99911505,0.0000061321857,0.00001698266,0.0002942578,0.000116556985,0.00012789285,0.000026433367,0.0000086044065,0.00019151738,0.000003325971],"about_ca_topic_score_codex":0.008306519,"about_ca_topic_score_gemma":0.008967015,"teacher_disagreement_score":0.008306519,"about_ca_system_score_codex":0.00045008317,"about_ca_system_score_gemma":0.0005073923,"threshold_uncertainty_score":0.016516387},"labels":[],"label_agreement":null},{"id":"W4281731899","doi":"10.1007/s13555-022-00743-9","title":"Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Adverse effect; Internal medicine; Discontinuation; Psoriasis; Incidence (geometry); Mace; Psoriatic arthritis; Gastroenterology; Pediatrics; Disease; Dermatology","score_opus":0.042917860359638765,"score_gpt":0.29590337731369254,"score_spread":0.2529855169540538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281731899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7789466,0.20862511,0.0015189276,0.00082662876,0.0001023201,0.0010076499,0.005735019,0.00006545426,0.0031722588],"genre_scores_gemma":[0.9496013,0.04279735,0.0012181654,0.0007181578,0.00028321097,0.0007524084,0.0042021195,0.00001559447,0.00041160572],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9953637,0.0020465092,0.0012019442,0.0004838581,0.00072579447,0.00017807336],"domain_scores_gemma":[0.9854113,0.005950222,0.0070440276,0.00060678826,0.0006368785,0.00035087782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008763782,0.00056892395,0.0018518462,0.0005321491,0.00024402284,0.0010270395,0.00039899643,0.00062864827,0.0025427141],"category_scores_gemma":[0.008182413,0.0003012217,0.00331797,0.0011708797,0.00038160174,0.00068205915,0.0004278908,0.0008571277,0.0002741458],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24198309,0.0022389286,0.29638863,0.03321084,0.08190615,0.00062098465,0.0003326406,0.0042811465,0.010888177,0.00034503816,0.0053523495,0.32245204],"study_design_scores_gemma":[0.14241497,0.1281875,0.5843183,0.0063613113,0.0866502,0.004544382,0.00025457016,0.0015635696,0.0072861603,0.0011048141,0.037164804,0.00014937873],"about_ca_topic_score_codex":0.0002065032,"about_ca_topic_score_gemma":0.0005252155,"teacher_disagreement_score":0.008763782,"about_ca_system_score_codex":0.00034627327,"about_ca_system_score_gemma":0.00067251525,"threshold_uncertainty_score":0.046347857},"labels":[],"label_agreement":null},{"id":"W4281877709","doi":"10.1007/s13555-022-00746-6","title":"Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis","year":2022,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Allergan; LEO Pharma; Bausch Health; Regeneron Pharmaceuticals; Sun Pharma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Galderma; Incyte; Valeant Pharmaceuticals International; Celgene; Amgen; Pfizer","keywords":"Medicine; Psoriasis; Dermatology; Ixekizumab; Secukinumab; Scalp; Psoriatic arthritis","score_opus":0.02688408479749728,"score_gpt":0.2961091200770096,"score_spread":0.26922503527951236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281877709","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006233081,0.99910694,0.000040916773,0.0001505812,0.0001606076,0.0000067352194,0.000024832972,0.0000029771518,0.00044407853],"genre_scores_gemma":[0.0003561339,0.99903345,0.00008638115,0.00018240491,0.00012461255,0.0000069545003,0.000028593207,8.1502174e-7,0.0001807784],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997589,0.000050712388,0.000060042497,0.00003945938,0.00007401938,0.000016819873],"domain_scores_gemma":[0.99945074,0.0003187882,0.00010619065,0.000009249857,0.00008733464,0.000027753818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005848207,0.0007151987,0.0016172095,0.0028231377,0.00026772163,0.0011627311,0.0007855967,0.0008955841,0.00513685],"category_scores_gemma":[0.001311398,0.00027778454,0.0008242119,0.0027106018,0.00028362637,0.001056785,0.00059591205,0.0011515926,0.0011551732],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013218251,0.00005633706,0.00014697714,0.15465604,0.0003101325,0.00036791322,0.00013799443,0.00031265258,0.0009742656,0.0026098697,0.054272767,0.78602284],"study_design_scores_gemma":[0.000038472896,0.00011642963,0.0009910517,0.045101143,0.00066134724,0.0025232236,0.00010328364,0.00008893693,0.0002660951,0.0012951798,0.9487879,0.000026939855],"about_ca_topic_score_codex":0.0010123256,"about_ca_topic_score_gemma":0.0018735888,"teacher_disagreement_score":0.00513685,"about_ca_system_score_codex":0.00052322407,"about_ca_system_score_gemma":0.0013331033,"threshold_uncertainty_score":0.017184496},"labels":[],"label_agreement":null},{"id":"W4285798219","doi":"10.1007/s13555-022-00763-5","title":"Elastic Silicone Occlusive Sheeting Versus Silicone Occlusive Sheeting in the Treatment of Scars: A Randomized Controlled Trial","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Thyroid and Parathyroid Surgery","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Army Medical University","keywords":"Medicine; Scars; Occlusive dressing; Silicone; Occlusive; Surgery; Visual analogue scale; Hypertrophic scars; Thyroidectomy; Total thyroidectomy; Pathology; Internal medicine; Thyroid","score_opus":0.019723960188578547,"score_gpt":0.287402240517108,"score_spread":0.26767828032852947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285798219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9589929,0.02218359,0.0012812888,0.0011635722,0.0014526813,0.012150977,0.0008049996,0.0001248317,0.0018452352],"genre_scores_gemma":[0.9647605,0.009261107,0.003003953,0.0013988048,0.001288288,0.0174922,0.00054891495,0.00001725535,0.002228951],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977723,0.0013949703,0.00022257413,0.000245423,0.00018697488,0.00017781883],"domain_scores_gemma":[0.9970926,0.0014834023,0.0006683646,0.00014591111,0.00015784819,0.00045179843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030702893,0.0013107818,0.004225249,0.0007599714,0.0004866908,0.0010551824,0.000990825,0.0027274017,0.0060972325],"category_scores_gemma":[0.004619551,0.0006392268,0.0026888063,0.00080574374,0.0012880107,0.0010918655,0.00044104937,0.0020127937,0.00046932153],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98592794,0.0034181979,0.00032691675,0.0014933997,0.00068976963,0.00002924587,0.000030445806,0.00007797143,0.00045287886,0.00007195756,0.00018384034,0.00729747],"study_design_scores_gemma":[0.9688552,0.02964384,0.0005054144,0.000079865276,0.00043167002,0.0000133746935,0.000013299283,0.00016124385,0.00009320818,0.000054451808,0.00014217525,0.0000061974165],"about_ca_topic_score_codex":0.0007879767,"about_ca_topic_score_gemma":0.0013146182,"teacher_disagreement_score":0.0060972325,"about_ca_system_score_codex":0.0006379514,"about_ca_system_score_gemma":0.0017190883,"threshold_uncertainty_score":0.020397246},"labels":[],"label_agreement":null},{"id":"W4288696372","doi":"10.1007/s13555-022-00768-0","title":"Evaluation of Psychological Wellbeing and Social Impact of Combined Facial and Truncal Acne: a Multi-national, Mixed-Methods Study","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Galderma","keywords":"Embarrassment; Feeling; Spouse; Psychology; Clinical psychology; Affection; Acne; Quality of life (healthcare); Developmental psychology; Medicine; Social psychology; Psychotherapist; Dermatology","score_opus":0.07886096000141292,"score_gpt":0.4828050190768056,"score_spread":0.4039440590753927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288696372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99803287,0.0004839703,0.00027422287,0.000030023584,0.000006501452,0.0005296555,0.00019563203,0.0000028627248,0.0004442904],"genre_scores_gemma":[0.99490696,0.0007307358,0.0014837625,0.00018270154,0.000019259576,0.0018525412,0.00031634417,0.0000034688221,0.00050414924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978604,0.0012045109,0.00023654616,0.00019222962,0.00032168863,0.00018462916],"domain_scores_gemma":[0.99743,0.0009091499,0.0007322969,0.00019854902,0.00040930824,0.00032069275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053263386,0.0005297824,0.0008824096,0.0014636758,0.0014853814,0.001342716,0.0006097499,0.00088675035,0.0017161049],"category_scores_gemma":[0.0042527206,0.0006504717,0.0013254187,0.0012988131,0.0005682931,0.00087889243,0.0011273613,0.0005915414,0.00034401013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001362356,0.0049534524,0.9436784,0.0009192698,0.00065261504,0.0005106767,0.017271135,0.00008059838,0.0015023185,0.000084960564,0.00029208386,0.028692152],"study_design_scores_gemma":[0.00023795436,0.008585484,0.95560265,0.0002974075,0.00030184851,0.00088838435,0.032052524,0.00028917275,0.00041013418,0.000092980896,0.0011884706,0.000052937103],"about_ca_topic_score_codex":0.0028203279,"about_ca_topic_score_gemma":0.0063020377,"teacher_disagreement_score":0.0053263386,"about_ca_system_score_codex":0.00085597445,"about_ca_system_score_gemma":0.0008178533,"threshold_uncertainty_score":0.028168738},"labels":[],"label_agreement":null},{"id":"W4290190465","doi":"10.1007/s13555-022-00764-4","title":"Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); SKiN Health","funders":"Pfizer","keywords":"Eczema Area and Severity Index; Discontinuation; Medicine; Atopic dermatitis; Placebo; Internal medicine; SCORAD; Gastroenterology; Dermatology; Disease; Dermatology Life Quality Index; Pathology","score_opus":0.011163809703424142,"score_gpt":0.2820543683081328,"score_spread":0.2708905586047087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290190465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841648,0.011044896,0.0003361424,0.00047153883,0.00015400026,0.00073565333,0.00079766655,0.00007207921,0.0022232004],"genre_scores_gemma":[0.9946426,0.0017123875,0.0003206397,0.00058440096,0.0001877747,0.00068598916,0.0009067466,0.000010973204,0.0009482973],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9991196,0.0004048958,0.000068373425,0.00016135021,0.00010307266,0.0001427432],"domain_scores_gemma":[0.99887556,0.00031241972,0.00032335857,0.00010234137,0.00008310873,0.00030315894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003405615,0.0006534296,0.00174732,0.00024626832,0.00038158684,0.0010770751,0.00044613672,0.00083961035,0.0031077035],"category_scores_gemma":[0.0015588157,0.00022243525,0.0013361438,0.00031746188,0.00034329167,0.00062946544,0.00023858609,0.0017055107,0.0006029207],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7842525,0.008796639,0.032496877,0.0017552521,0.00427904,0.00034348946,0.00023809755,0.0008132799,0.014850984,0.00020698507,0.0044013136,0.1475655],"study_design_scores_gemma":[0.60427576,0.24531819,0.13410358,0.00026049896,0.002242966,0.0010581904,0.00008842266,0.0013189653,0.0029583133,0.0005415674,0.007778272,0.00005526593],"about_ca_topic_score_codex":0.00017759402,"about_ca_topic_score_gemma":0.00050789985,"teacher_disagreement_score":0.003405615,"about_ca_system_score_codex":0.0004138888,"about_ca_system_score_gemma":0.0005344394,"threshold_uncertainty_score":0.018010855},"labels":[],"label_agreement":null},{"id":"W4293242071","doi":"10.1007/s13555-022-00790-2","title":"Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review","year":2022,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"LEO Pharma; Bausch Health; Castle Biosciences; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Sanofi Genzyme; Incyte; Regeneron Pharmaceuticals; Helsinn; Celgene; Biogen; Sanofi; Amgen; Helsinn Therapeutics; Meiji Seika Pharma; Pfizer","keywords":"Medicine; Psoriasis; Concomitant; Metabolic syndrome; Internal medicine; Exacerbation; Comorbidity; Observational study; Dermatology; Obesity","score_opus":0.035528050407611284,"score_gpt":0.3204511661888236,"score_spread":0.2849231157812123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293242071","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000053493073,0.9996321,0.00001791585,0.00008345605,0.000051803872,0.0000034114078,0.00001567242,0.0000015542917,0.00014053471],"genre_scores_gemma":[0.00057782856,0.9991266,0.000050418934,0.00011458406,0.000056665154,0.000005433091,0.000019512672,6.459438e-7,0.00004836143],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994382,0.00013065235,0.00017166804,0.000082861225,0.0001487092,0.000027864302],"domain_scores_gemma":[0.9976151,0.0017182505,0.00033557243,0.000029858173,0.00025289712,0.000048232578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013217233,0.00075930543,0.002493278,0.00280195,0.00025134897,0.0012760384,0.00096330233,0.0010403179,0.0032954891],"category_scores_gemma":[0.0035987112,0.0003446412,0.0013909485,0.003087124,0.00035509857,0.0010332336,0.00062704313,0.0010953721,0.00048648467],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024307315,0.000046238936,0.00030938565,0.25179756,0.0008951069,0.00011735812,0.000112287824,0.00024107323,0.0004751987,0.0014808719,0.019891264,0.7243905],"study_design_scores_gemma":[0.00014555389,0.00034685535,0.0038356006,0.25145477,0.0064346944,0.0024297207,0.0002675271,0.00022211637,0.00045637277,0.0022504034,0.7320872,0.00006919043],"about_ca_topic_score_codex":0.0013693736,"about_ca_topic_score_gemma":0.0025716226,"teacher_disagreement_score":0.0032954891,"about_ca_system_score_codex":0.00072950823,"about_ca_system_score_gemma":0.0017440295,"threshold_uncertainty_score":0.011024475},"labels":[],"label_agreement":null},{"id":"W4296977517","doi":"10.1007/s13555-022-00805-y","title":"Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; SKiN Health","funders":"LEO Pharma","keywords":"Atopic dermatitis; Medicine; Dermatology; Phase (matter); Pediatrics","score_opus":0.01822436368370999,"score_gpt":0.296372736844235,"score_spread":0.278148373160525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296977517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99249893,0.0055722953,0.00016798622,0.00015248523,0.000026892742,0.0003754284,0.0004283068,0.000015325302,0.0007623462],"genre_scores_gemma":[0.99609816,0.0017788375,0.00026994167,0.0003163848,0.000073032206,0.0004409428,0.0005624431,0.0000054516195,0.000454847],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99871683,0.00071548676,0.00011402765,0.00018205395,0.00015537233,0.00011624449],"domain_scores_gemma":[0.9986319,0.00035348363,0.00051722507,0.00012149076,0.0001652427,0.00021062909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00273927,0.000503939,0.0011518213,0.00029073295,0.0003572408,0.000595501,0.00030886618,0.00047052943,0.0012659156],"category_scores_gemma":[0.0013648942,0.00028661187,0.0019259069,0.00041982275,0.00037875542,0.00038490893,0.00025259532,0.0009618775,0.00023515309],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75648093,0.0066540604,0.09928068,0.0020014048,0.014640459,0.00022057959,0.00052164576,0.0009884335,0.021577304,0.00014481272,0.003062154,0.094427526],"study_design_scores_gemma":[0.19496413,0.16771512,0.60550225,0.00024411756,0.018945444,0.0007778499,0.0002931634,0.0010906655,0.0039140712,0.00024247517,0.0062473095,0.00006345632],"about_ca_topic_score_codex":0.00095035014,"about_ca_topic_score_gemma":0.003726753,"teacher_disagreement_score":0.00273927,"about_ca_system_score_codex":0.00049412705,"about_ca_system_score_gemma":0.000862609,"threshold_uncertainty_score":0.01448679},"labels":[],"label_agreement":null},{"id":"W4297878627","doi":"10.1007/s13555-022-00811-0","title":"Unmet Need in People with Psoriasis and Skin of Color in Canada and the United States","year":2022,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bell (Canada); EVERSANA (Canada); Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Canadian Institute for Energy Training; Women's College Hospital; University of Toronto","funders":"Janssen Canada","keywords":"Psoriasis; Medicine; Ethnic group; Incidence (geometry); Family medicine; Dermatology","score_opus":0.015535834025596386,"score_gpt":0.23544727240543967,"score_spread":0.21991143837984328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297878627","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.043349843,0.9337217,0.00013497531,0.010839977,0.00028546792,0.00009199576,0.0035860396,0.000013861429,0.007976287],"genre_scores_gemma":[0.31694666,0.6745168,0.0007873916,0.0054704435,0.00013435965,0.00011133729,0.0014430758,0.000010285067,0.0005796197],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99644744,0.000673461,0.00068253645,0.00024705054,0.0014942312,0.0004552756],"domain_scores_gemma":[0.98781526,0.0034930375,0.0021797866,0.00010393979,0.0053783664,0.0010296274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025545463,0.00027205187,0.001264961,0.004491575,0.0017320646,0.0028134785,0.000721678,0.0007218527,0.0022604181],"category_scores_gemma":[0.014295917,0.00024802994,0.0013864343,0.011601391,0.0008660945,0.0012582109,0.00096492725,0.00092110405,0.00009857783],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005560433,0.00009292762,0.17485683,0.14909448,0.003626636,0.0019758658,0.013308877,0.00058367086,0.00052791304,0.004904097,0.0518943,0.5985783],"study_design_scores_gemma":[0.00018237499,0.00020706729,0.5907444,0.19731668,0.005646353,0.0033603483,0.037779644,0.00050262944,0.00036486497,0.0031106859,0.16053031,0.0002547134],"about_ca_topic_score_codex":0.9017535,"about_ca_topic_score_gemma":0.9545224,"teacher_disagreement_score":0.098246515,"about_ca_system_score_codex":0.019790236,"about_ca_system_score_gemma":0.07342755,"threshold_uncertainty_score":0.1976502},"labels":[],"label_agreement":null},{"id":"W4301431315","doi":"10.1007/s13555-022-00819-6","title":"Burden of Atopic Dermatitis in Adults and Adolescents: a Systematic Literature Review","year":2022,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AbbVie Biotherapeutics","keywords":"Atopic dermatitis; Medicine; Dermatology; Systematic review; Psychology; MEDLINE; Political science","score_opus":0.015943405666096238,"score_gpt":0.3004818760617718,"score_spread":0.28453847039567554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301431315","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018726467,0.99672544,0.00008264411,0.00021742139,0.000061450926,0.00019716594,0.00058956974,0.000004805356,0.00024889476],"genre_scores_gemma":[0.017797261,0.9807778,0.00041722978,0.000291659,0.000057632864,0.00028667648,0.00029970406,0.0000034670622,0.000068633664],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99442434,0.0013465116,0.0026659216,0.00043322015,0.0009820458,0.00014786696],"domain_scores_gemma":[0.97633255,0.017267814,0.004548797,0.0002456766,0.0013904319,0.00021467035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052967444,0.0011765155,0.0059687025,0.013814314,0.00051164743,0.0023914976,0.0011721641,0.0014349937,0.003684417],"category_scores_gemma":[0.026288468,0.00085782673,0.0067230724,0.01252204,0.000604797,0.0019963877,0.0013725883,0.00095832517,0.00020934427],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014243305,0.000015239265,0.0020443653,0.952221,0.0082251355,0.00016711373,0.00022053187,0.00009438136,0.00008977703,0.00022827018,0.0012798662,0.035271954],"study_design_scores_gemma":[0.0001311166,0.00013933642,0.009183427,0.92191297,0.053066958,0.0007939102,0.0003799387,0.00008439615,0.000095724354,0.0002865989,0.013894135,0.000031429234],"about_ca_topic_score_codex":0.00774565,"about_ca_topic_score_gemma":0.020850424,"teacher_disagreement_score":0.013814314,"about_ca_system_score_codex":0.0028079613,"about_ca_system_score_gemma":0.007562887,"threshold_uncertainty_score":0.028012216},"labels":[],"label_agreement":null},{"id":"W4304687870","doi":"10.1007/s13555-022-00824-9","title":"Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"LEO Pharma","keywords":"Betamethasone dipropionate; Lotion; Calcipotriol; Tazarotene; Medicine; Dermatology; Psoriasis; Plaque psoriasis; Pharmacology","score_opus":0.05013840468471775,"score_gpt":0.3084369931753386,"score_spread":0.2582985884906209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304687870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98036593,0.005888703,0.0055438285,0.00020231503,0.00043932418,0.001953172,0.0029822264,0.00011040348,0.0025141237],"genre_scores_gemma":[0.992257,0.00042094287,0.0037579467,0.00016883896,0.00007940636,0.0017231832,0.0010033273,0.000014305015,0.0005751588],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.983011,0.0126012415,0.0010914751,0.0013768778,0.0014381596,0.0004812391],"domain_scores_gemma":[0.98526704,0.009476678,0.002973335,0.0012667744,0.0006352416,0.0003809825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015320634,0.0011933998,0.002817745,0.00096363924,0.00034208858,0.00093883544,0.0013513886,0.001059429,0.005439213],"category_scores_gemma":[0.022985421,0.0004212477,0.0057554804,0.0009645067,0.00066314824,0.0006839911,0.0012009998,0.0014310409,0.00029050905],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7917365,0.0025992128,0.057024945,0.004461226,0.073763065,0.0001006421,0.00023260352,0.0059735733,0.0025010097,0.00122677,0.0014788951,0.058901586],"study_design_scores_gemma":[0.25121263,0.26002508,0.30069736,0.0007543276,0.12580127,0.00050790503,0.0003425604,0.038994774,0.008225797,0.0055821706,0.007571819,0.00028441212],"about_ca_topic_score_codex":0.001775252,"about_ca_topic_score_gemma":0.0013557659,"teacher_disagreement_score":0.015320634,"about_ca_system_score_codex":0.0009876809,"about_ca_system_score_gemma":0.0009673329,"threshold_uncertainty_score":0.08102417},"labels":[],"label_agreement":null},{"id":"W4306809750","doi":"10.1007/s13555-022-00823-w","title":"The Impact of Global Health Disparities on Atopic Dermatitis in Displaced Populations: Narrowing the Health Equity Gap for Patients with Skin of Color","year":2022,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"UCB Pharma; Bausch Health; LEO Pharma; Galderma; Dermira; Regeneron Pharmaceuticals; Sanofi; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atopic dermatitis; Medicine; Disease; Refugee; Health equity; Population; Environmental health; Public health; Dermatology; Pathology","score_opus":0.06595687629110283,"score_gpt":0.42764834514242833,"score_spread":0.3616914688513255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306809750","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014019877,0.9986444,0.00003537583,0.0005751763,0.00014409689,0.0000038628987,0.000027624075,0.0000032424985,0.00042603776],"genre_scores_gemma":[0.00082663103,0.9987583,0.00005928653,0.00018549873,0.00006735905,0.0000040443606,0.000020321968,6.5503656e-7,0.00007779182],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99969065,0.000079723475,0.000057550245,0.000043986656,0.00009382647,0.00003435492],"domain_scores_gemma":[0.9992711,0.00046135057,0.00009494223,0.000012196724,0.00012191474,0.00003860506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008073455,0.0005335802,0.001218195,0.002112207,0.0002701369,0.0010279499,0.00055182003,0.0009278043,0.0038191099],"category_scores_gemma":[0.0019299889,0.00017003753,0.0010003609,0.0022468655,0.00030973606,0.00088395464,0.00075678725,0.0009959205,0.00048303686],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057191097,0.0000360067,0.0006547715,0.06396869,0.0003579243,0.00011414338,0.00015265247,0.00019925307,0.00029919844,0.0030394087,0.02636622,0.9047545],"study_design_scores_gemma":[0.000043380285,0.00013614038,0.007993663,0.087103486,0.0013509917,0.0014632578,0.00047485842,0.00017624664,0.00026994437,0.0031551388,0.8977957,0.00003718678],"about_ca_topic_score_codex":0.0031374982,"about_ca_topic_score_gemma":0.0055258754,"teacher_disagreement_score":0.0038191099,"about_ca_system_score_codex":0.0006264124,"about_ca_system_score_gemma":0.002343276,"threshold_uncertainty_score":0.012776196},"labels":[],"label_agreement":null},{"id":"W4307033179","doi":"10.1007/s13555-022-00822-x","title":"Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"LEO Pharma; Galderma; Incyte; Regeneron Pharmaceuticals; Sanofi; GlaxoSmithKline; Pfizer; Kiniksa Pharmaceuticals; AstraZeneca; Eli Lilly and Company","keywords":"Eczema Area and Severity Index; Atopic dermatitis; Dupilumab; Medicine; Placebo; Age of onset; Post-hoc analysis; Young adult; Severity of illness; Internal medicine; Clinical trial; Disease; Pediatrics; Dermatology; Pathology","score_opus":0.037025115743110085,"score_gpt":0.3742092569094753,"score_spread":0.33718414116636525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307033179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9465418,0.0407461,0.0014922287,0.00069809746,0.0005472406,0.00367194,0.0031330567,0.0001544881,0.0030151037],"genre_scores_gemma":[0.987598,0.005427967,0.0014579848,0.00075346057,0.0003819146,0.0017759452,0.001627481,0.000041134976,0.00093607826],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9938374,0.003923364,0.00061860605,0.0007078551,0.00046813834,0.00044476066],"domain_scores_gemma":[0.9941916,0.0030754616,0.0013712052,0.00044017335,0.00042517876,0.00049636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010361714,0.0018029897,0.0058627673,0.000614385,0.0005340816,0.0019798554,0.0008088555,0.0014213386,0.0036460096],"category_scores_gemma":[0.007227339,0.00071692385,0.011275543,0.00077077554,0.0008309357,0.0016573329,0.00067021156,0.0023802232,0.00046665184],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93881375,0.0014367491,0.0041978173,0.0019950008,0.030759206,0.00007647604,0.00010161136,0.0004809139,0.0028251703,0.00007562999,0.00090286066,0.018334744],"study_design_scores_gemma":[0.74166775,0.13731015,0.049852036,0.0004153615,0.06279015,0.00030082333,0.00014226383,0.0017231598,0.0018617909,0.00036742742,0.003457814,0.00011123709],"about_ca_topic_score_codex":0.0007200921,"about_ca_topic_score_gemma":0.0026530821,"teacher_disagreement_score":0.010361714,"about_ca_system_score_codex":0.0008825866,"about_ca_system_score_gemma":0.0011882716,"threshold_uncertainty_score":0.054798663},"labels":[],"label_agreement":null},{"id":"W4307429571","doi":"10.1007/s13555-022-00827-6","title":"Predicting Clinical Remission of Chronic Urticaria Using Random Survival Forests: Machine Learning Applied to Real-World Data","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharma; Genentech; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Random forest; Artificial intelligence; Machine learning; Medicine; Computer science","score_opus":0.062140667680051456,"score_gpt":0.36461659573821253,"score_spread":0.3024759280581611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307429571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89335835,0.0014679639,0.09996707,0.0010955632,0.00009715009,0.00014816898,0.002381121,0.00058752164,0.000897157],"genre_scores_gemma":[0.9780091,0.00020873125,0.019946234,0.000086329565,0.000060824368,0.00006521309,0.0014738202,0.0000121969815,0.000137448],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99844736,0.0008699194,0.000121938494,0.0002817218,0.00015630195,0.0001228549],"domain_scores_gemma":[0.9914063,0.0064720097,0.0009483961,0.00039610622,0.00058320514,0.00019388014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065889605,0.00072761445,0.00071566674,0.002048241,0.00037523036,0.0008366933,0.00055919396,0.0007025174,0.0007416412],"category_scores_gemma":[0.0123093985,0.00020062295,0.0010260566,0.0010364954,0.00031201582,0.0005316908,0.000426867,0.0008707913,0.0003169103],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005775547,0.00051539415,0.6753674,0.00015241656,0.00050065917,0.00025607285,0.0001551517,0.21867663,0.0008900089,0.0005054152,0.002723235,0.0996801],"study_design_scores_gemma":[0.000034800603,0.0002138611,0.047938604,0.000068039204,0.00007586414,0.0001942294,0.00006569483,0.9484394,0.00044026377,0.0020273854,0.00047945193,0.000022435535],"about_ca_topic_score_codex":0.006279345,"about_ca_topic_score_gemma":0.005017523,"teacher_disagreement_score":0.0065889605,"about_ca_system_score_codex":0.000549074,"about_ca_system_score_gemma":0.00085597043,"threshold_uncertainty_score":0.034846187},"labels":[],"label_agreement":null},{"id":"W4307851580","doi":"10.1007/s13555-022-00840-9","title":"A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians","year":2022,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Dermatrials Research; University of Ottawa","funders":"","keywords":"Medicine; Clinical trial; Psoriasis; Intensive care medicine; Food and drug administration; Limiting; Modalities; Drug; Disease; First line; Pharmacology; Internal medicine; Dermatology","score_opus":0.1323058363091473,"score_gpt":0.40444072710116097,"score_spread":0.2721348907920137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307851580","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003147051,0.99673456,0.00011686938,0.0019379223,0.00063226855,0.000015648915,0.000031742667,0.000009407001,0.0004899875],"genre_scores_gemma":[0.00034618008,0.9959506,0.00043939325,0.0021607522,0.0007657281,0.000039064962,0.000045998837,0.0000061405053,0.0002462186],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964972,0.001336746,0.0009659205,0.0002656565,0.00082442345,0.00011009692],"domain_scores_gemma":[0.9821973,0.012352152,0.0016992352,0.00028158634,0.0028856916,0.0005839313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007868878,0.0010110788,0.0033218374,0.0054010595,0.0006069136,0.002976603,0.0017340314,0.0032359494,0.0070190337],"category_scores_gemma":[0.018416226,0.0005859925,0.0017073879,0.0065259114,0.0010345288,0.0044440315,0.0013251593,0.0038205178,0.0024716246],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018362275,0.000047416448,0.00020228114,0.05613893,0.00017614845,0.00017289503,0.000119248594,0.00017081996,0.00032598624,0.002791557,0.09799156,0.8416796],"study_design_scores_gemma":[0.00011317053,0.00014675749,0.00085372373,0.09470191,0.0005008102,0.0011887635,0.00014548466,0.00011568658,0.00010051724,0.0035202005,0.8985767,0.000036247235],"about_ca_topic_score_codex":0.0013903731,"about_ca_topic_score_gemma":0.0036021275,"teacher_disagreement_score":0.007868878,"about_ca_system_score_codex":0.0024976043,"about_ca_system_score_gemma":0.005307697,"threshold_uncertainty_score":0.04161507},"labels":[],"label_agreement":null},{"id":"W4309247569","doi":"10.1007/s13555-022-00843-6","title":"Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; LEO Pharma; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Janssen Pharmaceuticals; Gilead Sciences; Union Chimique Belge; Sanofi; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Psoriasis; Dermatology Life Quality Index; Psoriatic arthritis; Body mass index; Odds ratio; Body surface area; Internal medicine; Visual analogue scale; Confidence interval; Physical therapy; Dermatology","score_opus":0.017252792669996294,"score_gpt":0.22538397874167568,"score_spread":0.20813118607167938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309247569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99679875,0.0002787524,0.000076473276,0.000048542384,0.000004344691,0.000013526363,0.0018186738,0.000005606893,0.0009552675],"genre_scores_gemma":[0.99809235,0.00010288699,0.00006233755,0.000043952023,0.0000073229066,0.00001767051,0.0015829318,0.0000028027257,0.000087668595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879706,0.00037614658,0.00016605335,0.00024138209,0.00031389194,0.00010545384],"domain_scores_gemma":[0.99684083,0.00042943456,0.0020114894,0.00019388998,0.0003021997,0.00022213405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019312274,0.00013701283,0.00029666675,0.00057401316,0.0002417898,0.0005740192,0.0003000125,0.0001427888,0.0010580618],"category_scores_gemma":[0.0031659037,0.00010661912,0.00047330314,0.0011509965,0.000157701,0.00035806609,0.0003873607,0.00032312085,0.00016156105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003517077,0.000034288973,0.9972236,0.000021514557,0.00011312659,0.000015810976,0.000056303106,0.000045546145,0.00008879544,0.000017540522,0.00024249766,0.0017891887],"study_design_scores_gemma":[0.00003035473,0.000097561824,0.9988784,0.0000114702025,0.00009001473,0.00012911267,0.00017283428,0.00015560257,0.00008991923,0.000016594915,0.0003246347,0.0000036019283],"about_ca_topic_score_codex":0.009093889,"about_ca_topic_score_gemma":0.011487404,"teacher_disagreement_score":0.009093889,"about_ca_system_score_codex":0.00036347157,"about_ca_system_score_gemma":0.00053565897,"threshold_uncertainty_score":0.018081903},"labels":[],"label_agreement":null},{"id":"W4310275920","doi":"10.1007/s13555-022-00853-4","title":"Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Eli Lilly (Canada); SKiN Health; Memorial University of Newfoundland","funders":"Eli Lilly Canada; Eli Lilly and Company","keywords":"Ixekizumab; Plaque psoriasis; Persistence (discontinuity); Medicine; Psoriasis; Physical therapy; Dermatology; Psoriatic arthritis; Engineering; Secukinumab","score_opus":0.022458528999022054,"score_gpt":0.23913844214158805,"score_spread":0.216679913142566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310275920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99310136,0.00090992055,0.000071974624,0.0002869126,0.000007864828,0.000075842436,0.0036079446,0.0000067890546,0.001931468],"genre_scores_gemma":[0.997726,0.00042484383,0.0001254478,0.00010839914,0.000009615531,0.000026286485,0.0013973588,0.0000012148234,0.00018081132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991172,0.000068411486,0.000059221584,0.00012612424,0.00042474928,0.00020432897],"domain_scores_gemma":[0.99850583,0.000107251995,0.000726561,0.000038584032,0.0003186764,0.00030309788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006691833,0.00015290327,0.00026521258,0.00058676035,0.0014921401,0.0006204025,0.0005991143,0.00024297304,0.0020853826],"category_scores_gemma":[0.0022819932,0.00012741002,0.0002988572,0.0019348016,0.00025002175,0.00023616308,0.0003218956,0.0005699114,0.00011723238],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009345404,0.000044937686,0.9943826,0.000046699373,0.000029947943,0.000041468276,0.00014995622,0.000030865045,0.00006680738,0.000030258596,0.0007358213,0.0043471814],"study_design_scores_gemma":[0.000011164048,0.000054914854,0.99861443,0.00004383383,0.000020826497,0.00012469648,0.000272188,0.0001234376,0.000026425236,0.000010380236,0.00069370336,0.000004051035],"about_ca_topic_score_codex":0.815883,"about_ca_topic_score_gemma":0.85769004,"teacher_disagreement_score":0.18411702,"about_ca_system_score_codex":0.0059091076,"about_ca_system_score_gemma":0.0098941345,"threshold_uncertainty_score":0.37040263},"labels":[],"label_agreement":null},{"id":"W4310942033","doi":"10.1007/s13555-022-00865-0","title":"Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Janssen Biotech","keywords":"Psoriasis; Plaque psoriasis; Medicine; Dermatology; Internal medicine","score_opus":0.010904188158029003,"score_gpt":0.21603245469819568,"score_spread":0.20512826654016666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310942033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892651,0.0017114594,0.00018806511,0.00018646264,0.000026746999,0.00016025579,0.00526909,0.000043229324,0.0031495206],"genre_scores_gemma":[0.9912373,0.0006712757,0.0003843553,0.000111833084,0.000044097433,0.00018549839,0.0070130983,0.0000151059785,0.0003374884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964695,0.0015324565,0.00043882066,0.0006515512,0.0006910189,0.00021664826],"domain_scores_gemma":[0.99469876,0.0009602863,0.002953393,0.0005684058,0.0004040507,0.00041513535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042034653,0.00016830864,0.00073358056,0.0006393797,0.0003387412,0.0008656007,0.000568545,0.00022978653,0.001855921],"category_scores_gemma":[0.005376519,0.00017532479,0.0007410047,0.0010728958,0.00018440578,0.000510238,0.0006841821,0.00045178563,0.00039949312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012046523,0.0007213304,0.9354464,0.00036218303,0.000816646,0.00015469184,0.0001789924,0.0004172706,0.0010556298,0.00016028289,0.0055438583,0.043096133],"study_design_scores_gemma":[0.00162468,0.0024004208,0.98747444,0.00013194648,0.00074390863,0.00095437985,0.00023921311,0.0008605264,0.000775008,0.000096681346,0.0046706875,0.00002810959],"about_ca_topic_score_codex":0.0024759562,"about_ca_topic_score_gemma":0.0035827751,"teacher_disagreement_score":0.0042034653,"about_ca_system_score_codex":0.0005447909,"about_ca_system_score_gemma":0.0012400298,"threshold_uncertainty_score":0.022230327},"labels":[],"label_agreement":null},{"id":"W4310949919","doi":"10.1007/s13555-022-00864-1","title":"The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Communications Security Establishment","funders":"Pfizer","keywords":"Alopecia areata; Medicine; Dermatology; Association (psychology); Psychology; Psychotherapist","score_opus":0.0038044302198502974,"score_gpt":0.1912139926317998,"score_spread":0.1874095624119495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310949919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994294,0.00023565082,0.000018675704,0.000030312562,0.0000022217184,0.000002825262,0.00006576739,0.0000010939713,0.00021392829],"genre_scores_gemma":[0.9998447,0.000043465716,0.000013647284,0.000008033634,0.000004904492,0.0000021051696,0.000049210103,2.2460539e-7,0.000033709737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99955696,0.00013805398,0.00006677331,0.00006311548,0.00010787632,0.00006733368],"domain_scores_gemma":[0.99773467,0.0005383873,0.0012580729,0.000053286338,0.0001692897,0.00024631908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005545758,0.00016375659,0.00021081953,0.00063969754,0.00025959275,0.0004883873,0.00020767844,0.00027473847,0.0018995255],"category_scores_gemma":[0.0024955927,0.00011540461,0.00023825963,0.00059112074,0.0001743828,0.00034409954,0.00033962622,0.0003298916,0.00018045111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027574759,0.000020691297,0.998898,0.000006744403,0.000016768152,0.00003398222,0.0000335071,0.000013112313,0.00006246164,0.0000017843845,0.000029226474,0.00085614034],"study_design_scores_gemma":[0.0000028939244,0.000046774487,0.999516,0.0000025564088,0.0000074206087,0.00022688565,0.00008713951,0.00005179632,0.000011537542,0.0000027328329,0.000043597785,7.907514e-7],"about_ca_topic_score_codex":0.001275342,"about_ca_topic_score_gemma":0.0018113755,"teacher_disagreement_score":0.0018995255,"about_ca_system_score_codex":0.0001762223,"about_ca_system_score_gemma":0.00015194825,"threshold_uncertainty_score":0.006354511},"labels":[],"label_agreement":null},{"id":"W4311115017","doi":"10.1007/s13555-022-00849-0","title":"Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Novartis (Canada); Probity Medical Research","funders":"Novartis Pharma","keywords":"Secukinumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Clinical trial; Latin Americans; Observational study; Population; Dermatology Life Quality Index; Dermatology; Internal medicine; Psoriatic arthritis; Environmental health","score_opus":0.01111867910410766,"score_gpt":0.2270354545668102,"score_spread":0.21591677546270255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311115017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97539926,0.0027266666,0.000335886,0.00022225897,0.000014737422,0.0002594031,0.016936744,0.000049011964,0.0040560025],"genre_scores_gemma":[0.97798735,0.001237513,0.0003794296,0.00033571903,0.00006889456,0.00034641204,0.018919317,0.00002227224,0.00070311036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790573,0.0007652473,0.0003576269,0.00037410023,0.0004368743,0.00016056221],"domain_scores_gemma":[0.98933977,0.0015462781,0.0056467564,0.0012245104,0.0017172366,0.0005254586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038279677,0.00041379154,0.0009059669,0.0011524771,0.00043582267,0.0011005144,0.00069491385,0.00050482724,0.0020307582],"category_scores_gemma":[0.004187995,0.00032569873,0.0010270053,0.0018643183,0.00044750565,0.00067407265,0.0007446365,0.0005065584,0.0007343831],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006417161,0.00038244086,0.9791828,0.00029074374,0.0010577154,0.0001139201,0.00014407128,0.0002123683,0.0005225438,0.00005479856,0.001924472,0.009697038],"study_design_scores_gemma":[0.0017957686,0.0015838454,0.9910272,0.000094621915,0.0008058875,0.0003869985,0.00023394705,0.0003292365,0.00029131098,0.00004750503,0.0033792874,0.000024455265],"about_ca_topic_score_codex":0.007122167,"about_ca_topic_score_gemma":0.009437676,"teacher_disagreement_score":0.007122167,"about_ca_system_score_codex":0.0010441849,"about_ca_system_score_gemma":0.0012503583,"threshold_uncertainty_score":0.02024448},"labels":[],"label_agreement":null},{"id":"W4311220073","doi":"10.1007/s13555-022-00861-4","title":"Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; UCB Pharma; Regeneron Pharmaceuticals; Sun Pharma; Valeant Pharmaceuticals International; Case Western Reserve University; XBiotech; Celgene; Incyte; Dermira; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Certolizumab pegol; Medicine; Plaque psoriasis; Psoriasis; Term (time); Quality of life (healthcare); Internal medicine; Dermatology; Adalimumab; Disease","score_opus":0.03323950638803691,"score_gpt":0.28825304511501404,"score_spread":0.25501353872697713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311220073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99215806,0.0056529245,0.00020182849,0.00019585258,0.000085168285,0.00078844145,0.00044130886,0.000019348694,0.00045695703],"genre_scores_gemma":[0.99473464,0.0019149877,0.00039409765,0.00037790192,0.0001465282,0.0012469183,0.00079986313,0.00000693257,0.00037804304],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979913,0.0011836336,0.00017423127,0.00022791604,0.00019088063,0.00023215698],"domain_scores_gemma":[0.9976349,0.00066767726,0.0008059849,0.00019951675,0.00015315026,0.00053876155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004619266,0.0011829467,0.002694606,0.00038652576,0.00043627052,0.0012428322,0.0006852827,0.0017408088,0.002619041],"category_scores_gemma":[0.0031228468,0.0006207724,0.004787284,0.00059007766,0.0011126932,0.00084615283,0.00061236956,0.0025318868,0.00043143032],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9568565,0.0070200125,0.0058023264,0.0008100851,0.0033426979,0.000061182815,0.00013886242,0.00040296893,0.0029561599,0.000030141626,0.00039246038,0.02218663],"study_design_scores_gemma":[0.8071257,0.15302937,0.035864953,0.000089514375,0.0023255015,0.000086645865,0.00005151032,0.00030286956,0.00049047894,0.00008592691,0.0005151374,0.000032482345],"about_ca_topic_score_codex":0.001041188,"about_ca_topic_score_gemma":0.0013053269,"teacher_disagreement_score":0.004619266,"about_ca_system_score_codex":0.0010611699,"about_ca_system_score_gemma":0.0009395324,"threshold_uncertainty_score":0.024429321},"labels":[],"label_agreement":null},{"id":"W4312163186","doi":"10.1007/s13555-022-00870-3","title":"Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Novartis (Canada); SKiN Health; University of British Columbia; Ottawa Hospital; Lynde Centre for Dermatology; University of Toronto; University of Ottawa; Probity Medical Research; Queen's University","funders":"Novartis Pharmaceuticals Canada","keywords":"Secukinumab; Medicine; Psoriasis; Erythema; Plaque psoriasis; Observational study; Psoriasis Area and Severity Index; Body surface area; Dermatology; Internal medicine; Psoriatic arthritis","score_opus":0.0072825027337107915,"score_gpt":0.2210104133937281,"score_spread":0.2137279106600173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312163186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99531627,0.001260882,0.00013838257,0.00004769134,0.000010059461,0.00005746576,0.001877037,0.000030472838,0.0012617795],"genre_scores_gemma":[0.99366224,0.0006937432,0.00023396232,0.00008781079,0.000034897123,0.00006582535,0.0048938245,0.000014411684,0.0003133686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831057,0.00052485714,0.00024339157,0.00030783805,0.00046098756,0.00015228339],"domain_scores_gemma":[0.99706954,0.00047138863,0.0009320109,0.0006814531,0.0005665788,0.00027910373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025575953,0.00028644197,0.0010449806,0.000518366,0.0004217922,0.0014324349,0.00048350304,0.0002582636,0.0010872507],"category_scores_gemma":[0.0028466186,0.00025951405,0.0007874772,0.0010412034,0.00033092446,0.0005207485,0.00055850705,0.00036023406,0.00038604482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016416406,0.0007329956,0.9333325,0.00033531987,0.001696988,0.0003580156,0.00025139845,0.000372886,0.004194202,0.00012720827,0.002680499,0.039501544],"study_design_scores_gemma":[0.0014611995,0.0044775195,0.9848807,0.000062771396,0.0013905019,0.001347828,0.00032652775,0.00059120107,0.0012666858,0.000081235325,0.0040799766,0.000033847653],"about_ca_topic_score_codex":0.0033017946,"about_ca_topic_score_gemma":0.0075505385,"teacher_disagreement_score":0.0033017946,"about_ca_system_score_codex":0.00049740024,"about_ca_system_score_gemma":0.0012992277,"threshold_uncertainty_score":0.013526022},"labels":[],"label_agreement":null},{"id":"W4313339834","doi":"10.1007/s13555-022-00879-8","title":"Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Janssen Biotech","keywords":"Plaque psoriasis; Psoriasis; Medicine; Dermatology","score_opus":0.012117338014736839,"score_gpt":0.23112417089595352,"score_spread":0.2190068328812167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313339834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905614,0.0011566568,0.00020416634,0.00023337484,0.000021617809,0.00018923274,0.005804394,0.000026432239,0.0018026589],"genre_scores_gemma":[0.9918576,0.00050472573,0.0004820303,0.00010892072,0.00004651704,0.0002605283,0.0065459874,0.000011932172,0.00018185657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99187475,0.0045946445,0.00091562484,0.00096687494,0.0013132818,0.0003348169],"domain_scores_gemma":[0.986241,0.003522736,0.007433572,0.000998419,0.0008613831,0.0009428414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008592855,0.00022107191,0.0010612877,0.00052163005,0.00042832724,0.0010831945,0.0006305261,0.0003598759,0.0013995757],"category_scores_gemma":[0.011440607,0.0002049547,0.0011852466,0.0012432892,0.00026116392,0.0006758042,0.00072303135,0.000752873,0.00039603494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017214822,0.0009832672,0.94674677,0.00036283958,0.0010353791,0.00011952747,0.0002753741,0.0007774535,0.00055121875,0.00012102054,0.0037885127,0.028023837],"study_design_scores_gemma":[0.0023344143,0.0045868116,0.98541796,0.00013177936,0.00096054794,0.00059210096,0.00036885144,0.0014561787,0.00047261725,0.00008594983,0.003549054,0.00004376102],"about_ca_topic_score_codex":0.004032704,"about_ca_topic_score_gemma":0.004802755,"teacher_disagreement_score":0.008592855,"about_ca_system_score_codex":0.000983657,"about_ca_system_score_gemma":0.0016611558,"threshold_uncertainty_score":0.045443952},"labels":[],"label_agreement":null},{"id":"W4316927819","doi":"10.1007/s13555-022-00883-y","title":"Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma; Sun Pharma; Mitsubishi Tanabe Pharma Corporation; Taiho Pharmaceutical; Celgene; Eisai; Sanofi; Amgen; Pfizer; Meiji Seika Pharma; Kyowa Hakko Kirin; LEO Pharma; Torii Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ustekinumab; Plaque psoriasis; Placebo; Medicine; Psoriasis; Dermatology; Internal medicine; Alternative medicine; Pathology; Disease","score_opus":0.013551954605158692,"score_gpt":0.2571772653719167,"score_spread":0.24362531076675803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316927819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991327,0.0055707386,0.00032307737,0.00026101846,0.000062778745,0.0011601357,0.0003464107,0.000041270137,0.0009075978],"genre_scores_gemma":[0.99174714,0.003354837,0.0013446332,0.0006974435,0.00013755655,0.001327818,0.000683217,0.000011850964,0.00069549604],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99940765,0.00032678276,0.00004517817,0.00006866646,0.0000775429,0.00007416038],"domain_scores_gemma":[0.9994398,0.000082808736,0.00013958012,0.00005803032,0.000057240806,0.00022248691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023721005,0.0008140183,0.0025132129,0.00020788409,0.0004757264,0.0006833897,0.00058710016,0.00074018247,0.0021583482],"category_scores_gemma":[0.000959134,0.000474089,0.0014197688,0.00038767842,0.0006941259,0.0004231419,0.00029791016,0.0016105061,0.00033836],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83392495,0.025251206,0.009551071,0.0032844914,0.0032043087,0.0002566578,0.00046621278,0.00064249476,0.042783022,0.00022831559,0.0023928443,0.07801444],"study_design_scores_gemma":[0.75859565,0.19810368,0.0334237,0.000115465904,0.0027224433,0.00037154916,0.000107397,0.00068869075,0.0025277815,0.00013347734,0.0031700567,0.00004018831],"about_ca_topic_score_codex":0.0011318463,"about_ca_topic_score_gemma":0.0024885575,"teacher_disagreement_score":0.0025132129,"about_ca_system_score_codex":0.0005282797,"about_ca_system_score_gemma":0.0013348318,"threshold_uncertainty_score":0.01254499},"labels":[],"label_agreement":null},{"id":"W4318914418","doi":"10.1007/s13555-023-00895-2","title":"Healthcare Provider Experience in Diagnosing and Treating Cutaneous T-Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Health care; Medicine; Lymphoma; Dermatology; Internal medicine; Political science","score_opus":0.037843031647061945,"score_gpt":0.3486308470208937,"score_spread":0.31078781537383177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318914418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902772,0.0012532447,0.0003480968,0.0032609096,0.00005316102,0.000040209485,0.00023447334,0.000017384866,0.0045154127],"genre_scores_gemma":[0.9976387,0.0007757271,0.0004497938,0.000758348,0.00003095454,0.00001202328,0.00010106409,0.0000043472073,0.00022904528],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9964316,0.0021348288,0.00031601207,0.00021564912,0.00050382613,0.00039802707],"domain_scores_gemma":[0.98069245,0.009297755,0.005730347,0.00031729098,0.0014364597,0.0025257315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020631815,0.00009480427,0.00015136201,0.00035150192,0.0007782914,0.0008658775,0.00030209255,0.00043250242,0.004488197],"category_scores_gemma":[0.016843872,0.00021022157,0.00020680427,0.00046486242,0.00037221378,0.00073045987,0.00080590695,0.0006169892,0.0003710724],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000097362186,0.00023377924,0.9478076,0.00025184732,0.000064803964,0.001129746,0.009330601,0.0002714961,0.00054607866,0.00013376173,0.0041715964,0.035961326],"study_design_scores_gemma":[0.000042567495,0.00074443535,0.9140507,0.00069439615,0.00007884238,0.009977163,0.0523764,0.0016810864,0.00070082926,0.00018076725,0.01942783,0.000044954617],"about_ca_topic_score_codex":0.010109756,"about_ca_topic_score_gemma":0.0113916835,"teacher_disagreement_score":0.010109756,"about_ca_system_score_codex":0.0010182317,"about_ca_system_score_gemma":0.0015144324,"threshold_uncertainty_score":0.020101786},"labels":[],"label_agreement":null},{"id":"W4323653185","doi":"10.1007/s13555-023-00913-3","title":"Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"AbbVie","keywords":"Medicine; Placebo; Adverse effect; Internal medicine; Randomized controlled trial; Discontinuation; Clinical endpoint","score_opus":0.026307948664639046,"score_gpt":0.33334590657781665,"score_spread":0.3070379579131776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323653185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96919227,0.012116866,0.0011475519,0.0011240016,0.0009287227,0.010281436,0.0018968051,0.00020325379,0.0031090816],"genre_scores_gemma":[0.9727686,0.0061642695,0.0025280311,0.0017331436,0.000966479,0.011002358,0.0015395455,0.000031560514,0.0032661236],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99920696,0.00042312001,0.00006417246,0.00014460439,0.00007502564,0.0000860746],"domain_scores_gemma":[0.9990088,0.00032128152,0.0002696899,0.00007156485,0.00009062585,0.00023794307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025544052,0.0016275987,0.0029682228,0.00037267854,0.00042698925,0.0011133914,0.00088627095,0.0019190566,0.007050871],"category_scores_gemma":[0.0018775826,0.0007623092,0.0020041552,0.0003438396,0.00094264385,0.00085144554,0.00032148373,0.0019992914,0.0009660987],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9804247,0.004887011,0.00039641926,0.0009333051,0.0007787462,0.000039202747,0.000038907503,0.0001757299,0.0024968241,0.00007942461,0.0006146045,0.009135133],"study_design_scores_gemma":[0.9724789,0.026000174,0.000570387,0.000026757427,0.0002465006,0.000018160576,0.000006575274,0.00015595692,0.00016625294,0.00003743673,0.00028719794,0.0000057577877],"about_ca_topic_score_codex":0.00045636247,"about_ca_topic_score_gemma":0.0009578956,"teacher_disagreement_score":0.007050871,"about_ca_system_score_codex":0.000586466,"about_ca_system_score_gemma":0.0013371559,"threshold_uncertainty_score":0.023587525},"labels":[],"label_agreement":null},{"id":"W4324324651","doi":"10.1007/s13555-022-00850-7","title":"Similarities and Differences in the Perception of Atopic Dermatitis Burden Between Patients, Caregivers, and Independent Physicians (AD-GAP Survey)","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Atopic dermatitis; Medicine; Perception; Dermatology; Family medicine; Psychology","score_opus":0.029108896522085082,"score_gpt":0.26912485975688044,"score_spread":0.24001596323479535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324324651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992105,0.00013195741,0.00003041969,0.00004885643,0.000002890299,0.000011410115,0.00022789609,0.0000015232577,0.00033450732],"genre_scores_gemma":[0.9995485,0.00006393388,0.000063726126,0.000026088952,0.0000031854493,0.000015921962,0.0002222776,6.6219195e-7,0.00005569105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982376,0.0006928335,0.0002694755,0.00016525718,0.00041056148,0.00022419468],"domain_scores_gemma":[0.99485093,0.0013626057,0.0023732162,0.00014273933,0.00054943055,0.0007210484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026785478,0.00017496475,0.00034781353,0.0009496368,0.00033507944,0.00065587414,0.00026847926,0.0003131832,0.0012151847],"category_scores_gemma":[0.006239733,0.0001593726,0.00040420413,0.00079374464,0.00030615783,0.0006317391,0.0011123064,0.00037245374,0.00014338327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006138107,0.000033525488,0.9951652,0.000029608242,0.000035466583,0.000055740336,0.0016471235,0.000027387849,0.00009833628,0.0000132844025,0.00020869632,0.0026243033],"study_design_scores_gemma":[0.0000066491652,0.00008588636,0.9966539,0.000012720574,0.000008476567,0.00018318667,0.0026910757,0.000058362715,0.000036179947,0.000009857964,0.00025016523,0.0000034407399],"about_ca_topic_score_codex":0.002575347,"about_ca_topic_score_gemma":0.0036534583,"teacher_disagreement_score":0.0026785478,"about_ca_system_score_codex":0.00048160268,"about_ca_system_score_gemma":0.00039158756,"threshold_uncertainty_score":0.01416564},"labels":[],"label_agreement":null},{"id":"W4327676480","doi":"10.1007/s13555-023-00910-6","title":"Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Secukinumab; Medicine; Discontinuation; Ixekizumab; Adalimumab; Psoriasis; Psoriasis Area and Severity Index; Psoriatic arthritis; Ustekinumab; Cohort; Dermatology; Internal medicine; Pediatrics; Rheumatoid arthritis","score_opus":0.022863082856469093,"score_gpt":0.2595506901935598,"score_spread":0.2366876073370907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327676480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99004096,0.0042046383,0.00020099143,0.00077491725,0.00002941648,0.000017908995,0.0025372722,0.000012135133,0.0021818788],"genre_scores_gemma":[0.99701595,0.00073659443,0.00008067845,0.0002271333,0.000041867523,0.000013367698,0.0015853505,0.000003229496,0.0002958862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99923706,0.00020518579,0.0000831113,0.00014689917,0.00022492952,0.00010285991],"domain_scores_gemma":[0.99746823,0.00042020952,0.0014039301,0.00008988336,0.00027433236,0.00034337817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011694138,0.00008924886,0.0002168484,0.00043877424,0.00023572304,0.00065406674,0.0001841273,0.00020763765,0.0012802088],"category_scores_gemma":[0.0023013502,0.000079282996,0.00042399668,0.0011151247,0.00018732993,0.00027845489,0.00028321077,0.000515099,0.00015390306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021389674,0.00023890779,0.95685476,0.000090149406,0.0003683278,0.000116894305,0.000095831936,0.00019019346,0.00041646755,0.00011632981,0.003071393,0.036301803],"study_design_scores_gemma":[0.00014546899,0.00043218303,0.9944593,0.00005931949,0.00022753607,0.00028392195,0.00010413576,0.00045604116,0.00024568872,0.00007879335,0.0035009398,0.0000067520486],"about_ca_topic_score_codex":0.011340582,"about_ca_topic_score_gemma":0.016290003,"teacher_disagreement_score":0.011340582,"about_ca_system_score_codex":0.00086815143,"about_ca_system_score_gemma":0.00073959376,"threshold_uncertainty_score":0.022549152},"labels":[],"label_agreement":null},{"id":"W4327676963","doi":"10.1007/s13555-023-00905-3","title":"Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Lynde Centre for Dermatology; University of Toronto; University of Alberta; BC Children's Hospital; Dalhousie University; SKiN Health; McMaster University; Juravinski Cancer Centre; BC Cancer Agency; Dermatrials Research; Ottawa Hospital; Probity Medical Research; University of British Columbia; University of Ottawa","funders":"Sun Pharma; AbbVie; AbbVie Canada; LEO Pharma; Janssen Canada; Novartis; Amgen Canada; Amgen","keywords":"Psoriasis; Medicine; Systemic therapy; Malignancy; Population; Intensive care medicine; Immunosuppression; Disease; Cancer; Dermatology; Internal medicine; Breast cancer","score_opus":0.05779641493854979,"score_gpt":0.26736302212177254,"score_spread":0.20956660718322276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327676963","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.050618593,0.03434984,0.7798659,0.07739721,0.00079431944,0.009361648,0.010583471,0.0012132927,0.035815805],"genre_scores_gemma":[0.30239382,0.008097671,0.6725895,0.007176764,0.000572988,0.0030848377,0.0050394027,0.00012822478,0.0009168537],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.8652035,0.10748647,0.014299873,0.005042198,0.0069120256,0.0010558716],"domain_scores_gemma":[0.5453194,0.40983203,0.012401872,0.0072969696,0.02254972,0.0025999965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.16390988,0.0017329166,0.002945027,0.0072486065,0.0013875444,0.0045859595,0.0042413557,0.0039926935,0.0059790034],"category_scores_gemma":[0.29501912,0.0011537645,0.005771506,0.0030096679,0.0014063168,0.0031058695,0.0052035,0.0045286985,0.0016187215],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030987258,0.0006565357,0.07102345,0.035320748,0.006761852,0.0033480476,0.0105384,0.12199477,0.004050873,0.03632563,0.08861953,0.61826146],"study_design_scores_gemma":[0.0029778078,0.0012528796,0.033771858,0.06589434,0.014148586,0.002275824,0.00489335,0.3677651,0.0072168657,0.267411,0.23142692,0.0009654539],"about_ca_topic_score_codex":0.0069516846,"about_ca_topic_score_gemma":0.013032133,"teacher_disagreement_score":0.16390988,"about_ca_system_score_codex":0.003921445,"about_ca_system_score_gemma":0.014224029,"threshold_uncertainty_score":0.8668487},"labels":[],"label_agreement":null},{"id":"W4380730064","doi":"10.1007/s13555-023-00942-y","title":"Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"LEO Pharma; Allergan; Argenx; Sanofi Genzyme; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; Celgene; Sanofi; Galderma; Ortho Dermatologics; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer; National Psoriasis Foundation; Amgen","keywords":"Eczema Area and Severity Index; Medicine; Discontinuation; Atopic dermatitis; Adverse effect; Dermatology Life Quality Index; Clinical endpoint; Internal medicine; Body surface area; Quality of life (healthcare); Clinical trial; Dermatology; Disease","score_opus":0.029611087225123456,"score_gpt":0.3179160238496889,"score_spread":0.28830493662456547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380730064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968178,0.001070975,0.00026291414,0.00012149278,0.000030518226,0.0007735425,0.00037598793,0.000022464841,0.0005241463],"genre_scores_gemma":[0.9954568,0.00081668276,0.0009627703,0.0006147672,0.00006407432,0.00087864115,0.0006660179,0.000009808112,0.00053029816],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995658,0.00020537645,0.000032329313,0.00006968928,0.00006476864,0.000062021834],"domain_scores_gemma":[0.9990126,0.00019545299,0.00024304113,0.00007464418,0.00010679404,0.00036739488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018062786,0.0005631743,0.0013666918,0.00015966038,0.000353956,0.0006170609,0.00037888216,0.00071290816,0.0016257146],"category_scores_gemma":[0.0010012677,0.00027552462,0.0013573497,0.00016976052,0.00040166843,0.00054040266,0.00024461898,0.0021060368,0.00039908505],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5172659,0.12198485,0.0909801,0.0018966305,0.0028457127,0.0009988933,0.0011049609,0.0022346512,0.0792444,0.0003542553,0.0065244166,0.17456515],"study_design_scores_gemma":[0.25597477,0.6026167,0.12712607,0.00013523361,0.00083044707,0.0012287606,0.00023828108,0.0022860556,0.004618043,0.0002010558,0.004690067,0.000054462438],"about_ca_topic_score_codex":0.00047987714,"about_ca_topic_score_gemma":0.0016118813,"teacher_disagreement_score":0.0018062786,"about_ca_system_score_codex":0.0004352097,"about_ca_system_score_gemma":0.0008810418,"threshold_uncertainty_score":0.009552598},"labels":[],"label_agreement":null},{"id":"W4383302158","doi":"10.1007/s13555-023-00950-y","title":"Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel","year":2023,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lynde Centre for Dermatology; University of Alberta; BC Children's Hospital; Toronto General Hospital; McMaster University; SKiN Health; Probity Medical Research; University of British Columbia; University Health Network; Ottawa Hospital; Dermatrials Research; University of Ottawa; Centre de Recherche Dermatologique du Québec Métropolitain; Innovaderm (Canada)","funders":"","keywords":"Psoriasis; Multidisciplinary approach; Inference; Human immunodeficiency virus (HIV); Medicine; Intensive care medicine; Computer science; Dermatology; Artificial intelligence; Family medicine; Sociology","score_opus":0.03847214964924443,"score_gpt":0.2729562787058102,"score_spread":0.23448412905656574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383302158","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008598391,0.0012440782,0.0013018762,0.12189979,0.8662997,0.0000739337,0.003257479,0.00032078207,0.0055163535],"genre_scores_gemma":[0.009132648,0.0103699155,0.016894754,0.29545766,0.479123,0.00067980075,0.0056820824,0.0025544267,0.18010575],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99412584,0.001717827,0.0013802963,0.0005480706,0.0018254357,0.0004026113],"domain_scores_gemma":[0.941648,0.02593752,0.0025592993,0.0021847985,0.025721963,0.0019484889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076021776,0.002008162,0.0023326543,0.0028618565,0.0022272768,0.004114925,0.003111674,0.008259755,0.08061763],"category_scores_gemma":[0.1244189,0.001286972,0.0019741284,0.0017888373,0.0021971734,0.002179548,0.0016641731,0.0156194065,0.03653443],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017631126,0.000003546869,0.000038746053,0.000105500825,0.000008236516,0.00006294961,0.000013968267,0.000030500452,0.000008360887,0.00031379022,0.9962458,0.0031509004],"study_design_scores_gemma":[0.00012468886,0.000013386037,0.00057291624,0.0011685619,0.000051391453,0.00036228212,0.000076859535,0.00027795497,0.00015265807,0.0018828147,0.99528366,0.00003270626],"about_ca_topic_score_codex":0.028221086,"about_ca_topic_score_gemma":0.03725971,"teacher_disagreement_score":0.08061763,"about_ca_system_score_codex":0.003730095,"about_ca_system_score_gemma":0.008919708,"threshold_uncertainty_score":0.26969284},"labels":[],"label_agreement":null},{"id":"W4383302909","doi":"10.1007/s13555-023-00949-5","title":"Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel","year":2023,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Lynde Centre for Dermatology; University of Toronto; University of Alberta; BC Children's Hospital; Dalhousie University; SKiN Health; McMaster University; Juravinski Cancer Centre; BC Cancer Agency; Dermatrials Research; Ottawa Hospital; Probity Medical Research; University of British Columbia; University of Ottawa","funders":"","keywords":"Inference; Psoriasis; Multidisciplinary approach; Medicine; Intensive care medicine; Medical physics; Computer science; Dermatology; Artificial intelligence","score_opus":0.26335187940229954,"score_gpt":0.38045325279385916,"score_spread":0.11710137339155963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383302909","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000115304225,0.0010111653,0.0010806165,0.09723109,0.88407254,0.00009596011,0.010900182,0.00038115296,0.005112024],"genre_scores_gemma":[0.011957717,0.00752937,0.014845035,0.23569193,0.50245476,0.0011249504,0.0158496,0.0027614576,0.20778519],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99122566,0.0020794147,0.0023392586,0.00080561475,0.002857208,0.0006928312],"domain_scores_gemma":[0.91525835,0.03431171,0.0051326104,0.0038169343,0.038659446,0.002820954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008864356,0.0025410785,0.0032839333,0.0040197605,0.0018535232,0.0046259733,0.0038238713,0.009239968,0.094412185],"category_scores_gemma":[0.15398155,0.0016024718,0.0027499397,0.0030948927,0.001730368,0.0023440665,0.0016928818,0.015013719,0.047729626],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021565751,0.0000041012845,0.00005356463,0.000100334786,0.000010828068,0.000039759223,0.000007013778,0.00003438332,0.0000055586033,0.00018673902,0.99721044,0.0023257397],"study_design_scores_gemma":[0.00035742816,0.000022230975,0.002121225,0.0017253143,0.00009377978,0.00035960265,0.000077312085,0.000554589,0.00020854466,0.002815338,0.99160284,0.00006175289],"about_ca_topic_score_codex":0.03872374,"about_ca_topic_score_gemma":0.049859248,"teacher_disagreement_score":0.094412185,"about_ca_system_score_codex":0.004456496,"about_ca_system_score_gemma":0.0092681665,"threshold_uncertainty_score":0.31584018},"labels":[],"label_agreement":null},{"id":"W4385073537","doi":"10.1007/s13555-023-00980-6","title":"Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; LEO Pharma; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Janssen Pharmaceuticals; Gilead Sciences; Union Chimique Belge; Sanofi; Amgen; Pfizer; GlaxoSmithKline","keywords":"Atopic dermatitis; Ethnic group; Medicine; Dermatology; Political science","score_opus":0.057398201719399536,"score_gpt":0.31788014163360145,"score_spread":0.26048193991420193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385073537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98985857,0.0003610464,0.00008634768,0.00019456413,0.0000056573535,0.000022962926,0.0082049435,0.000007675773,0.0012582651],"genre_scores_gemma":[0.99670935,0.00019810817,0.0000973678,0.000077610166,0.000004422117,0.0000142670115,0.0027163995,0.0000024830422,0.00017994741],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992378,0.00010815592,0.0000703022,0.00013219453,0.00027282603,0.0001787922],"domain_scores_gemma":[0.9985091,0.00012721175,0.000570229,0.000086403685,0.000460569,0.00024646395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000642846,0.00015859236,0.0002340961,0.0007454711,0.0007875046,0.0005801119,0.00049596385,0.00022075447,0.0013818115],"category_scores_gemma":[0.0018896007,0.0001688484,0.00030478818,0.002192297,0.00030290236,0.00027527806,0.00042004592,0.00043570116,0.00018852636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022568487,0.000009450713,0.99880254,0.000006794991,0.000020686006,0.000012834743,0.000050622486,0.00002201111,0.000028779663,0.00001369877,0.0003231919,0.00068691536],"study_design_scores_gemma":[0.0000035151681,0.000007691904,0.999244,0.000008898614,0.0000125416045,0.000046570658,0.0002845625,0.00009448982,0.000021336245,0.000008170852,0.0002656348,0.0000025585907],"about_ca_topic_score_codex":0.8593163,"about_ca_topic_score_gemma":0.88032037,"teacher_disagreement_score":0.14068371,"about_ca_system_score_codex":0.0037910577,"about_ca_system_score_gemma":0.0042752074,"threshold_uncertainty_score":0.28302443},"labels":[],"label_agreement":null},{"id":"W4385155802","doi":"10.1007/s13555-023-00948-6","title":"Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice","year":2023,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Queen's University","funders":"Pfizer","keywords":"JADE (particle detector); Medicine; Tolerability; Atopic dermatitis; Clinical Practice; Expert opinion; Regimen; Dermatology; Adverse effect; Intensive care medicine; Internal medicine; Family medicine","score_opus":0.12393620639195801,"score_gpt":0.4554051293645459,"score_spread":0.3314689229725879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385155802","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014529793,0.9976597,0.00012472871,0.00086361397,0.00019834888,0.000021775086,0.000050327195,0.0000058912874,0.00093036087],"genre_scores_gemma":[0.0012668759,0.99708456,0.000265807,0.00082428614,0.0001692412,0.00002867941,0.000060562044,0.000002524786,0.00029746836],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99904436,0.00026220718,0.0002375305,0.00011068403,0.00031432285,0.00003098376],"domain_scores_gemma":[0.9980367,0.0010811315,0.00034829116,0.000029825815,0.0004525213,0.0000517132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018381788,0.00048311075,0.0014807831,0.0016884048,0.00028330527,0.001161805,0.00093598844,0.0011036084,0.0048548137],"category_scores_gemma":[0.0037853029,0.0002987381,0.0013979924,0.0016203508,0.00039451374,0.0010899606,0.00046214476,0.0013648662,0.0013284133],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016917441,0.00005892709,0.00020221881,0.06937261,0.00032895978,0.000120253004,0.00008279233,0.00016766254,0.0007858707,0.0012555472,0.0382473,0.8892086],"study_design_scores_gemma":[0.00026581224,0.0003307063,0.0017694767,0.06809519,0.0016067668,0.0014026402,0.00012008814,0.00018744546,0.0004219591,0.0020289395,0.9237312,0.000039802064],"about_ca_topic_score_codex":0.0012380359,"about_ca_topic_score_gemma":0.003484401,"teacher_disagreement_score":0.0048548137,"about_ca_system_score_codex":0.0005822451,"about_ca_system_score_gemma":0.0015965825,"threshold_uncertainty_score":0.016241014},"labels":[],"label_agreement":null},{"id":"W4385429790","doi":"10.1007/s13555-023-00977-1","title":"Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; LEO Pharma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Genentech; Valeant Pharmaceuticals International; Sanofi; GlaxoSmithKline; Pfizer; Kyowa Hakko Kirin","keywords":"Adalimumab; Plaque psoriasis; Psoriasis; Term (time); Medicine; Internal medicine; Matching (statistics); Dermatology; Pathology; Disease; Physics","score_opus":0.05121365840193167,"score_gpt":0.3044505649306275,"score_spread":0.25323690652869585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385429790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820363,0.006567525,0.0037127456,0.00027768433,0.0007297278,0.0018246396,0.0018254498,0.00008990655,0.0029360713],"genre_scores_gemma":[0.99332315,0.0006144361,0.0022753342,0.0002630449,0.00012667627,0.0013591929,0.00081528403,0.000014183843,0.0012087518],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9896763,0.007576569,0.00075927284,0.0008596533,0.00066260615,0.00046562843],"domain_scores_gemma":[0.9912076,0.0050772256,0.001810944,0.0010464591,0.00046312326,0.00039470303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009921545,0.0014970496,0.0032645466,0.0005651232,0.0003035942,0.0011210633,0.0012822308,0.0015585433,0.007368814],"category_scores_gemma":[0.017460719,0.0006028196,0.007600667,0.0004845215,0.00062641385,0.0010274157,0.0012290722,0.0022965993,0.0005973735],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92849565,0.0026538821,0.005849585,0.0019301474,0.028203515,0.000051381434,0.00012217338,0.003116528,0.0012741641,0.00064508343,0.0007338853,0.026924],"study_design_scores_gemma":[0.5019237,0.30842802,0.0685007,0.0007501365,0.084622085,0.00032831694,0.0002738031,0.020053718,0.004626974,0.0041668867,0.0061034136,0.00022233135],"about_ca_topic_score_codex":0.001460431,"about_ca_topic_score_gemma":0.0014004175,"teacher_disagreement_score":0.009921545,"about_ca_system_score_codex":0.001022925,"about_ca_system_score_gemma":0.0009805813,"threshold_uncertainty_score":0.052470803},"labels":[],"label_agreement":null},{"id":"W4386332794","doi":"10.1007/s13555-023-01007-w","title":"Causal Associations Between Gut Microbiota and Psoriasis: A Mendelian Randomization Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Natural Science Foundation of China","keywords":"Mendelian randomization; Psoriasis; Odds ratio; Medicine; Internal medicine; Genome-wide association study; Observational study; Genetics; Single-nucleotide polymorphism; Biology; Dermatology; Gene; Genotype","score_opus":0.02638600789472362,"score_gpt":0.2723551934737127,"score_spread":0.24596918557898906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386332794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5209634,0.010638652,0.45284447,0.002586374,0.0011226234,0.0028330781,0.0033069279,0.0012290637,0.0044755237],"genre_scores_gemma":[0.9289752,0.0008322067,0.065486886,0.0006933429,0.00023808559,0.0016798624,0.00091947144,0.0001807143,0.0009941049],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9010954,0.07196808,0.0041175713,0.016041921,0.0051715504,0.0016053903],"domain_scores_gemma":[0.9110734,0.06395078,0.006928674,0.015398934,0.0019192996,0.00072892284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06512612,0.0013441585,0.0031358984,0.0015091304,0.001123146,0.0018056836,0.0019263147,0.002062883,0.007670272],"category_scores_gemma":[0.12358145,0.00079824607,0.0058721295,0.0022739982,0.0018333861,0.001273101,0.0012721017,0.0021000348,0.00052572513],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067213066,0.0013079116,0.54071695,0.0046967855,0.103994966,0.009937193,0.002393011,0.016176188,0.010637279,0.0816246,0.015100991,0.14620103],"study_design_scores_gemma":[0.022750001,0.01625188,0.29986364,0.0018281578,0.124956325,0.018185167,0.0011843134,0.29995316,0.007092199,0.16318932,0.043973945,0.00077189645],"about_ca_topic_score_codex":0.0023391896,"about_ca_topic_score_gemma":0.0012914244,"teacher_disagreement_score":0.06512612,"about_ca_system_score_codex":0.00067040866,"about_ca_system_score_gemma":0.0013148003,"threshold_uncertainty_score":0.34442395},"labels":[],"label_agreement":null},{"id":"W4386350153","doi":"10.1007/s13555-023-01000-3","title":"Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"AbbVie","keywords":"Atopic dermatitis; Medicine; Meta-analysis; Dermatology; Internal medicine","score_opus":0.06894312748235608,"score_gpt":0.3402872439910531,"score_spread":0.271344116508697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386350153","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031999562,0.95250404,0.0052352306,0.0012300779,0.00076673186,0.0005747095,0.005626723,0.00019986532,0.0018631077],"genre_scores_gemma":[0.77181464,0.20494325,0.009828621,0.0031747194,0.0008470101,0.0018684183,0.0062384526,0.00024642702,0.0010384716],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97878987,0.013624199,0.0032200965,0.0023819534,0.0016026848,0.00038121088],"domain_scores_gemma":[0.9707146,0.02323743,0.0027862939,0.0016982324,0.0012739173,0.0002895355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02703092,0.0028064463,0.01253791,0.0042273058,0.00039708515,0.0030642424,0.0020026756,0.0015321121,0.00423335],"category_scores_gemma":[0.036818817,0.0011045161,0.046437543,0.004084181,0.00050038425,0.0017600291,0.0013747318,0.001866807,0.00037220793],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045978925,0.000016719056,0.0061082733,0.029028822,0.9513709,0.00004758716,0.000030027591,0.00097204023,0.0002016583,0.00016242548,0.00081902836,0.0066446066],"study_design_scores_gemma":[0.0013974303,0.0002045694,0.0046389853,0.0018906033,0.98912,0.00005482207,0.00001820034,0.000526373,0.00009344662,0.0004631201,0.0015720957,0.000020352862],"about_ca_topic_score_codex":0.0044598565,"about_ca_topic_score_gemma":0.0065484876,"teacher_disagreement_score":0.02703092,"about_ca_system_score_codex":0.0015106379,"about_ca_system_score_gemma":0.0015578736,"threshold_uncertainty_score":0.14295483},"labels":[],"label_agreement":null},{"id":"W4386884687","doi":"10.1007/s13555-023-01002-1","title":"Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Boehringer Ingelheim","keywords":"Medicine; Placebo; Clinical endpoint; Tolerability; Adverse effect; Palmoplantar pustulosis; Internal medicine; Dosing; Confidence interval; Randomized controlled trial; Gastroenterology; Psoriasis; Dermatology","score_opus":0.022892398002283324,"score_gpt":0.27479690215286845,"score_spread":0.25190450415058513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386884687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853389,0.009574124,0.00085674645,0.0004820256,0.00016880975,0.0017038552,0.00042430937,0.000093238494,0.0013580301],"genre_scores_gemma":[0.9926777,0.0024192422,0.0011016498,0.00092221453,0.00030476475,0.00092179823,0.0006744647,0.000012550599,0.0009656134],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988312,0.00068013906,0.00012418212,0.0001244732,0.00012244096,0.000117571464],"domain_scores_gemma":[0.9989249,0.00028268484,0.0003064079,0.00009034745,0.00010308876,0.00029254606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033398597,0.00134322,0.0030579038,0.00038553454,0.0003134105,0.0008404908,0.0007216154,0.0017418517,0.0032961627],"category_scores_gemma":[0.0018568337,0.0006349803,0.002571159,0.0004218613,0.00069534074,0.0008527982,0.00030419335,0.0018315922,0.0007735205],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8723629,0.013279579,0.0036532742,0.0017809944,0.0023631149,0.00025596432,0.00018280721,0.0010869986,0.034323998,0.00014367845,0.0013521119,0.06921453],"study_design_scores_gemma":[0.67293584,0.31214285,0.009993115,0.000054978747,0.00082999334,0.00028962444,0.000031331983,0.00072213536,0.0014092799,0.00012724075,0.0014349117,0.000028773567],"about_ca_topic_score_codex":0.00023141883,"about_ca_topic_score_gemma":0.00045567434,"teacher_disagreement_score":0.0033398597,"about_ca_system_score_codex":0.0004147512,"about_ca_system_score_gemma":0.000701018,"threshold_uncertainty_score":0.017663062},"labels":[],"label_agreement":null},{"id":"W4386981197","doi":"10.1007/s13555-023-01035-6","title":"Efficacy and Tolerability of a Novel Topical Treatment Containing Pea Protein and Xyloglucan in the Management of Atopic Dermatitis in Children: A Prospective, Multicenter Clinical Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Tolerability; SCORAD; Medicine; Atopic dermatitis; Internal medicine; Adverse effect; Gastroenterology; Eczema Area and Severity Index; Prospective cohort study; Dermatology; Disease; Dermatology Life Quality Index","score_opus":0.03321193788164409,"score_gpt":0.34616846948883384,"score_spread":0.3129565316071897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386981197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99801034,0.0013801025,0.00008856666,0.000024899004,0.000011492784,0.00024227086,0.00011503097,0.000005138876,0.00012218446],"genre_scores_gemma":[0.99775285,0.00093145313,0.00042137678,0.00008677459,0.000076371616,0.0003136876,0.00028593847,0.0000027602719,0.0001288698],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99912876,0.00042700666,0.00007086241,0.00016438053,0.000121401994,0.00008766752],"domain_scores_gemma":[0.9988024,0.00020476196,0.0004217971,0.00008633252,0.0001028542,0.0003817654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019804114,0.000977194,0.0018887357,0.00031486244,0.00038991135,0.0005495001,0.0005597168,0.0008187231,0.0011611107],"category_scores_gemma":[0.0010318933,0.00036083677,0.0012331664,0.00047279964,0.0009371758,0.0006421813,0.000295464,0.0012909466,0.00022055526],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63814604,0.09013022,0.12758161,0.0022141896,0.0037544211,0.0009310669,0.00077962154,0.0012829581,0.062781624,0.00014133738,0.0008189905,0.07143788],"study_design_scores_gemma":[0.07122503,0.801029,0.12072314,0.00005891076,0.0011441095,0.0008551391,0.00019199307,0.0003978096,0.0033166409,0.00003188899,0.0009956305,0.000030776217],"about_ca_topic_score_codex":0.00046721668,"about_ca_topic_score_gemma":0.0008085122,"teacher_disagreement_score":0.0019804114,"about_ca_system_score_codex":0.0005727382,"about_ca_system_score_gemma":0.0007053407,"threshold_uncertainty_score":0.010473549},"labels":[],"label_agreement":null},{"id":"W4387060869","doi":"10.1007/s13555-023-01017-8","title":"Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA","year":2023,"lang":"en","type":"letter","venue":"Dermatology and Therapy","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Secukinumab; Discontinuation; Ixekizumab; Medicine; Adalimumab; Psoriasis; Dermatology; Dosing; Internal medicine; Psoriatic arthritis","score_opus":0.15795601982015503,"score_gpt":0.3788201942551079,"score_spread":0.22086417443495285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387060869","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005214222,0.00064217177,0.00009520408,0.9743634,0.023159433,0.000015227323,0.0001108633,0.0000317381,0.0010606202],"genre_scores_gemma":[0.005999016,0.000771715,0.00030684317,0.9292948,0.0597106,0.000045064957,0.000047159752,0.000041732404,0.0037829294],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966608,0.0010255993,0.0005639853,0.00050428044,0.00088998943,0.00035534013],"domain_scores_gemma":[0.9864694,0.0072735013,0.00091164,0.00033558172,0.0032727367,0.0017372617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004275506,0.0007269082,0.0019459893,0.00074360264,0.0024098128,0.0027184463,0.0020960753,0.034488257,0.004853367],"category_scores_gemma":[0.028075205,0.00061534136,0.0012249803,0.0010498441,0.001554293,0.0026387423,0.0008136472,0.028751366,0.0041684685],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054420616,0.000037377853,0.000626218,0.00005226726,0.000014143924,0.0011119151,0.00006612156,0.00004667355,0.00008185349,0.00047780725,0.99313825,0.004292837],"study_design_scores_gemma":[0.00025044256,0.00018215721,0.0046562566,0.0007652524,0.00008616791,0.0053762957,0.0006990298,0.0016705734,0.00056792446,0.0050715874,0.9805406,0.00013374665],"about_ca_topic_score_codex":0.004311446,"about_ca_topic_score_gemma":0.0069280434,"teacher_disagreement_score":0.034488257,"about_ca_system_score_codex":0.0035926192,"about_ca_system_score_gemma":0.0041629635,"threshold_uncertainty_score":0.026066422},"labels":[],"label_agreement":null},{"id":"W4387637030","doi":"10.1007/s13555-023-01049-0","title":"Microneedling with a Novel, n-3-PUFA-Rich Formulation Accelerates Inflammation Resolution to Improve Skin Recovery Outcomes in Adults with Healthy Skin","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Advancements in Transdermal Drug Delivery","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Medical Association","funders":"","keywords":"Erythema; Hyaluronic acid; Medicine; Dermatology; Inflammation; Human skin; Wound healing; Surgery; Internal medicine","score_opus":0.04599631668778354,"score_gpt":0.3712524305762064,"score_spread":0.32525611388842285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387637030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981823,0.000976709,0.00036073633,0.000035847785,0.000026062587,0.0001585587,0.000040304978,0.000014097467,0.00020550647],"genre_scores_gemma":[0.9952791,0.0008548779,0.0024274695,0.00008671295,0.000027292912,0.00020876639,0.00006325955,0.000004973989,0.0010475082],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99990046,0.000019693747,0.000009837633,0.000027372378,0.000028389411,0.000014191951],"domain_scores_gemma":[0.9998965,0.000020877931,0.00003968765,0.0000056588638,0.000014192938,0.000023015979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034239414,0.00023139258,0.00042964955,0.00015460866,0.00013131773,0.00014981012,0.00018611216,0.00029675502,0.0018062149],"category_scores_gemma":[0.00023761195,0.00009060018,0.0002343708,0.000072726274,0.0001238718,0.00019885787,0.0001519678,0.00030645775,0.00015412261],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049283046,0.014672853,0.004774038,0.0013305675,0.00017272242,0.00016073359,0.00017506118,0.00012443554,0.83434117,0.00008474694,0.0004323904,0.094448246],"study_design_scores_gemma":[0.013246657,0.66163695,0.083725624,0.00015978426,0.00051806454,0.0011148375,0.00031715012,0.0010628818,0.23372923,0.00010807977,0.00435265,0.00002807864],"about_ca_topic_score_codex":0.00020698358,"about_ca_topic_score_gemma":0.0005191111,"teacher_disagreement_score":0.0018062149,"about_ca_system_score_codex":0.00011259138,"about_ca_system_score_gemma":0.00013295392,"threshold_uncertainty_score":0.006042421},"labels":[],"label_agreement":null},{"id":"W4387653887","doi":"10.1007/s13555-023-01042-7","title":"Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Bausch Health; Sun Pharma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Galderma; Incyte; Les Laboratories Pierre Fabre; Valeant Pharmaceuticals International; Amgen; Pfizer","keywords":"Acne; Medicine; Scars; Lesion; Adverse effect; Incidence (geometry); Dermatology; Internal medicine; Acne scars; Gastroenterology; Surgery","score_opus":0.03201773447421207,"score_gpt":0.34535312270904195,"score_spread":0.31333538823482987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387653887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98287547,0.010168476,0.0010540514,0.00029284612,0.00017729639,0.0036403898,0.0006863614,0.00014782,0.0009573243],"genre_scores_gemma":[0.9792843,0.010340638,0.0023378269,0.0005877576,0.00037763067,0.0038091438,0.0011791538,0.000041329295,0.0020421199],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991061,0.00046912412,0.00008479949,0.000111975256,0.00011663011,0.00011135632],"domain_scores_gemma":[0.9986505,0.00043997893,0.00036639883,0.00013616699,0.00019231156,0.0002146592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026332901,0.0008799512,0.0026909283,0.0005446118,0.0003633879,0.0006815123,0.0009139712,0.0014028817,0.0042550676],"category_scores_gemma":[0.0019433625,0.0004240749,0.0016671703,0.00045179573,0.00079443364,0.00063334417,0.00019955458,0.0012384552,0.0006395202],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82385945,0.04899241,0.002256633,0.0034486272,0.0027519288,0.00019036056,0.00018244036,0.00041350877,0.041541077,0.0000827311,0.0011527331,0.07512812],"study_design_scores_gemma":[0.5724178,0.41177735,0.010120644,0.00012887066,0.0014337039,0.00018267927,0.000071300456,0.00033566545,0.0021437076,0.0000736967,0.0012889702,0.000025751573],"about_ca_topic_score_codex":0.00054926006,"about_ca_topic_score_gemma":0.001109325,"teacher_disagreement_score":0.0042550676,"about_ca_system_score_codex":0.00029753748,"about_ca_system_score_gemma":0.00063223904,"threshold_uncertainty_score":0.014234602},"labels":[],"label_agreement":null},{"id":"W4388341603","doi":"10.1007/s13555-023-01054-3","title":"Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review","year":2023,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University","funders":"Novo Nordisk Fonden; Lundbeckfonden","keywords":"Atopic dermatitis; Medicine; Psoriasis; Narrative review; Dermatology; Immunology; Pharmacology; Intensive care medicine","score_opus":0.09997692723435789,"score_gpt":0.3631811042809679,"score_spread":0.26320417704661003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388341603","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013210595,0.9984358,0.00010441544,0.00022768161,0.00019148758,0.00000995108,0.000039936644,0.0000065316876,0.00085196097],"genre_scores_gemma":[0.0005274254,0.9984376,0.0001784052,0.00022890276,0.000109460256,0.000009852963,0.000048496597,0.0000013167664,0.00045851924],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998667,0.000018807119,0.000024015979,0.000027666356,0.000048351074,0.00001437572],"domain_scores_gemma":[0.99974257,0.00013756649,0.00004243102,0.0000055410583,0.000053159856,0.000018780212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004625899,0.000709918,0.0011133081,0.0018733114,0.00021981374,0.00083665975,0.0006609556,0.0006628525,0.0058824127],"category_scores_gemma":[0.00067448773,0.0002362678,0.0007555291,0.001569927,0.00020792414,0.0009511871,0.0005121617,0.001345877,0.0016670084],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000110975045,0.000073858086,0.0001638668,0.051070664,0.00019930942,0.00022397058,0.00007797607,0.00035550882,0.0016341734,0.0032609215,0.039676387,0.90315235],"study_design_scores_gemma":[0.000037602087,0.00012421637,0.00062940817,0.009745494,0.00033251676,0.0011796396,0.000053352545,0.0001020508,0.00037289047,0.0011507845,0.9862546,0.000017466511],"about_ca_topic_score_codex":0.0008326724,"about_ca_topic_score_gemma":0.0020191253,"teacher_disagreement_score":0.0058824127,"about_ca_system_score_codex":0.00041702527,"about_ca_system_score_gemma":0.0010770732,"threshold_uncertainty_score":0.019678652},"labels":[],"label_agreement":null},{"id":"W4388539637","doi":"10.1007/s13555-023-01059-y","title":"Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Pembrolizumab; Quality of life (healthcare); Cohort; Confidence interval; Internal medicine; Interim analysis; Cohort study; Physical therapy; Oncology; Cancer; Clinical trial","score_opus":0.026956228862862187,"score_gpt":0.29670510977548353,"score_spread":0.26974888091262134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388539637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980757,0.00080790825,0.000104726576,0.00008896441,0.0000051212382,0.00006524325,0.00022544872,0.00000955339,0.0006173146],"genre_scores_gemma":[0.9988257,0.00019746234,0.00018497898,0.00007514442,0.000012066757,0.000069776615,0.0004351243,0.0000015381769,0.00019825826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996247,0.0001221751,0.00003283125,0.00007537585,0.00008630996,0.000058579797],"domain_scores_gemma":[0.9996369,0.000060904913,0.00015036264,0.000029719677,0.00003507462,0.000087035674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014931969,0.00018510323,0.000637183,0.00011337656,0.00016800096,0.00041210238,0.00020901019,0.00024244562,0.0009828054],"category_scores_gemma":[0.0011701939,0.00011038507,0.0006096282,0.00028160634,0.00016204534,0.0003547093,0.00026061744,0.00072944735,0.00022492686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14525932,0.007413798,0.53410494,0.0007749743,0.0017930515,0.0005606343,0.0005248566,0.0030631672,0.031503167,0.00010758185,0.0033450052,0.27154967],"study_design_scores_gemma":[0.0065175015,0.06295061,0.9221095,0.00006245483,0.0006367271,0.0006100801,0.00010118816,0.0012001469,0.003593496,0.000070063325,0.0021277575,0.000020402038],"about_ca_topic_score_codex":0.0006133363,"about_ca_topic_score_gemma":0.00095520617,"teacher_disagreement_score":0.0014931969,"about_ca_system_score_codex":0.000475631,"about_ca_system_score_gemma":0.0003956327,"threshold_uncertainty_score":0.0078969},"labels":[],"label_agreement":null},{"id":"W4389832881","doi":"10.1007/s13555-023-01080-1","title":"The Burden of Air Pollution on Skin Health: a Brief Report and Call to Action","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Air Quality and Health Impacts","field":"Environmental Science","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Air pollution; Atopic dermatitis; Air quality index; Environmental health; Medicine; Pollution; Air pollutants; Environmental protection; Environmental science; Geography; Meteorology; Dermatology; Ecology","score_opus":0.05050114616673506,"score_gpt":0.35361261426895907,"score_spread":0.303111468102224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389832881","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01388131,0.30038953,0.00082607276,0.6042169,0.064199366,0.00038198914,0.0022439242,0.00030454682,0.013556433],"genre_scores_gemma":[0.06992969,0.6553445,0.002696331,0.14732897,0.10148053,0.0005410904,0.003543385,0.000077065044,0.019058483],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987607,0.00023688402,0.00028029797,0.00015129162,0.00034031822,0.00023064137],"domain_scores_gemma":[0.99595416,0.0011789515,0.0004319441,0.0000980716,0.0014516446,0.00088520034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002910217,0.0011079151,0.0007073622,0.0016018784,0.0015280697,0.0033816162,0.0008987966,0.0070820665,0.0043106684],"category_scores_gemma":[0.0037418015,0.00054401386,0.0011362236,0.0013356507,0.00068767485,0.00355781,0.0019648578,0.0052689384,0.0015545002],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017202405,0.00042352497,0.015798738,0.005610519,0.00010186083,0.002916681,0.001518369,0.00026242094,0.0014815236,0.0017093996,0.69632727,0.27367768],"study_design_scores_gemma":[0.000038375227,0.00062723726,0.046765782,0.008163319,0.00019143545,0.003163435,0.007700454,0.0003004313,0.00046678205,0.001349588,0.9311315,0.000101647915],"about_ca_topic_score_codex":0.0113237975,"about_ca_topic_score_gemma":0.02155917,"teacher_disagreement_score":0.0113237975,"about_ca_system_score_codex":0.0027218615,"about_ca_system_score_gemma":0.0064179874,"threshold_uncertainty_score":0.022515774},"labels":[],"label_agreement":null},{"id":"W4390590043","doi":"10.1007/s13555-023-01061-4","title":"Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Dupilumab; Eczema Area and Severity Index; Atopic dermatitis; Medicine; Dermatology Life Quality Index; Observational study; Quality of life (healthcare); Adverse effect; Interim analysis; Telephone interview; Pediatrics; Dermatology; Randomized controlled trial; Internal medicine; Disease","score_opus":0.014897983470864842,"score_gpt":0.28452558923269516,"score_spread":0.2696276057618303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390590043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889864,0.0013185747,0.0004284389,0.00021188705,0.000019055235,0.00025804673,0.00782566,0.0000186958,0.0009332326],"genre_scores_gemma":[0.9815595,0.0007232007,0.0012191327,0.0002533966,0.000067280074,0.0005493238,0.015363524,0.000010535652,0.00025408194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9922694,0.0039463006,0.0010145836,0.0008688359,0.0014096568,0.0004911976],"domain_scores_gemma":[0.98091435,0.004758297,0.009348575,0.0018188254,0.0021889599,0.00097102823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012654519,0.00039824098,0.0012741133,0.0007249183,0.00055400445,0.0016811283,0.0006875693,0.00067374826,0.0010657092],"category_scores_gemma":[0.014183297,0.00033068637,0.0022672638,0.0010417085,0.0003513532,0.0015584269,0.0009872378,0.001320638,0.00034286827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012937018,0.0011540325,0.96125466,0.000295893,0.00136594,0.00021302377,0.0002884257,0.0009829511,0.0005000869,0.00014443575,0.0016156412,0.019247958],"study_design_scores_gemma":[0.0015297332,0.011805271,0.9778854,0.00011988752,0.0014741461,0.0007801628,0.00035269427,0.0015869095,0.00087683316,0.00007733466,0.0034600769,0.00005148073],"about_ca_topic_score_codex":0.00255291,"about_ca_topic_score_gemma":0.0030966497,"teacher_disagreement_score":0.012654519,"about_ca_system_score_codex":0.0010218156,"about_ca_system_score_gemma":0.0014544161,"threshold_uncertainty_score":0.066924274},"labels":[],"label_agreement":null},{"id":"W4391689991","doi":"10.1007/s13555-023-01075-y","title":"Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McMaster University; Dermatrials Research; Probity Medical Research; University of British Columbia; SKiN Health","funders":"Celgene; Pfizer; Eli Lilly and Company; Amgen","keywords":"Ixekizumab; Plaque psoriasis; Psoriasis; Medicine; Interleukin 17; Interleukin 23; Antagonist; Interleukin; Interleukin 1 receptor antagonist; Pharmacology; Internal medicine; Receptor antagonist; Dermatology; Secukinumab; Cytokine; Receptor","score_opus":0.017409283018732104,"score_gpt":0.2538951513793576,"score_spread":0.2364858683606255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391689991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99941015,0.00023817219,0.000065312284,0.0000088346915,0.0000046306604,0.000025746696,0.000039870647,0.0000036485771,0.00020364759],"genre_scores_gemma":[0.9996119,0.00005193529,0.00008621901,0.000014995899,0.00001155897,0.000025797295,0.000080072794,0.0000012132964,0.0001164417],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994642,0.00025672093,0.00004850861,0.00008353049,0.000057250778,0.00008977834],"domain_scores_gemma":[0.99828523,0.0007661877,0.0004221657,0.00010942435,0.000083473016,0.0003336247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001441402,0.00022002071,0.0008312545,0.0002771045,0.00014007482,0.00029763623,0.00011429718,0.00027663462,0.0009962042],"category_scores_gemma":[0.0016073649,0.00014414794,0.00067266333,0.00019471785,0.00016172767,0.00037257624,0.00022253983,0.0004957228,0.00014770207],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44429952,0.0037025202,0.4366392,0.0002693277,0.001236775,0.00029493246,0.00030474737,0.0035300525,0.028714923,0.00012600188,0.0005628173,0.08031911],"study_design_scores_gemma":[0.0055771545,0.11403887,0.87205327,0.000018107836,0.00069358945,0.00030518128,0.00015839649,0.0035238452,0.0028525838,0.00012442966,0.00061911443,0.00003542463],"about_ca_topic_score_codex":0.00022825954,"about_ca_topic_score_gemma":0.00037485402,"teacher_disagreement_score":0.001441402,"about_ca_system_score_codex":0.00021632966,"about_ca_system_score_gemma":0.00016046914,"threshold_uncertainty_score":0.007622957},"labels":[],"label_agreement":null},{"id":"W4391942083","doi":"10.1007/s13555-024-01097-0","title":"Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Placebo; Medicine; Psoriasis; Pharmacodynamics; Proinflammatory cytokine; Pharmacokinetics; Psoriasis Area and Severity Index; Internal medicine; Pharmacology; Randomized controlled trial; Gastroenterology; Inflammation; Immunology; Pathology","score_opus":0.020706768672432423,"score_gpt":0.2805420094087598,"score_spread":0.25983524073632736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391942083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746464,0.013396269,0.0014450685,0.0006816191,0.00087057194,0.0061084186,0.0010725803,0.00030035077,0.001478683],"genre_scores_gemma":[0.97716546,0.00792119,0.0025367842,0.0012605514,0.00091289787,0.006851692,0.0010783215,0.000044713317,0.0022283457],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990575,0.00048056108,0.00008355114,0.00015958953,0.00010445287,0.00011436521],"domain_scores_gemma":[0.9992681,0.00018102759,0.00021263016,0.000066748675,0.000078206736,0.00019317536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027480887,0.0015537958,0.0034148039,0.0004522712,0.00045207728,0.0008375695,0.00084814173,0.0017218621,0.004218816],"category_scores_gemma":[0.0015605593,0.00068075705,0.0017550221,0.0005547825,0.0010056812,0.00095072953,0.00028478826,0.0020984185,0.0007561881],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.965399,0.008137215,0.00042721772,0.0011279855,0.0009849557,0.0000434094,0.00003208923,0.00020981378,0.007511725,0.000070889895,0.0006794772,0.015376254],"study_design_scores_gemma":[0.9557306,0.041851144,0.0010897098,0.00002234515,0.0003018564,0.000024112094,0.000007964249,0.00024053722,0.00036397466,0.000036801106,0.00032218455,0.000008859751],"about_ca_topic_score_codex":0.0005141,"about_ca_topic_score_gemma":0.0012378396,"teacher_disagreement_score":0.004218816,"about_ca_system_score_codex":0.00050180644,"about_ca_system_score_gemma":0.0009915475,"threshold_uncertainty_score":0.01453346},"labels":[],"label_agreement":null},{"id":"W4392860426","doi":"10.1007/s13555-024-01114-2","title":"Development and Psychometric Validation of a Patient-Reported Outcome Measure to Assess the Signs and Symptoms of Chronic Hand Eczema: The Hand Eczema Symptom Diary (HESD)","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Contact Dermatitis and Allergies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Cronbach's alpha; Debriefing; Clinical psychology; Construct validity; Rasch model; Psychology; Intraclass correlation; Patient-reported outcome; Psychometrics; Cognitive interview; Reliability (semiconductor); Content validity; Cognition; Medicine; Physical therapy; Quality of life (healthcare); Psychiatry; Developmental psychology; Psychotherapist","score_opus":0.039253434468810786,"score_gpt":0.2948297921970807,"score_spread":0.2555763577282699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392860426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9324533,0.0030655696,0.02918519,0.0011190035,0.00038239814,0.01963717,0.0056373356,0.000176338,0.008343826],"genre_scores_gemma":[0.92662233,0.0011801774,0.04245331,0.000538549,0.00009651081,0.022256574,0.005823115,0.000036296045,0.0009931941],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98408556,0.0073999627,0.002524984,0.0008237709,0.0048236814,0.00034202266],"domain_scores_gemma":[0.9804268,0.0064818845,0.004103704,0.0012243376,0.0071121,0.0006511049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02445432,0.00046485488,0.00068964146,0.001403765,0.00041871943,0.0010173881,0.00093881163,0.00093894225,0.0012750336],"category_scores_gemma":[0.025265913,0.00030407534,0.0011759872,0.0009372601,0.00045403646,0.00085219875,0.0013458527,0.0012780902,0.00045660263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042691077,0.0065912902,0.64074224,0.0020023403,0.0012782644,0.00016060013,0.0020298827,0.0021784015,0.01016244,0.00090977066,0.007181678,0.3224939],"study_design_scores_gemma":[0.0016581677,0.014865939,0.96193314,0.00065718166,0.00043672216,0.0005706544,0.0008019304,0.005116218,0.0041746027,0.00050863397,0.009186819,0.00009008404],"about_ca_topic_score_codex":0.0007791685,"about_ca_topic_score_gemma":0.0011576689,"teacher_disagreement_score":0.02445432,"about_ca_system_score_codex":0.0007692178,"about_ca_system_score_gemma":0.00170374,"threshold_uncertainty_score":0.12932837},"labels":[],"label_agreement":null},{"id":"W4393277811","doi":"10.1007/s13555-024-01129-9","title":"Maintenance of Investigator’s Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Toronto","funders":"Bausch Health; Celgene; Amgen; Pfizer; Eli Lilly and Company; LEO Pharma; Galderma; Incyte","keywords":"Medicine; Atopic dermatitis; Dermatology","score_opus":0.022725379298938423,"score_gpt":0.3237260048102253,"score_spread":0.30100062551128687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393277811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963439,0.0010609479,0.0003916798,0.000078177145,0.000029400397,0.0004113973,0.00036410868,0.000045301545,0.0012750609],"genre_scores_gemma":[0.9974976,0.00022130364,0.0006993857,0.0000853094,0.000023021254,0.0006099778,0.00038854632,0.000009120529,0.00046560215],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979668,0.0010827801,0.00018199481,0.00027568624,0.00033377158,0.00015886349],"domain_scores_gemma":[0.9971687,0.0006799713,0.0010476824,0.00034241777,0.00052845373,0.00023271011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071056206,0.0003819149,0.0009855335,0.00032986578,0.00041201813,0.0004817351,0.00041775955,0.00054391584,0.0019119796],"category_scores_gemma":[0.005829312,0.00021240197,0.0010308316,0.00030635027,0.00025656552,0.00055251736,0.00039053685,0.0007628821,0.00036787562],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3421538,0.013240003,0.2729505,0.0029863054,0.002991527,0.0003904026,0.002396746,0.00066197896,0.07506487,0.0002508674,0.004611173,0.2823019],"study_design_scores_gemma":[0.018482165,0.22493832,0.73336726,0.0002540959,0.0022861797,0.0007355132,0.00063670694,0.0010174494,0.0117460275,0.00036805554,0.0060816426,0.00008659904],"about_ca_topic_score_codex":0.00062954257,"about_ca_topic_score_gemma":0.0012685856,"teacher_disagreement_score":0.0071056206,"about_ca_system_score_codex":0.00025204444,"about_ca_system_score_gemma":0.0005736634,"threshold_uncertainty_score":0.037578523},"labels":[],"label_agreement":null},{"id":"W4394999927","doi":"10.1007/s13555-024-01147-7","title":"Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Quality of life (healthcare); Psoriasis; Scalp; Dermatology; Physical therapy; Psoriatic arthritis; Nursing","score_opus":0.02612450247803453,"score_gpt":0.28405261176407526,"score_spread":0.2579281092860407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394999927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99389327,0.004186815,0.00043804006,0.00005867303,0.000020198286,0.00012329956,0.0006373837,0.00001897819,0.00062339916],"genre_scores_gemma":[0.9984731,0.00045769018,0.00020119718,0.000049955957,0.000024383116,0.000094886855,0.00050089747,0.0000025430043,0.00019521243],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9986513,0.0005459534,0.00016973764,0.00026786554,0.00022124077,0.00014394749],"domain_scores_gemma":[0.9984617,0.0005239838,0.0005185048,0.0001617925,0.0001608192,0.00017318894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00383771,0.00035775625,0.0015266589,0.00040004036,0.00017912599,0.0005980124,0.00023010313,0.00030510683,0.0016932148],"category_scores_gemma":[0.0024240483,0.00021735908,0.0020563398,0.00043246636,0.00020536043,0.00042150155,0.00033317204,0.00051618885,0.00016651364],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4141864,0.003238889,0.36530596,0.0017397556,0.021016767,0.00018682847,0.00038330912,0.001899273,0.020957919,0.00014928968,0.0019025308,0.1690331],"study_design_scores_gemma":[0.02323558,0.063450314,0.8935573,0.000121507175,0.012543379,0.00040994602,0.00013163568,0.0015247124,0.002364464,0.00019568614,0.0024233756,0.000042103035],"about_ca_topic_score_codex":0.00029682915,"about_ca_topic_score_gemma":0.00034875667,"teacher_disagreement_score":0.00383771,"about_ca_system_score_codex":0.00025212878,"about_ca_system_score_gemma":0.00047000067,"threshold_uncertainty_score":0.020295978},"labels":[],"label_agreement":null},{"id":"W4396592360","doi":"10.1007/s13555-024-01157-5","title":"Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; University of Calgary","funders":"","keywords":"Atopic dermatitis; Medicine; Quality of life (healthcare); Clinical trial; Dermatology; Internal medicine","score_opus":0.0809078995283674,"score_gpt":0.3963929099982119,"score_spread":0.3154850104698445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396592360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801911,0.015372831,0.00047346237,0.0002636746,0.00010226529,0.0011848502,0.001364218,0.00005837618,0.0009892491],"genre_scores_gemma":[0.9876338,0.0062175915,0.001032466,0.0005695398,0.000119752265,0.0015106588,0.0020295861,0.000018444167,0.00086818106],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986399,0.00073721673,0.00011622733,0.00013704569,0.00020648571,0.0001631909],"domain_scores_gemma":[0.9988311,0.00028714596,0.00047473612,0.000110514964,0.000118521835,0.00017803708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004149389,0.0007476528,0.002155496,0.00036632997,0.00028683848,0.00082021224,0.0004501849,0.00068999315,0.0015190489],"category_scores_gemma":[0.0021252362,0.00027007383,0.0026868684,0.00051347713,0.00033858878,0.0005216805,0.0003915478,0.0016008972,0.00022558254],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6282922,0.021139277,0.018781431,0.0035641112,0.010916529,0.00022935508,0.00034858196,0.0025363034,0.033621766,0.00016365122,0.005252176,0.27515465],"study_design_scores_gemma":[0.43395635,0.39554173,0.14471115,0.00035851347,0.008185474,0.0006013876,0.00013792836,0.0016616923,0.007921271,0.00021421314,0.006614324,0.00009599136],"about_ca_topic_score_codex":0.00046871172,"about_ca_topic_score_gemma":0.0015435383,"teacher_disagreement_score":0.004149389,"about_ca_system_score_codex":0.00048220076,"about_ca_system_score_gemma":0.0007789384,"threshold_uncertainty_score":0.021944344},"labels":[],"label_agreement":null},{"id":"W4396614562","doi":"10.1007/s13555-024-01158-4","title":"Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Probity Medical Research; University of British Columbia","funders":"Eli Lilly and Company","keywords":"Medicine; Eczema Area and Severity Index; Erythema; Atopic dermatitis; Placebo; Edema; Dermatology; Vital signs; Surgery; Pathology","score_opus":0.03469532938656195,"score_gpt":0.351548121458112,"score_spread":0.31685279207155004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396614562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632937,0.002565436,0.0001611939,0.000079871985,0.000018647093,0.000078118544,0.000071810544,0.000021431013,0.0006741918],"genre_scores_gemma":[0.9981719,0.00080121524,0.0004276756,0.000092464965,0.00003795851,0.000047374713,0.0001063844,0.0000033696458,0.0003116083],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9998331,0.000056551147,0.000017530074,0.000022921735,0.000041504158,0.000028417402],"domain_scores_gemma":[0.9995796,0.00012983038,0.00012117066,0.000018219222,0.000047304493,0.00010389631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006710642,0.00021635357,0.0005415688,0.00010339453,0.00011910067,0.00025713438,0.00014649316,0.0003233301,0.0015878613],"category_scores_gemma":[0.00080208096,0.00013554431,0.0003089569,0.00008433023,0.00012435312,0.00022887257,0.00017590837,0.00064798654,0.00021846942],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11342328,0.0158453,0.23779489,0.0015827193,0.0005656002,0.0006741822,0.0007746362,0.0010350852,0.1919851,0.00017349207,0.003162186,0.4329835],"study_design_scores_gemma":[0.032338407,0.33478075,0.5890377,0.00022143274,0.00056672294,0.002673922,0.00038184907,0.0016633634,0.030330285,0.000116359806,0.00785585,0.00003325334],"about_ca_topic_score_codex":0.00028056596,"about_ca_topic_score_gemma":0.00081944425,"teacher_disagreement_score":0.0015878613,"about_ca_system_score_codex":0.00014419,"about_ca_system_score_gemma":0.00022573702,"threshold_uncertainty_score":0.005311966},"labels":[],"label_agreement":null},{"id":"W4396765528","doi":"10.1007/s13555-024-01155-7","title":"Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"National Center for Advancing Translational Sciences; Janssen Biotech; Allergan; LEO Pharma; Bausch Health; Regeneron Pharmaceuticals; Sun Pharma; Eli Lilly and Company; Ortho Dermatologics; Galderma; Sanofi Genzyme; Incyte; Dermira; Sanofi; Amgen; Pfizer","keywords":"Adapalene; Benzoyl peroxide; Acne; Clindamycin; Phosphate; Dermatology; Chemistry; Medicine; Pharmacology; Organic chemistry; Antibiotics; Biochemistry","score_opus":0.015053563414246117,"score_gpt":0.31822211126592104,"score_spread":0.3031685478516749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396765528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8690671,0.10512643,0.0077366545,0.0006868643,0.00041084382,0.0075240526,0.0054915906,0.00033545704,0.0036209102],"genre_scores_gemma":[0.9769315,0.014209225,0.0029109973,0.0004932639,0.00017687578,0.0024753162,0.0016859444,0.00005405752,0.0010626554],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9972145,0.0016085707,0.00029122352,0.00033574668,0.00042326492,0.00012667842],"domain_scores_gemma":[0.99622935,0.0012367857,0.0013711384,0.0003912745,0.0005097573,0.0002617932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009186512,0.0010649277,0.0029640533,0.0007125404,0.0002944581,0.0014363711,0.0005249137,0.0007975032,0.0038656986],"category_scores_gemma":[0.0058234595,0.00055047305,0.006602204,0.00075096457,0.0004851743,0.00081667653,0.00048891414,0.0011097859,0.00049202074],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6801423,0.0053887707,0.011941696,0.0134704225,0.1136046,0.00014976354,0.00033761325,0.0023136965,0.026104903,0.00026265776,0.003532568,0.14275102],"study_design_scores_gemma":[0.46976534,0.26049516,0.06527548,0.0019748162,0.17852156,0.00056268356,0.00022429046,0.0022972554,0.008525809,0.0007113804,0.011462518,0.0001836542],"about_ca_topic_score_codex":0.0006988215,"about_ca_topic_score_gemma":0.002352456,"teacher_disagreement_score":0.009186512,"about_ca_system_score_codex":0.0007319245,"about_ca_system_score_gemma":0.0016187871,"threshold_uncertainty_score":0.048583448},"labels":[],"label_agreement":null},{"id":"W4396813342","doi":"10.1007/s13555-024-01164-6","title":"Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AbbVie; Biogen; Amgen","keywords":"Medicine; Psoriasis; Term (time); Chart; Pediatrics; Intensive care medicine; Dermatology; Statistics; Mathematics","score_opus":0.012119976135845978,"score_gpt":0.28454329913593046,"score_spread":0.2724233230000845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396813342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813107,0.0042104335,0.00024773905,0.00014976677,0.00001351269,0.00027506502,0.01261488,0.000021733684,0.0011561401],"genre_scores_gemma":[0.9891195,0.0011463205,0.00039252086,0.00011505454,0.00003552577,0.00021234366,0.008845763,0.000007685302,0.00012516978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929832,0.0028062223,0.0013945939,0.0009390456,0.0015912079,0.00028581783],"domain_scores_gemma":[0.9598882,0.0072078337,0.027267559,0.0014827355,0.0030822803,0.0010713775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055828947,0.0002971239,0.00074990187,0.002641354,0.00034693873,0.0012906312,0.0005281324,0.00043785103,0.0010024867],"category_scores_gemma":[0.012986177,0.00027359775,0.0011479902,0.004867766,0.0003182349,0.0006648293,0.0006069156,0.0004170054,0.00023412936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011297858,0.000102288,0.99128854,0.00033480782,0.0005040125,0.000071440685,0.00014528936,0.000111466295,0.0001391666,0.00003320261,0.00084933604,0.0052908002],"study_design_scores_gemma":[0.00015577172,0.0003401142,0.99764675,0.00007979216,0.00025496676,0.00018952851,0.00013157862,0.00021835495,0.00008035842,0.000008480197,0.0008803163,0.000014114084],"about_ca_topic_score_codex":0.0061731944,"about_ca_topic_score_gemma":0.006006849,"teacher_disagreement_score":0.0061731944,"about_ca_system_score_codex":0.0010055562,"about_ca_system_score_gemma":0.0012963859,"threshold_uncertainty_score":0.029525518},"labels":[],"label_agreement":null},{"id":"W4396834167","doi":"10.1007/s13555-024-01175-3","title":"Comparison of the Efficacy of Clascoterone, Trifarotene, and Tazarotene for the Treatment of Acne: A Systematic Literature Review and Meta-Analysis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Impact; McMaster University","funders":"","keywords":"Tazarotene; Medicine; Confidence interval; Meta-analysis; Acne; Randomized controlled trial; Lotion; Dermatology; Internal medicine; Traditional medicine","score_opus":0.04836278206880886,"score_gpt":0.36593009688497774,"score_spread":0.3175673148161689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396834167","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0057258555,0.99275595,0.00035570364,0.00015532356,0.00011738512,0.0003511404,0.00030809225,0.000019065727,0.00021148313],"genre_scores_gemma":[0.1762867,0.8179281,0.0022622924,0.00093677617,0.00028854902,0.0012210935,0.0007377776,0.000029160085,0.0003095911],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.991779,0.0036995516,0.0024366484,0.00087751384,0.0009529956,0.0002541909],"domain_scores_gemma":[0.9867736,0.009125275,0.0024644951,0.00032087287,0.0011004785,0.00021530617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012001734,0.0031704123,0.022836098,0.0061996556,0.0006535704,0.0034631472,0.00215914,0.0024571198,0.0033808097],"category_scores_gemma":[0.023565268,0.0014902346,0.040148128,0.0062216697,0.00082248665,0.0019233805,0.0012481981,0.001960941,0.00028856078],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004146346,0.000066347566,0.0019768397,0.3887958,0.5922613,0.000115057366,0.00007059887,0.0005204366,0.0003420486,0.000115213945,0.00036824818,0.01122173],"study_design_scores_gemma":[0.0011260401,0.00035689815,0.0019744406,0.018581012,0.9765717,0.00006957192,0.000037751794,0.00015293341,0.00012611058,0.00012852922,0.0008551521,0.000019847937],"about_ca_topic_score_codex":0.0052243816,"about_ca_topic_score_gemma":0.010569896,"teacher_disagreement_score":0.022836098,"about_ca_system_score_codex":0.0025921823,"about_ca_system_score_gemma":0.003498581,"threshold_uncertainty_score":0.06347203},"labels":[],"label_agreement":null},{"id":"W4400017087","doi":"10.1007/s13555-024-01204-1","title":"Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SKiN Health; University of Calgary; Guenther Dermatology Research Centre; Probity Medical Research; Innovaderm (Canada); Dermatrials Research; Dalhousie University","funders":"Bausch Health; Amgen","keywords":"Psoriasis; Tazarotene; Medicine; Lotion; Plaque psoriasis; Dermatology; Session (web analytics); Panel discussion; Consensus conference; Expert opinion; Dermatologic agents; Medical physics; Intensive care medicine; Pharmacology; Internal medicine; Computer science; World Wide Web; Business","score_opus":0.05041861591236199,"score_gpt":0.25564226531527123,"score_spread":0.20522364940290924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400017087","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033421014,0.16956258,0.046228513,0.5440634,0.027421158,0.01012959,0.0075922273,0.00057918776,0.1610024],"genre_scores_gemma":[0.5614789,0.13499211,0.1677925,0.08340414,0.0055945814,0.006922027,0.009378775,0.0004085215,0.030028543],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.8782728,0.038751833,0.02022396,0.005193076,0.0508602,0.0066981274],"domain_scores_gemma":[0.70202684,0.030756256,0.010140383,0.003357148,0.2396074,0.0141119305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.10357231,0.0010555651,0.0019114909,0.007169469,0.0057631475,0.0045565637,0.007012635,0.005041203,0.0060130414],"category_scores_gemma":[0.16347031,0.00093258487,0.002692796,0.005179374,0.003387347,0.0022295574,0.0052268878,0.0050450526,0.001428894],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047632342,0.00010782227,0.010522317,0.018767606,0.00038423424,0.0012735218,0.014215333,0.0019303882,0.003549024,0.009613963,0.60375404,0.33540547],"study_design_scores_gemma":[0.00019344236,0.00015691666,0.017322054,0.026397115,0.0004901226,0.0009313798,0.010349461,0.001579952,0.0018522888,0.0055382065,0.9348484,0.0003405558],"about_ca_topic_score_codex":0.47556278,"about_ca_topic_score_gemma":0.5220266,"teacher_disagreement_score":0.5244372,"about_ca_system_score_codex":0.04459317,"about_ca_system_score_gemma":0.21657202,"threshold_uncertainty_score":0.9455894},"labels":[],"label_agreement":null},{"id":"W4400078729","doi":"10.1007/s13555-024-01210-3","title":"Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Lynde Centre for Dermatology; University of Toronto","funders":"UCB Pharma; National Institute for Health and Care Research","keywords":"Certolizumab pegol; Plaque psoriasis; Medicine; Psoriasis; Clinical Practice; Medical physics; Dermatology; Internal medicine; Physical therapy; Adalimumab","score_opus":0.05889889606803407,"score_gpt":0.34748839995163283,"score_spread":0.2885895038835988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400078729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99064714,0.006222927,0.00011226978,0.0002649582,0.000023624092,0.0002751078,0.0011104685,0.000011552377,0.0013319175],"genre_scores_gemma":[0.9949822,0.0020642031,0.00028471948,0.00029248968,0.00008656978,0.00013626015,0.0017972649,0.00000490243,0.00035140765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967573,0.0015940998,0.00028258166,0.00036530933,0.0007792451,0.00022147581],"domain_scores_gemma":[0.99037594,0.002452528,0.0037166516,0.0007052612,0.0011788644,0.0015707561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008045596,0.0004561652,0.0007708112,0.00042151505,0.00029234533,0.0011358935,0.0004015044,0.00074000616,0.0011018242],"category_scores_gemma":[0.009109758,0.0002712503,0.0010685582,0.0006048281,0.00041159513,0.0005316634,0.0006645224,0.0010492477,0.00031848502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13374309,0.012946748,0.72475964,0.001189088,0.0038842226,0.00037935044,0.0011483941,0.0014529042,0.0023474977,0.0001328753,0.0037746779,0.11424155],"study_design_scores_gemma":[0.01839176,0.03723726,0.9368469,0.00023058223,0.0018859272,0.00038002225,0.00041234918,0.00090463524,0.00048553236,0.000037715246,0.0031370847,0.0000501455],"about_ca_topic_score_codex":0.006121711,"about_ca_topic_score_gemma":0.006003735,"teacher_disagreement_score":0.008045596,"about_ca_system_score_codex":0.0016098759,"about_ca_system_score_gemma":0.0015676216,"threshold_uncertainty_score":0.04254973},"labels":[],"label_agreement":null},{"id":"W4400239828","doi":"10.1007/s13555-024-01200-5","title":"Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"LEO Pharma; Bausch Health; Astellas Pharma; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Sanofi Genzyme; Incyte; Castle Biosciences; Dermira; Regeneron Pharmaceuticals; Celgene; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer","keywords":"Atopic dermatitis; Dermatology; Clinical Practice; Medicine; Family medicine","score_opus":0.03828749553093205,"score_gpt":0.39440680892066493,"score_spread":0.3561193133897329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400239828","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008519956,0.874333,0.01580866,0.07040453,0.003004373,0.00019739242,0.00016007369,0.00033215393,0.027239766],"genre_scores_gemma":[0.06748606,0.82510084,0.033456337,0.047949452,0.012721208,0.00038591836,0.00038336054,0.00016990378,0.012346938],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986197,0.0004644249,0.00029325485,0.00010924441,0.00043397956,0.00007935582],"domain_scores_gemma":[0.9980361,0.0009825211,0.00031212144,0.000053484528,0.00043396754,0.00018178436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018621403,0.0005369963,0.0009682217,0.0008042763,0.00056329696,0.0016690141,0.0007161505,0.0025399064,0.003847477],"category_scores_gemma":[0.005245555,0.00022503432,0.00086076243,0.0004927503,0.0006463388,0.0021167195,0.0009450386,0.0032720056,0.0023886121],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014415635,0.000113790455,0.002000702,0.0049039815,0.00008366571,0.009785036,0.00076737656,0.00057708094,0.0025003518,0.0031379284,0.116445564,0.8595404],"study_design_scores_gemma":[0.00015162195,0.00034598712,0.0039283102,0.0056500076,0.00018712797,0.06522168,0.0008083574,0.00072257424,0.0011617184,0.0057728016,0.9159777,0.00007216725],"about_ca_topic_score_codex":0.0007905746,"about_ca_topic_score_gemma":0.0018329228,"teacher_disagreement_score":0.003847477,"about_ca_system_score_codex":0.0005233315,"about_ca_system_score_gemma":0.0012234022,"threshold_uncertainty_score":0.012871087},"labels":[],"label_agreement":null},{"id":"W4401056715","doi":"10.1007/s13555-024-01231-y","title":"Dupilumab Reduces Urticaria Activity, Itch, and Hives in Patients with Chronic Spontaneous Urticaria Regardless of Baseline Serum Immunoglobulin E Levels","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Dupilumab; Medicine; Placebo; Immunoglobulin E; Interquartile range; Internal medicine; Atopic dermatitis; Immunology; Gastroenterology; Antibody; Pathology","score_opus":0.008369914756186187,"score_gpt":0.24339278957256022,"score_spread":0.23502287481637404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401056715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957188,0.003384231,0.000076066695,0.00007050783,0.000018810779,0.000058941623,0.00007374022,0.000020790341,0.00057813857],"genre_scores_gemma":[0.99852115,0.0007839043,0.00016960227,0.00009151782,0.00002842985,0.000037383485,0.00010783434,0.0000019455213,0.00025822833],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998779,0.00003493301,0.000010582958,0.000015413407,0.000024999732,0.000036082205],"domain_scores_gemma":[0.9997881,0.00005818767,0.00006220678,0.00000867891,0.000022735217,0.000060111284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002859849,0.0003030537,0.0005881097,0.00012645818,0.00014118715,0.00022103249,0.00015731441,0.00021327661,0.0011917697],"category_scores_gemma":[0.00045024688,0.000109330584,0.0002925938,0.00010743682,0.00012650268,0.00015453156,0.0000974845,0.00040125125,0.00015130284],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1459278,0.011749636,0.051114187,0.0025717241,0.0021109888,0.0008482612,0.00035081728,0.00173882,0.15075257,0.00015117283,0.004892083,0.6277919],"study_design_scores_gemma":[0.08553642,0.3119202,0.55222213,0.00029101069,0.0018609742,0.0040762476,0.00033863753,0.0057983752,0.02931603,0.00014923066,0.008424782,0.00006593481],"about_ca_topic_score_codex":0.0006628345,"about_ca_topic_score_gemma":0.0024954288,"teacher_disagreement_score":0.0011917697,"about_ca_system_score_codex":0.00022019028,"about_ca_system_score_gemma":0.00022629862,"threshold_uncertainty_score":0.0039868355},"labels":[],"label_agreement":null},{"id":"W4401114827","doi":"10.1007/s13555-024-01224-x","title":"Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Janssen Biotech; LEO Pharma; Regeneron Pharmaceuticals; Sun Pharma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Incyte; Dermira; Celgene; Sanofi; Amgen; Pfizer","keywords":"Randomized controlled trial; Psoriasis; Medicine; Phase (matter); Physical therapy; Internal medicine; Dermatology; Physics","score_opus":0.020853798424552844,"score_gpt":0.27203108451029606,"score_spread":0.2511772860857432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401114827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97731316,0.017788995,0.0004028113,0.00058047497,0.000132649,0.0009398131,0.00080183346,0.00006164735,0.0019786456],"genre_scores_gemma":[0.99286133,0.0040942193,0.0005706616,0.0004944112,0.00017857546,0.0005139752,0.00086754,0.000008862754,0.00041043948],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988298,0.00070657977,0.00010233921,0.00014021127,0.0001329057,0.000088318055],"domain_scores_gemma":[0.9983012,0.0005709341,0.0005992583,0.000103836384,0.00012432874,0.00030044105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002982721,0.00066576543,0.0014026681,0.00020436988,0.0002846292,0.00082162657,0.00047870982,0.0008402638,0.00228866],"category_scores_gemma":[0.0023789066,0.00026094588,0.001986268,0.0003223148,0.00044288335,0.00048809065,0.0002394573,0.0015495592,0.00026216134],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8570671,0.008876042,0.010398637,0.002288691,0.005755906,0.00011015793,0.00012374563,0.00090298016,0.012849576,0.00012174711,0.0028650821,0.09864028],"study_design_scores_gemma":[0.770689,0.16317442,0.05538509,0.00018222391,0.0037030196,0.0005204529,0.0000651765,0.0008220359,0.0022782965,0.0002579025,0.002876109,0.00004619124],"about_ca_topic_score_codex":0.0004571775,"about_ca_topic_score_gemma":0.0014281872,"teacher_disagreement_score":0.002982721,"about_ca_system_score_codex":0.00047008827,"about_ca_system_score_gemma":0.0006691617,"threshold_uncertainty_score":0.01577431},"labels":[],"label_agreement":null},{"id":"W4401124751","doi":"10.1007/s13555-024-01240-x","title":"Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic Dermatitis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"AbbVie","keywords":"Dupilumab; Atopic dermatitis; Medicine; Dermatology","score_opus":0.017742762335356127,"score_gpt":0.30180964369604607,"score_spread":0.2840668813606899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401124751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9623167,0.018817397,0.0023092977,0.0006414324,0.00063132436,0.0021005427,0.008820755,0.00007041841,0.0042920928],"genre_scores_gemma":[0.9884439,0.0019721931,0.0023315707,0.00047553788,0.00016851493,0.0021981949,0.0032758664,0.000016605012,0.0011176431],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.990341,0.0068953685,0.0007072404,0.001096931,0.0006096598,0.00034984137],"domain_scores_gemma":[0.9892202,0.0065280274,0.0025127532,0.00079594314,0.00051793666,0.00042519558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010461551,0.0022636426,0.0038683782,0.00088294747,0.0005212623,0.00172332,0.0013929231,0.0017900254,0.007897676],"category_scores_gemma":[0.018997604,0.00088183087,0.0132254725,0.0009685673,0.0008455073,0.0013784197,0.002085468,0.0033962252,0.00068518665],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64912397,0.0037305334,0.07829378,0.013031863,0.21291175,0.00022811601,0.0004901781,0.0043872646,0.00084601296,0.0013344375,0.0025346526,0.033087406],"study_design_scores_gemma":[0.23759921,0.110495515,0.2160537,0.002921095,0.40428537,0.0009912498,0.0007304562,0.011759205,0.0027039128,0.0051614973,0.0069831526,0.0003155339],"about_ca_topic_score_codex":0.0035965731,"about_ca_topic_score_gemma":0.003349295,"teacher_disagreement_score":0.010461551,"about_ca_system_score_codex":0.0011743875,"about_ca_system_score_gemma":0.0009747266,"threshold_uncertainty_score":0.05532664},"labels":[],"label_agreement":null},{"id":"W4401323330","doi":"10.1007/s13555-024-01241-w","title":"Assessing Participants’ Experiences with Vitiligo from Patient Interviews","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"melanin and skin pigmentation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Incyte","keywords":"Vitiligo; Psychology; Medicine; Dermatology","score_opus":0.03071425254390989,"score_gpt":0.3150189943196743,"score_spread":0.28430474177576437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401323330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97814125,0.0016239019,0.0066521806,0.0054409853,0.00022274884,0.0009051927,0.00053562404,0.00005992574,0.006418251],"genre_scores_gemma":[0.98840743,0.0011227002,0.003886525,0.0023623467,0.0000546664,0.001551249,0.00022883223,0.00004922072,0.0023370213],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9743157,0.02125977,0.0006939317,0.0007849337,0.0012204458,0.0017251687],"domain_scores_gemma":[0.949456,0.03927561,0.0030296491,0.0009145996,0.0038807204,0.0034434202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028535848,0.0009483063,0.00096462935,0.0013215471,0.0054961275,0.0038543418,0.002257816,0.0024394556,0.004501868],"category_scores_gemma":[0.052325003,0.00082495995,0.0006970685,0.0010131791,0.0051094033,0.0036831745,0.008170654,0.0038335884,0.00075626676],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000091711445,0.00003582687,0.0027216582,0.00019482251,0.000007921896,0.00032884188,0.99081683,0.00004546042,0.0010433957,0.00028990206,0.000505038,0.003918631],"study_design_scores_gemma":[0.000019772024,0.00013750722,0.0012541786,0.00022361807,0.000008847235,0.00029993348,0.98803025,0.00013826502,0.0004179573,0.00044847603,0.00898893,0.000032241947],"about_ca_topic_score_codex":0.0025242176,"about_ca_topic_score_gemma":0.00439873,"teacher_disagreement_score":0.028535848,"about_ca_system_score_codex":0.0030431487,"about_ca_system_score_gemma":0.003095215,"threshold_uncertainty_score":0.15091377},"labels":[],"label_agreement":null},{"id":"W4401385117","doi":"10.1007/s13555-024-01242-9","title":"More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"Janssen Pharmaceuticals; LEO Pharma; Coherus Biosciences; Argenx; Daewoong Pharmaceutical Company; Sanofi Genzyme; Pfizer; Incyte; National Eczema Association; Celldex Therapeutics; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; AbbVie; Sanofi; GlaxoSmithKline; Celgene; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Castle Biosciences","keywords":"Dupilumab; Atopic dermatitis; Medicine; Dermatology; Placebo; Pathology","score_opus":0.010931536450276514,"score_gpt":0.26854148577621756,"score_spread":0.25760994932594106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401385117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463993,0.0035666684,0.00023066287,0.000051463918,0.000040611496,0.0002599375,0.00066728855,0.000013815758,0.00052966754],"genre_scores_gemma":[0.99855644,0.00043557218,0.00016581049,0.000063680054,0.000034044675,0.00019247235,0.00036286056,0.0000024860947,0.00018663405],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988626,0.00053646596,0.00011032037,0.00020644139,0.00017471614,0.00010949578],"domain_scores_gemma":[0.9982942,0.00081836246,0.00054176257,0.00008540066,0.00007928563,0.00018110294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020769334,0.0006028075,0.0014753859,0.00033366727,0.00025587564,0.000590546,0.0003950977,0.00037170865,0.0030092543],"category_scores_gemma":[0.0020020162,0.0002456431,0.0021912719,0.00040925934,0.0003405139,0.00043327882,0.00030400057,0.0006946321,0.00020406571],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8068152,0.0032068272,0.08876722,0.0021113292,0.0113487,0.00009026761,0.00013535959,0.0018023143,0.0067028217,0.00011484993,0.001150438,0.077754594],"study_design_scores_gemma":[0.11274856,0.25541988,0.5856919,0.0003143789,0.027514948,0.00065755117,0.00021912281,0.0031903242,0.008830337,0.00045487983,0.0048596347,0.00009854067],"about_ca_topic_score_codex":0.00049077644,"about_ca_topic_score_gemma":0.0011069577,"teacher_disagreement_score":0.0030092543,"about_ca_system_score_codex":0.0004880062,"about_ca_system_score_gemma":0.00062283274,"threshold_uncertainty_score":0.010984004},"labels":[],"label_agreement":null},{"id":"W4401431929","doi":"10.1007/s13555-024-01243-8","title":"Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK Inhibitors","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Dalhousie University; University of Toronto; Queen's University; University of British Columbia; SKiN Health; University of Calgary; Ottawa Hospital; Innovaderm (Canada); Probity Medical Research; University of Ottawa","funders":"AbbVie Canada; Pfizer Canada","keywords":"Medicine; Population; Adverse effect; Clinical trial; Atopic dermatitis; Intensive care medicine; Dermatology; Internal medicine; Environmental health","score_opus":0.018453949013327173,"score_gpt":0.31425420651798586,"score_spread":0.29580025750465866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401431929","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009504723,0.1470128,0.03944087,0.7437995,0.017830806,0.0037220358,0.0018665672,0.0010081141,0.035814535],"genre_scores_gemma":[0.13737898,0.19495535,0.37442088,0.25783998,0.009702307,0.009922548,0.0040358067,0.00035379722,0.01139042],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.93014103,0.037780005,0.017452387,0.0018929814,0.0110678505,0.0016657196],"domain_scores_gemma":[0.78362584,0.10449837,0.017080942,0.0053675366,0.08345047,0.0059768776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06161069,0.0013184858,0.0024346414,0.004673076,0.0021529775,0.0047219465,0.0049740123,0.009770764,0.0052078683],"category_scores_gemma":[0.18502246,0.0009728748,0.004449066,0.0030964084,0.0026226556,0.0060264375,0.0038183932,0.011074057,0.0033527396],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003465832,0.0005339893,0.0086781345,0.02036831,0.0005412337,0.0012585423,0.004142079,0.0010528554,0.0019662154,0.007039445,0.39061767,0.5634549],"study_design_scores_gemma":[0.0007918871,0.0006313167,0.014041214,0.10741841,0.0011447041,0.0015518552,0.008876944,0.0017055764,0.0022338706,0.028275512,0.83288974,0.0004389371],"about_ca_topic_score_codex":0.005346714,"about_ca_topic_score_gemma":0.0095512355,"teacher_disagreement_score":0.06161069,"about_ca_system_score_codex":0.0028393622,"about_ca_system_score_gemma":0.013384113,"threshold_uncertainty_score":0.3258323},"labels":[],"label_agreement":null},{"id":"W4401606908","doi":"10.1007/s13555-024-01253-6","title":"Extended Half-life Antibodies: A Narrative Review of a New Approach in the Management of Atopic Dermatitis","year":2024,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Atopic dermatitis; Quality of life (healthcare); Dosing; Immune system; Immunology; Immune dysregulation; Antibody; Disease; Clinical trial; Regimen; Pharmacology; Internal medicine","score_opus":0.05275818304034082,"score_gpt":0.3716207093072084,"score_spread":0.3188625262668676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401606908","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006347225,0.99900275,0.000059567155,0.00028292614,0.00022673153,0.000005731307,0.000010876213,0.0000022911313,0.00034572792],"genre_scores_gemma":[0.0004354976,0.99843925,0.00013825593,0.00044392358,0.00033520008,0.00001065352,0.000021159089,0.0000012075525,0.00017475754],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995234,0.000114954266,0.00012504197,0.000076542754,0.0001279777,0.000032195305],"domain_scores_gemma":[0.99836427,0.001081193,0.0002135915,0.00002791464,0.00023759756,0.00007546331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010066988,0.0008690133,0.0014973041,0.0031677838,0.0003661589,0.0015061708,0.0010661945,0.0014160575,0.0034690665],"category_scores_gemma":[0.0025403255,0.00030581155,0.0011686856,0.0029158762,0.0005805411,0.002059895,0.0007622314,0.0020476475,0.0010692491],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000177832,0.000072693285,0.00021982811,0.09691951,0.00023391143,0.0004344437,0.00020717259,0.00037007497,0.0008640259,0.0047176057,0.050743457,0.84503937],"study_design_scores_gemma":[0.000036486184,0.00016720254,0.00090200506,0.052067753,0.0004831982,0.003162919,0.00013691359,0.00009639471,0.00020820026,0.0018154649,0.9408904,0.00003297969],"about_ca_topic_score_codex":0.0013400804,"about_ca_topic_score_gemma":0.0026663737,"teacher_disagreement_score":0.0034690665,"about_ca_system_score_codex":0.00091604306,"about_ca_system_score_gemma":0.0014118992,"threshold_uncertainty_score":0.011605203},"labels":[],"label_agreement":null},{"id":"W4401668701","doi":"10.1007/s13555-024-01238-5","title":"Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Bausch Health; Sanofi Genzyme; Incyte; CTI Biopharma; Les Laboratories Pierre Fabre; Celldex Therapeutics; Valeant Pharmaceuticals International; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Medac; AbbVie; Baxalta; Celgene; Biogen; Gilead Sciences; Sanofi; Amgen; Pfizer; Galderma; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Discontinuation; Psoriatic arthritis; Psoriasis; Adverse effect; Population; Internal medicine; Dermatology; Surgery","score_opus":0.04121194750481737,"score_gpt":0.3684384994092988,"score_spread":0.3272265519044814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401668701","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4388994,0.53686035,0.0053674737,0.00149156,0.00014815273,0.0017172516,0.011648598,0.00014890345,0.0037182756],"genre_scores_gemma":[0.89952755,0.082772344,0.0035404703,0.0013196403,0.00025975323,0.0009581361,0.011274808,0.00005112123,0.0002961918],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9710298,0.012275767,0.007545393,0.002642997,0.005982189,0.0005238774],"domain_scores_gemma":[0.9041693,0.053236768,0.031648736,0.004330307,0.0052236905,0.0013912143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03831578,0.00067470246,0.0036798143,0.0028219004,0.0003188353,0.00207747,0.000712859,0.00087613275,0.0012576993],"category_scores_gemma":[0.04121556,0.0004756638,0.00715662,0.0047459677,0.00057078415,0.0012516225,0.0009600765,0.0009689526,0.00021735617],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024619283,0.00044194408,0.47042197,0.03525429,0.16903035,0.00046162787,0.00038595067,0.003702412,0.0030038229,0.00047498467,0.005023524,0.2871799],"study_design_scores_gemma":[0.0061953724,0.00929852,0.82947785,0.0065848557,0.119204536,0.0020369529,0.00020480725,0.0024170391,0.0013261621,0.0010690662,0.022004874,0.00018002509],"about_ca_topic_score_codex":0.00043758628,"about_ca_topic_score_gemma":0.0013193864,"teacher_disagreement_score":0.03831578,"about_ca_system_score_codex":0.0008669606,"about_ca_system_score_gemma":0.0016713756,"threshold_uncertainty_score":0.2026357},"labels":[],"label_agreement":null},{"id":"W4401802229","doi":"10.1007/s13555-024-01250-9","title":"Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Janssen Pharmaceuticals; Janssen Scientific Affairs","keywords":"Dermatology Life Quality Index; Adalimumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Quality of life (healthcare); Anxiety; Placebo; Depression (economics); Internal medicine; Mediation; Dermatology; Psychiatry; Pathology; Disease","score_opus":0.00909996769524771,"score_gpt":0.2415113970875818,"score_spread":0.23241142939233408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401802229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769333,0.01123164,0.0031868685,0.0026644024,0.00028415018,0.00063695444,0.0016978042,0.000070522656,0.003294288],"genre_scores_gemma":[0.9960448,0.0010851128,0.0011401018,0.00024546092,0.00009415713,0.0004768851,0.00028498605,0.000010339457,0.0006181233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9862324,0.01094745,0.00036255186,0.0010097731,0.00065422227,0.00079350645],"domain_scores_gemma":[0.9739337,0.022431972,0.0015597402,0.0009158481,0.00057171384,0.00058710284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014209342,0.0017570683,0.002144703,0.0008294738,0.00073710433,0.0019183945,0.001768995,0.00123283,0.01083321],"category_scores_gemma":[0.023966886,0.0009386963,0.0097691,0.000791556,0.0007528892,0.001178223,0.0023722032,0.0024038225,0.0004420796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05290264,0.003525184,0.7764916,0.0029057665,0.08814307,0.0010188542,0.002015351,0.004222919,0.0014469719,0.00347962,0.0021772059,0.061670825],"study_design_scores_gemma":[0.01878731,0.018741993,0.73321694,0.0015467267,0.16855212,0.0012730466,0.002267916,0.037194766,0.0023907374,0.010082467,0.005696515,0.0002494654],"about_ca_topic_score_codex":0.0053820936,"about_ca_topic_score_gemma":0.0034220389,"teacher_disagreement_score":0.014209342,"about_ca_system_score_codex":0.0011162619,"about_ca_system_score_gemma":0.002528018,"threshold_uncertainty_score":0.07514709},"labels":[],"label_agreement":null},{"id":"W4402497013","doi":"10.1007/s13555-024-01264-3","title":"Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses","year":2024,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Post-hoc analysis; Medicine; Psoriasis; Post hoc; Dermatology; Internal medicine","score_opus":0.03730252384487797,"score_gpt":0.3197305289108256,"score_spread":0.2824280050659476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402497013","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012961327,0.9973362,0.00018047869,0.00018155019,0.00016087662,0.00012055964,0.00026499116,0.000008142452,0.00045093647],"genre_scores_gemma":[0.03322975,0.9630471,0.0010948506,0.00081489317,0.00044942627,0.00034641314,0.0006760387,0.000023729708,0.0003179193],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99451584,0.001978407,0.0020054795,0.00047454285,0.00091294566,0.000112665126],"domain_scores_gemma":[0.9731408,0.018716607,0.004674078,0.0005205477,0.0027593307,0.00018861602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010592059,0.00084595854,0.0054080896,0.0022521836,0.00023620788,0.0017690194,0.0012833953,0.0007124677,0.0035881107],"category_scores_gemma":[0.021782456,0.0004177938,0.008329683,0.0020968206,0.0005017833,0.0009809101,0.0004927896,0.0013409314,0.00036621597],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008531604,0.0001487442,0.0040577766,0.447213,0.056952454,0.00012049235,0.0002117435,0.000406208,0.001032237,0.00068198366,0.007408993,0.47323483],"study_design_scores_gemma":[0.006597891,0.008715779,0.056666642,0.32606924,0.40181035,0.0015558465,0.00036276947,0.0009904064,0.0039998223,0.0019839332,0.19097523,0.00027214084],"about_ca_topic_score_codex":0.0010800987,"about_ca_topic_score_gemma":0.0030002268,"teacher_disagreement_score":0.010592059,"about_ca_system_score_codex":0.0014069552,"about_ca_system_score_gemma":0.002073561,"threshold_uncertainty_score":0.056016803},"labels":[],"label_agreement":null},{"id":"W4402580541","doi":"10.1007/s13555-024-01258-1","title":"Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; LEO Pharma; UCB Pharma; Regeneron Pharmaceuticals; Celgene; Eli Lilly and Company; Bristol-Myers Squibb; Ortho Dermatologics; Janssen Pharmaceuticals; UCB US; Gilead Sciences; Sanofi; Pfizer; Genentech; National Psoriasis Foundation; Amgen","keywords":"Psoriasis; Psoriatic arthritis; Medicine; Dermatology; Disease; Arthritis; Internal medicine","score_opus":0.0255114006844872,"score_gpt":0.27182321956590577,"score_spread":0.24631181888141856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402580541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99114555,0.004146917,0.00020603079,0.00030908984,0.00003152358,0.000026937767,0.0029640535,0.000007675469,0.0011621095],"genre_scores_gemma":[0.996783,0.00088752265,0.0001171688,0.00008434733,0.000031797295,0.000013413453,0.002001811,0.0000031057434,0.00007775475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995544,0.0021738238,0.0004690999,0.00066610007,0.00085014827,0.00029690342],"domain_scores_gemma":[0.9730383,0.010265552,0.011580897,0.0024678584,0.0016415212,0.00100584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050710915,0.00022875301,0.00045232428,0.0007614278,0.00036042611,0.001086366,0.0006698166,0.0004808724,0.0012508056],"category_scores_gemma":[0.021296022,0.00030736247,0.0012595328,0.0017059937,0.0003115655,0.0006803958,0.00053853536,0.00094822276,0.00015094936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005365638,0.00003901125,0.995814,0.00004149982,0.00040068312,0.00001656887,0.000034574412,0.0000821669,0.000015556498,0.000026915257,0.00022822442,0.0027642522],"study_design_scores_gemma":[0.000051896874,0.00011305221,0.9983582,0.00004510603,0.00029977786,0.00009341606,0.000087229186,0.0003675657,0.000022833568,0.00003529662,0.00051722216,0.000008298219],"about_ca_topic_score_codex":0.019268475,"about_ca_topic_score_gemma":0.018694717,"teacher_disagreement_score":0.019268475,"about_ca_system_score_codex":0.0005612931,"about_ca_system_score_gemma":0.0009005531,"threshold_uncertainty_score":0.038312674},"labels":[],"label_agreement":null},{"id":"W4402938707","doi":"10.1007/s13555-024-01271-4","title":"Correction: Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study","year":2024,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Lynde Centre for Dermatology; University of Toronto","funders":"","keywords":"Certolizumab pegol; Plaque psoriasis; Medicine; Psoriasis; Medical physics; Dermatology; Internal medicine; Adalimumab","score_opus":0.04964615182662028,"score_gpt":0.33680599483069884,"score_spread":0.28715984300407854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402938707","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029591293,0.0019366111,0.00028290926,0.03833335,0.95540786,0.000024639558,0.0019056235,0.00012886612,0.0016842162],"genre_scores_gemma":[0.03113639,0.020440176,0.0069636395,0.12145045,0.60317266,0.00035072645,0.008900785,0.0021096012,0.2054756],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958139,0.0007733031,0.00082969246,0.0005086485,0.0017296654,0.00034488586],"domain_scores_gemma":[0.96989644,0.009286839,0.0019025356,0.0016138706,0.015638897,0.001661452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049963617,0.0021435583,0.0018796141,0.0030622939,0.0014288239,0.0037379693,0.002651624,0.0047127227,0.027315954],"category_scores_gemma":[0.06278424,0.0008505495,0.0019057039,0.0022357714,0.0011040516,0.0014243312,0.0011166274,0.00664385,0.014754884],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011233452,0.000012427808,0.00027684923,0.00023702314,0.000033982134,0.00031931375,0.00001721681,0.000039110662,0.00002781644,0.0002860051,0.9914397,0.0071983216],"study_design_scores_gemma":[0.00041087272,0.00006142205,0.004857958,0.001353217,0.00025783284,0.0016105559,0.00013715212,0.00031539137,0.00050739973,0.00084722345,0.98956525,0.00007573003],"about_ca_topic_score_codex":0.020050805,"about_ca_topic_score_gemma":0.019222839,"teacher_disagreement_score":0.027315954,"about_ca_system_score_codex":0.0032604001,"about_ca_system_score_gemma":0.006049144,"threshold_uncertainty_score":0.091380954},"labels":[],"label_agreement":null},{"id":"W4403061875","doi":"10.1007/s13555-024-01268-z","title":"A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"AbbVie","keywords":"Post-hoc analysis; Ethnic group; Medicine; Psoriasis; Post hoc; Descriptive statistics; Internal medicine; Dermatology; Political science; Statistics; Mathematics","score_opus":0.026430391181251064,"score_gpt":0.2666626916384742,"score_spread":0.24023230045722316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403061875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99599385,0.0002031269,0.000852489,0.000047080353,0.000024269233,0.0003285734,0.0015428024,0.00001812964,0.0009897528],"genre_scores_gemma":[0.9974874,0.000036897352,0.00051853765,0.00006164029,0.000021382302,0.00043493914,0.001154818,0.0000057135067,0.00027876813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99632794,0.0014491209,0.00051206356,0.00060218654,0.0008580883,0.00025055584],"domain_scores_gemma":[0.9910198,0.0051334836,0.0019015839,0.0007251993,0.0009098744,0.00031003953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052493885,0.0002709285,0.00073605496,0.0006274981,0.00031442265,0.0005285398,0.00038803468,0.0002802262,0.0037408562],"category_scores_gemma":[0.008432037,0.00014449749,0.0010420171,0.00067451055,0.00031461907,0.0005590085,0.00035566723,0.0004569854,0.00027684253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030021688,0.0016243104,0.94110733,0.0002798628,0.002283677,0.0002552151,0.00053877354,0.00044447972,0.0028534054,0.00025010225,0.0019561762,0.018385204],"study_design_scores_gemma":[0.0011018395,0.022280717,0.96748614,0.00004137797,0.001065818,0.0005057853,0.0008669755,0.0023860026,0.0016394166,0.00018379767,0.0024163139,0.000025870175],"about_ca_topic_score_codex":0.0004186897,"about_ca_topic_score_gemma":0.0005461765,"teacher_disagreement_score":0.0052493885,"about_ca_system_score_codex":0.00034757255,"about_ca_system_score_gemma":0.0006502861,"threshold_uncertainty_score":0.027761817},"labels":[],"label_agreement":null},{"id":"W4403840641","doi":"10.1007/s13555-024-01288-9","title":"Patient and Healthcare Provider Perspectives on Disease Burden of Seborrheic Dermatitis in the United States: Results from a National Survey","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Seborrheic dermatitis; Health care; Medicine; Disease; Survey research; Family medicine; Dermatology; Psychology; Political science; Pathology","score_opus":0.02679554618663165,"score_gpt":0.316664420357197,"score_spread":0.28986887417056534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403840641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821769,0.00095159345,0.0001246383,0.0014007201,0.000027646716,0.000073697505,0.012732739,0.000013731744,0.0024983387],"genre_scores_gemma":[0.99452114,0.0008336401,0.0002267089,0.0004361739,0.000023155244,0.00008560348,0.0035746768,0.0000029575467,0.0002959299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998787,0.00048640437,0.00022437861,0.00013926924,0.00022462718,0.00013826427],"domain_scores_gemma":[0.9958072,0.0010926026,0.002118825,0.00011137863,0.00043832144,0.00043171088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018018888,0.0001405534,0.0002489537,0.0009408192,0.0003369417,0.0006041385,0.00024184168,0.000445009,0.0028907517],"category_scores_gemma":[0.005430656,0.00018265864,0.0005755622,0.0014538448,0.00018891487,0.0007023866,0.0007744141,0.0005539474,0.00028716712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039108036,0.00004467411,0.9930841,0.00007805427,0.00006879126,0.000022642134,0.0003293389,0.000055731558,0.000029331464,0.00001632724,0.0018491875,0.004382822],"study_design_scores_gemma":[0.0000063314774,0.00003869205,0.9979646,0.000059042464,0.00002283249,0.000048904618,0.001138811,0.000077109944,0.000017919172,0.000015211242,0.0006054814,0.000004886669],"about_ca_topic_score_codex":0.016661251,"about_ca_topic_score_gemma":0.023450179,"teacher_disagreement_score":0.016661251,"about_ca_system_score_codex":0.00048714894,"about_ca_system_score_gemma":0.0005475216,"threshold_uncertainty_score":0.03312856},"labels":[],"label_agreement":null},{"id":"W4404293285","doi":"10.1007/s13555-024-01303-z","title":"Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Kyowa Kirin International","keywords":"Atopic dermatitis; Placebo; Double blind; Medicine; Dermatology; Double blind study; Internal medicine; Alternative medicine; Pathology","score_opus":0.01786456798619309,"score_gpt":0.30138050329688326,"score_spread":0.2835159353106902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404293285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99178195,0.0054808147,0.00035278234,0.00020046506,0.00008640663,0.0009913648,0.0004431664,0.000060822254,0.00060221215],"genre_scores_gemma":[0.99460185,0.0019192441,0.0007697903,0.0004913883,0.00021230656,0.0009181379,0.0005881285,0.0000134341535,0.0004856843],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989177,0.0006385495,0.000101428726,0.00013933063,0.00011122198,0.00009170481],"domain_scores_gemma":[0.998741,0.0004410355,0.00037411833,0.000090471345,0.00011897373,0.0002344995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032657322,0.0010360882,0.0021699157,0.0002936549,0.00028662718,0.0007076798,0.0005451405,0.0010448019,0.0026670964],"category_scores_gemma":[0.0023118749,0.00038493556,0.0012757963,0.0002809343,0.0005007648,0.0005407597,0.00024416228,0.0012151407,0.00040225452],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8603135,0.026584225,0.008926111,0.001988658,0.0032630076,0.00011095727,0.0001852768,0.00042466057,0.015030625,0.00004730079,0.0014741812,0.08165154],"study_design_scores_gemma":[0.6475412,0.2902943,0.057629887,0.00008578247,0.0014780798,0.00017584272,0.000041625983,0.00050088303,0.0013037592,0.000055593777,0.00086398405,0.000029023891],"about_ca_topic_score_codex":0.0002959814,"about_ca_topic_score_gemma":0.0006301023,"teacher_disagreement_score":0.0032657322,"about_ca_system_score_codex":0.00028844582,"about_ca_system_score_gemma":0.0005958493,"threshold_uncertainty_score":0.017271101},"labels":[],"label_agreement":null},{"id":"W4404544951","doi":"10.1007/s13555-024-01308-8","title":"A Narrative Review of the OX40-OX40L Pathway as a Potential Therapeutic Target in Atopic Dermatitis: Focus on Rocatinlimab and Amlitelimab","year":2024,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Atopic dermatitis; Focus (optics); Narrative; Dermatology; Medicine; Narrative review; Immunology; Intensive care medicine; Art; Literature; Physics","score_opus":0.019116775874798195,"score_gpt":0.3224888187418461,"score_spread":0.3033720428670479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404544951","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000054596243,0.9992399,0.00003487212,0.00015197882,0.00015767709,0.0000066731227,0.000021175896,0.0000027016213,0.00033037693],"genre_scores_gemma":[0.00028061125,0.99909353,0.00008528031,0.00017099768,0.00011724265,0.000009319107,0.000028548413,9.244474e-7,0.00021361504],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99969804,0.00006183384,0.00007738029,0.00004817806,0.000093136514,0.00002145337],"domain_scores_gemma":[0.9990884,0.0005625483,0.00015263449,0.00001375715,0.00014231955,0.000040231072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076672196,0.00091920677,0.0017759476,0.003704591,0.0003141392,0.0013114923,0.0008959557,0.0011184248,0.006452234],"category_scores_gemma":[0.001777547,0.00032492244,0.001293033,0.0037392376,0.0003191105,0.0013300242,0.0006573858,0.0013542288,0.0014327433],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001703774,0.00007388893,0.00016697259,0.22473505,0.00044458214,0.0003113017,0.0001483866,0.0003735786,0.0011500783,0.0032899021,0.06627396,0.70286196],"study_design_scores_gemma":[0.000050309067,0.00014311234,0.001035359,0.073069505,0.0010924365,0.0015919199,0.00010191614,0.00009580603,0.00025366043,0.0012618692,0.92127514,0.000029066994],"about_ca_topic_score_codex":0.0013713731,"about_ca_topic_score_gemma":0.0026851196,"teacher_disagreement_score":0.006452234,"about_ca_system_score_codex":0.0006897857,"about_ca_system_score_gemma":0.0018717999,"threshold_uncertainty_score":0.021584868},"labels":[],"label_agreement":null},{"id":"W4404627081","doi":"10.1007/s13555-024-01295-w","title":"Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"UCB Pharma; XBiotech; National Institute for Health and Care Research; Sanofi; Manchester Biomedical Research Centre; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Scalp; Medicine; Dermatology; Randomized controlled trial; Psoriasis; Internal medicine; Surgery","score_opus":0.016499543770947603,"score_gpt":0.29786979812062464,"score_spread":0.28137025434967705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404627081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81970304,0.16199069,0.004985283,0.0005769682,0.00078262185,0.002795861,0.006567449,0.0002701734,0.0023279851],"genre_scores_gemma":[0.9760987,0.013587641,0.001903033,0.0008022122,0.00044520787,0.0018504424,0.0045419903,0.00007013363,0.0007005646],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9879759,0.0073426533,0.0015870691,0.0012327351,0.0011978112,0.0006638717],"domain_scores_gemma":[0.9874449,0.0054689785,0.0039601363,0.0013694618,0.0010594417,0.000697209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026996786,0.0017519129,0.007831438,0.0012849333,0.000507978,0.0025805004,0.0007821881,0.001758325,0.0016931591],"category_scores_gemma":[0.013478048,0.0009398794,0.017339034,0.0018881273,0.0006767861,0.0015347952,0.0009233121,0.0024945058,0.00025000935],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7278639,0.0010398969,0.026357321,0.007559363,0.19717284,0.00014714838,0.00012878404,0.0021944281,0.004249124,0.00015353355,0.0022810304,0.030852681],"study_design_scores_gemma":[0.3864533,0.07497149,0.19132301,0.0012747669,0.3331697,0.00049729255,0.00017424801,0.0029232649,0.0025550271,0.000741773,0.005713253,0.00020290028],"about_ca_topic_score_codex":0.00083511183,"about_ca_topic_score_gemma":0.001776472,"teacher_disagreement_score":0.026996786,"about_ca_system_score_codex":0.00077819644,"about_ca_system_score_gemma":0.0015001998,"threshold_uncertainty_score":0.1427744},"labels":[],"label_agreement":null},{"id":"W4406730782","doi":"10.1007/s13555-024-01323-9","title":"Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto; Memorial University of Newfoundland","funders":"Eli Lilly and Company; Bristol-Myers Squibb; Galderma; Incyte; XBiotech; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Teijin Pharma; Teva Pharmaceutical Industries; Sanofi; Pfizer; National Psoriasis Foundation; Amgen","keywords":"Ixekizumab; Psoriatic arthritis; Medicine; Psoriasis; Post-hoc analysis; Arthritis; Term (time); Dermatology; Internal medicine","score_opus":0.006849029917933229,"score_gpt":0.24418872447783002,"score_spread":0.23733969455989679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406730782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99551576,0.0021639022,0.0005830649,0.000060274288,0.000050053317,0.00023060809,0.0009611443,0.000024644685,0.00041055016],"genre_scores_gemma":[0.99787784,0.00023997543,0.00030000793,0.000056878176,0.000058935286,0.00020645156,0.0009290989,0.0000079111915,0.00032295796],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9951073,0.0027090968,0.00045923417,0.00084882847,0.0004510343,0.0004246444],"domain_scores_gemma":[0.9936499,0.0032999106,0.0013618865,0.0007586841,0.0004784297,0.00045128522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008212478,0.0010806802,0.0028198776,0.00074064254,0.0003070652,0.0012638681,0.00076604704,0.0006938567,0.0028402805],"category_scores_gemma":[0.005886036,0.00041593943,0.009374226,0.00069137017,0.00044665544,0.0007252162,0.0008049296,0.0012005543,0.00023176684],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.509621,0.0021347585,0.31708413,0.0016569224,0.13823663,0.00028647485,0.00019251573,0.0045009637,0.0047377027,0.00013432818,0.0012380376,0.020176511],"study_design_scores_gemma":[0.058150806,0.111157276,0.7053941,0.0001649165,0.10337689,0.00050437986,0.0002713263,0.0141747575,0.003770752,0.0003813029,0.0025323553,0.00012105982],"about_ca_topic_score_codex":0.0009784675,"about_ca_topic_score_gemma":0.0010776817,"teacher_disagreement_score":0.008212478,"about_ca_system_score_codex":0.0005807063,"about_ca_system_score_gemma":0.0009945594,"threshold_uncertainty_score":0.043432236},"labels":[],"label_agreement":null},{"id":"W4407134354","doi":"10.1007/s13555-025-01342-0","title":"Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto; Lynde Centre for Dermatology","funders":"AbbVie","keywords":"Observational study; Interim; Medicine; Psoriasis; Interim analysis; Value (mathematics); Dermatology; Internal medicine; Clinical trial; Political science; Statistics; Mathematics","score_opus":0.013512419789648596,"score_gpt":0.26710814172110503,"score_spread":0.2535957219314564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407134354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99466246,0.0014308085,0.0005321909,0.00010770218,0.00004104054,0.0001449041,0.0024534632,0.000027409695,0.0006000441],"genre_scores_gemma":[0.9926835,0.0002499867,0.0006118256,0.00016902189,0.00006626136,0.00024046787,0.0055354335,0.000011093658,0.00043235553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972658,0.0014087862,0.00020058246,0.00039826115,0.0003453385,0.00038128134],"domain_scores_gemma":[0.9936307,0.0018930522,0.0025513603,0.001077727,0.00034447404,0.00050265406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006851126,0.00065958063,0.0017106826,0.0003574682,0.00030823078,0.0012857137,0.0005718714,0.0007472425,0.0016949535],"category_scores_gemma":[0.0061502834,0.00046447862,0.0044738944,0.00055531424,0.00037020288,0.000772846,0.00047314662,0.001881053,0.00043701436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42165038,0.0052732043,0.5115799,0.00055200054,0.010060616,0.00039152798,0.00026263646,0.0035240764,0.004225138,0.0002716644,0.0036088105,0.03860011],"study_design_scores_gemma":[0.019944923,0.07500455,0.8871479,0.000102353035,0.007738287,0.0004386796,0.00015394697,0.0034040522,0.002559142,0.0003021764,0.003110802,0.00009311941],"about_ca_topic_score_codex":0.0005773836,"about_ca_topic_score_gemma":0.00079694827,"teacher_disagreement_score":0.006851126,"about_ca_system_score_codex":0.0005279578,"about_ca_system_score_gemma":0.00065599196,"threshold_uncertainty_score":0.03623265},"labels":[],"label_agreement":null},{"id":"W4407567762","doi":"10.1007/s13555-025-01357-7","title":"Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy","year":2025,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; SKiN Health","funders":"Sanofi Genzyme; Genentech; Glenmark Pharmaceuticals; Pfizer; Biogen; Incyte; Moderna; UCB Pharma; Valeant Pharmaceuticals International; Argenx; Kiniksa Pharmaceuticals; Ribon Therapeutics; Sun Pharma; Dermira; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; LEO Pharma; Gilead Sciences; Bausch Health; L'Oreal USA; Sanofi; Celgene; GlaxoSmithKline; Amgen; Galderma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atopic dermatitis; Medicine; Meta-analysis; Systemic therapy; Dermatology; Internal medicine","score_opus":0.07042809012567897,"score_gpt":0.35360654330752384,"score_spread":0.28317845318184487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407567762","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032324713,0.96172017,0.0019758267,0.0006944259,0.0003780571,0.0004934866,0.0015377852,0.0000877593,0.0007878146],"genre_scores_gemma":[0.72473866,0.26494986,0.0046961377,0.001349503,0.0005431616,0.0014304781,0.0016828714,0.00007839341,0.0005308582],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9840978,0.011048896,0.0019523349,0.0016123876,0.0009796413,0.00030885442],"domain_scores_gemma":[0.9761549,0.018461796,0.003271621,0.0009551099,0.0008505948,0.0003058805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022242453,0.0026348839,0.013077177,0.004670171,0.0005156499,0.0031359356,0.0017430666,0.0016682738,0.0034376595],"category_scores_gemma":[0.033155426,0.0012263632,0.04860415,0.0038902836,0.00065134675,0.0013032369,0.0013536859,0.0017354013,0.00026764403],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056537394,0.000030869705,0.0055134846,0.05060895,0.9276785,0.00005194631,0.000029132514,0.0010922359,0.00015633366,0.00010418308,0.00034057218,0.008740101],"study_design_scores_gemma":[0.0021520702,0.00038727402,0.003852278,0.0036953243,0.9880774,0.000052253257,0.000017524811,0.0005679141,0.00010091866,0.00034964192,0.0007308509,0.0000166288],"about_ca_topic_score_codex":0.0047949757,"about_ca_topic_score_gemma":0.007845745,"teacher_disagreement_score":0.022242453,"about_ca_system_score_codex":0.0021275573,"about_ca_system_score_gemma":0.0020015207,"threshold_uncertainty_score":0.11763078},"labels":[],"label_agreement":null},{"id":"W4407589934","doi":"10.1007/s13555-025-01343-z","title":"Abstracts of the 9th Annual Symposium on Hidradenitis Suppurativa Advances 2024","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of California, San Francisco; Sjællands Universitetshospital; University College Dublin; Cardiff University; University of Southern California; Hidradenitis Suppurativa Foundation; Erasmus Universitair Medisch Centrum Rotterdam; Northwell Health; Queen's University; Charles and Helen Schwab Foundation; Brigham and Women's Hospital","keywords":"Hidradenitis suppurativa; Medicine; Dermatology; Internal medicine; Disease","score_opus":0.007087350014536145,"score_gpt":0.2757539418132613,"score_spread":0.26866659179872515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407589934","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026428148,0.28469098,0.0010475293,0.046738163,0.5319646,0.00037008538,0.0008458688,0.0001626801,0.13153733],"genre_scores_gemma":[0.008765667,0.15010834,0.0011220806,0.009631079,0.3250309,0.00026625788,0.0013243199,0.00013054349,0.50362086],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99928707,0.00010467504,0.000053719854,0.0000837572,0.00033024728,0.00014053135],"domain_scores_gemma":[0.998762,0.0001346995,0.000087291024,0.00003448792,0.0005082013,0.00047343379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001581067,0.001899154,0.0011973053,0.0019014648,0.0011377751,0.0028364528,0.001031481,0.0034712052,0.072646305],"category_scores_gemma":[0.0013815962,0.0003970454,0.0013101602,0.0008502849,0.00039999018,0.0013604389,0.0017711138,0.0036336244,0.029899256],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035332108,0.00015607101,0.00026591244,0.00071894133,0.000030441757,0.00021935717,0.000047903257,0.00008099754,0.0016532213,0.0007591402,0.91697735,0.07873725],"study_design_scores_gemma":[0.000037662885,0.00013871814,0.0010507412,0.00035825878,0.000030343634,0.0002106127,0.000034578676,0.000044278797,0.00032046254,0.00038567762,0.9973797,0.000008943612],"about_ca_topic_score_codex":0.001369919,"about_ca_topic_score_gemma":0.0050282613,"teacher_disagreement_score":0.072646305,"about_ca_system_score_codex":0.0012257425,"about_ca_system_score_gemma":0.0015797549,"threshold_uncertainty_score":0.24302608},"labels":[],"label_agreement":null},{"id":"W4408191973","doi":"10.1007/s13555-024-01317-7","title":"Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials","year":2025,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Psoriasis; Randomized controlled trial; Medicine; Internal medicine; Dermatology","score_opus":0.01633031962578176,"score_gpt":0.26834044493712034,"score_spread":0.2520101253113386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408191973","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009677181,0.001922247,0.000306248,0.073134616,0.9210655,0.000044086988,0.0014744593,0.00019146061,0.0017645454],"genre_scores_gemma":[0.007183137,0.0112656355,0.0030135554,0.17657222,0.69618505,0.00038068998,0.0027892338,0.0009761443,0.10163433],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99494886,0.0011502756,0.0008774348,0.0007019374,0.0018418203,0.0004795918],"domain_scores_gemma":[0.9694299,0.010273223,0.0030825592,0.00135934,0.013702576,0.0021524287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006840693,0.0024338309,0.0031770032,0.00269824,0.001902084,0.0046125725,0.0033880603,0.007506871,0.05004012],"category_scores_gemma":[0.06357098,0.0013742377,0.0025154816,0.0019990013,0.0019024072,0.0017337854,0.00113877,0.014392283,0.02255441],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008068047,0.0000068641725,0.000052266383,0.00018026477,0.000029818797,0.00008453087,0.0000076033684,0.000025885114,0.000018509032,0.00017243015,0.99561274,0.0037284342],"study_design_scores_gemma":[0.00076530426,0.00006178891,0.0013811948,0.0012430568,0.00026816237,0.0006048042,0.000043501255,0.00033904074,0.0003129708,0.0012113118,0.9937058,0.00006304588],"about_ca_topic_score_codex":0.016186083,"about_ca_topic_score_gemma":0.023258965,"teacher_disagreement_score":0.05004012,"about_ca_system_score_codex":0.0050579705,"about_ca_system_score_gemma":0.0077837836,"threshold_uncertainty_score":0.1674009},"labels":[],"label_agreement":null},{"id":"W4408552243","doi":"10.1007/s13555-025-01369-3","title":"Brodalumab for Plaque Psoriasis in the Canadian Real-World Setting: A Retrospective Cohort Analysis of up to 4 Years","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SKiN Health; University of Calgary; McMaster University; Lynde Centre for Dermatology; Dalhousie University; University of Toronto; Probity Medical Research; Bausch Health (Canada); Health Canada","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Retrospective cohort study; Cohort; Dermatology; Internal medicine","score_opus":0.012138154383044289,"score_gpt":0.2727859351044288,"score_spread":0.2606477807213845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408552243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99374336,0.000968212,0.0001243695,0.00009063732,0.000012466679,0.00008693659,0.003923632,0.0000084564645,0.0010420395],"genre_scores_gemma":[0.99655664,0.00045020712,0.00017664545,0.00008368837,0.000015478889,0.000047327827,0.002401131,0.0000061375717,0.00026277907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980484,0.00013778884,0.00012845243,0.00051786355,0.00068582525,0.00048160827],"domain_scores_gemma":[0.99691355,0.0001742271,0.0011518747,0.00038268292,0.00093097065,0.0004466241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015642763,0.0006614301,0.00066926435,0.0015584396,0.0025112077,0.0013763432,0.0013400894,0.0006671161,0.0017850355],"category_scores_gemma":[0.002927894,0.000617228,0.0011233883,0.0034643766,0.00063633587,0.0005205272,0.000866954,0.0011137011,0.00035068876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023299624,0.0000350413,0.9973356,0.000025547044,0.00015845004,0.00012768456,0.00014562954,0.000043899603,0.000094723546,0.000038223257,0.00045539948,0.001306834],"study_design_scores_gemma":[0.00002647154,0.00010333905,0.9978231,0.000024213567,0.00012241903,0.00031147656,0.00032770346,0.00018622099,0.000042267973,0.000018289616,0.0009987893,0.00001572216],"about_ca_topic_score_codex":0.739561,"about_ca_topic_score_gemma":0.7450876,"teacher_disagreement_score":0.26043898,"about_ca_system_score_codex":0.0061434326,"about_ca_system_score_gemma":0.00924402,"threshold_uncertainty_score":0.52394545},"labels":[],"label_agreement":null},{"id":"W4409039284","doi":"10.1007/s13555-025-01366-6","title":"Single-Injection Options for Administering a 320 mg Dose of Bimekizumab: 2 mL Safety Syringe and Auto-injector","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB","keywords":"Medicine; Adverse effect; Syringe; Injection site; Discontinuation; Anesthesia; Pharmacokinetics; Adalimumab; Placebo; Bioequivalence; Self-administration; Surgery; Pharmacology; Internal medicine; Rheumatoid arthritis","score_opus":0.022848295447719286,"score_gpt":0.2676768045114574,"score_spread":0.24482850906373813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409039284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.814429,0.029443126,0.11719589,0.0023848042,0.0009531686,0.005993727,0.00333548,0.0037379484,0.022526957],"genre_scores_gemma":[0.90934277,0.0039883736,0.07240101,0.0013017274,0.00044591926,0.002536785,0.0016285013,0.00015233169,0.0082024885],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99853504,0.0004526285,0.00017760112,0.00024193703,0.000467818,0.00012495465],"domain_scores_gemma":[0.9987301,0.00042691285,0.00044409354,0.0002061728,0.000076838776,0.00011592477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002671781,0.0005272419,0.0007103575,0.00075167156,0.00020699798,0.0007353436,0.0007981871,0.0013651522,0.008882473],"category_scores_gemma":[0.0022489766,0.00034565764,0.0010762515,0.00035326308,0.0004273435,0.0008836325,0.00056201045,0.001356898,0.0025868951],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018988574,0.0113114575,0.008207761,0.001690476,0.00048661357,0.00057755527,0.00039810137,0.0009679858,0.12124453,0.0019212217,0.010426859,0.82377887],"study_design_scores_gemma":[0.0343309,0.28208733,0.08316244,0.0011890613,0.00178471,0.017578034,0.000526499,0.021547507,0.33843926,0.0039171483,0.21484074,0.00059639476],"about_ca_topic_score_codex":0.00024495155,"about_ca_topic_score_gemma":0.00035963958,"teacher_disagreement_score":0.008882473,"about_ca_system_score_codex":0.00023889789,"about_ca_system_score_gemma":0.00036371264,"threshold_uncertainty_score":0.029714823},"labels":[],"label_agreement":null},{"id":"W4409476142","doi":"10.1007/s13555-025-01395-1","title":"Complete/Near-Complete Itch Response Observed in Patients with Moderate-to-Severe Atopic Dermatitis Initiating Dupilumab: 3-Year, Real-World, Interim Data from the PROSE Registry","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lynde Centre for Dermatology; University of Toronto","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Dupilumab; Atopic dermatitis; Interim; Dermatology; Medicine; Interim analysis; Clinical trial; Internal medicine; Geography","score_opus":0.05460224207085992,"score_gpt":0.3047415583324011,"score_spread":0.2501393162615412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409476142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961653,0.00056948356,0.0001553407,0.000038328453,0.000009488061,0.00004564074,0.002352588,0.000010026533,0.000653862],"genre_scores_gemma":[0.9960485,0.00015398039,0.00012800496,0.000049851762,0.000018144437,0.000052048214,0.0034346548,0.0000032467278,0.00011164301],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971675,0.0010801147,0.0004610393,0.0004610169,0.0005289117,0.0003015455],"domain_scores_gemma":[0.9922578,0.0017339053,0.0039850036,0.0007043878,0.00078771304,0.0005313082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041864063,0.00025764998,0.0007658628,0.000567643,0.00041697462,0.0011962667,0.00036814628,0.00049101625,0.0009315863],"category_scores_gemma":[0.006291309,0.00023556306,0.0012535941,0.0007384539,0.00027651992,0.0010339377,0.0006551713,0.001020755,0.00026526698],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025009564,0.0001446307,0.9918412,0.000059539554,0.00027258348,0.00013575735,0.00009755527,0.00018920349,0.00021297262,0.000030603038,0.0004100084,0.004104969],"study_design_scores_gemma":[0.00017421678,0.0011336968,0.9960562,0.000023343093,0.0002244711,0.0006643081,0.00014185692,0.0004833078,0.00017126343,0.000033334152,0.00087429356,0.0000196923],"about_ca_topic_score_codex":0.0013336024,"about_ca_topic_score_gemma":0.0015571994,"teacher_disagreement_score":0.0041864063,"about_ca_system_score_codex":0.00034146104,"about_ca_system_score_gemma":0.0004422602,"threshold_uncertainty_score":0.022140086},"labels":[],"label_agreement":null},{"id":"W4409602439","doi":"10.1007/s13555-025-01402-5","title":"Canadian Consensus Guidelines for the Management of Vitiligo","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"melanin and skin pigmentation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Trent University; Lynde Centre for Dermatology; Dalhousie University; Women's College Hospital; University of Toronto; Nova Chemicals (Canada); Centre de Recherche Dermatologique du Québec Métropolitain; Vancouver Coastal Health Research Institute; University of British Columbia; Probity Medical Research; Blackberry (Canada); Calgary Laboratory Services; SKiN Health; McGill University; University of Calgary","funders":"Incyte","keywords":"Vitiligo; Medicine; Political science; Dermatology","score_opus":0.024369523344469252,"score_gpt":0.3249563532079566,"score_spread":0.3005868298634874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409602439","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016057245,0.52597845,0.036587723,0.24374308,0.025476681,0.009965638,0.013459576,0.0013423638,0.14184076],"genre_scores_gemma":[0.038790986,0.5316846,0.24520312,0.07311405,0.0055539147,0.01693587,0.031341884,0.000772982,0.05660272],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9604718,0.013305477,0.0077546574,0.0014190533,0.0149613125,0.0020876632],"domain_scores_gemma":[0.9036861,0.015188156,0.006313809,0.0022542886,0.06876538,0.0037923215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03400306,0.001863879,0.0025745083,0.012697958,0.004349525,0.004833888,0.009701309,0.008136618,0.021385606],"category_scores_gemma":[0.08950168,0.0012233648,0.0063105808,0.008701199,0.0029859375,0.0030247073,0.0047414317,0.010141367,0.008073244],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009271313,0.000078878606,0.0010958978,0.02038466,0.00023724897,0.000626208,0.0011544302,0.00073252094,0.00038468515,0.013967765,0.67082226,0.2904228],"study_design_scores_gemma":[0.00014621815,0.000043470445,0.002229379,0.048181795,0.0003412798,0.0010257203,0.000644281,0.00033856937,0.00022667542,0.0072109303,0.93951994,0.00009172885],"about_ca_topic_score_codex":0.22002931,"about_ca_topic_score_gemma":0.24649073,"teacher_disagreement_score":0.97653145,"about_ca_system_score_codex":0.023468537,"about_ca_system_score_gemma":0.12174333,"threshold_uncertainty_score":0.43749714},"labels":[],"label_agreement":null},{"id":"W4409602973","doi":"10.1007/s13555-025-01399-x","title":"In Vitro and In Vivo Assessment of an Innovative Peeling System with Azelaic and Tranexamic Acids for Targeted Hyperpigmentation Reduction","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"melanin and skin pigmentation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Covenant Health","funders":"","keywords":"Hyperpigmentation; Tranexamic acid; In vivo; Azelaic acid; Dermatology; In vitro; Reduction (mathematics); Medicine; Pharmacology; Chemistry; Surgery; Biology; Biochemistry; Blood loss; Mathematics; Biotechnology","score_opus":0.007048688154364181,"score_gpt":0.2857926015899777,"score_spread":0.27874391343561356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409602973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964011,0.0013573013,0.0017735513,0.0000146635375,0.000012745273,0.000057474324,0.00005363433,0.000010780213,0.00031885132],"genre_scores_gemma":[0.9937395,0.0009236774,0.0043761805,0.000019652249,0.000008369516,0.000065283355,0.00008415229,0.00000667143,0.00077655766],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983335,0.000037960246,0.00001280779,0.00004010674,0.00005085711,0.000024879557],"domain_scores_gemma":[0.9998653,0.00004224858,0.000038340317,0.000013356743,0.000023087367,0.000017533583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040943827,0.00032363483,0.00024046765,0.0001565247,0.00012451164,0.00019205181,0.00017393792,0.0002790265,0.0009067299],"category_scores_gemma":[0.0002256305,0.00013591912,0.0002510757,0.00011378738,0.00014303233,0.00019585332,0.00013284507,0.00028551792,0.00013193047],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026107449,0.00010827311,0.000110606736,0.00005623186,0.000007430584,0.000017728242,0.000017373744,0.00007699123,0.99766624,0.000007590519,0.0000093566605,0.001661206],"study_design_scores_gemma":[0.000050013634,0.007861971,0.003344467,0.000007731027,0.000044571585,0.00014540696,0.000026190493,0.0008442076,0.9869986,0.000009242941,0.0006622613,0.0000053512613],"about_ca_topic_score_codex":0.0003458155,"about_ca_topic_score_gemma":0.00050444243,"teacher_disagreement_score":0.0009067299,"about_ca_system_score_codex":0.000121511184,"about_ca_system_score_gemma":0.000121584315,"threshold_uncertainty_score":0.00303334},"labels":[],"label_agreement":null},{"id":"W4409783088","doi":"10.1007/s13555-025-01386-2","title":"Canadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical Therapies","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Dalhousie University; McGill University; Blackberry (Canada); University of Toronto; Lynde Centre for Dermatology; Centre de Recherche Dermatologique du Québec Métropolitain; Vancouver Coastal Health Research Institute; University of British Columbia; Probity Medical Research; SKiN Health; Women's College Hospital; Queen's University","funders":"Incyte","keywords":"Atopic dermatitis; Medicine; Dermatology; Consensus conference; Internal medicine","score_opus":0.025676813470825493,"score_gpt":0.3126022110351191,"score_spread":0.2869253975642936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409783088","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024042274,0.49536294,0.039951235,0.25834376,0.023313258,0.013003335,0.012242805,0.0013575687,0.15402085],"genre_scores_gemma":[0.042459853,0.4952324,0.29964295,0.06659407,0.0048677535,0.014152521,0.03013753,0.00053565175,0.0463773],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9659476,0.00981904,0.0069655613,0.0010725004,0.014500672,0.0016945851],"domain_scores_gemma":[0.9150763,0.009753698,0.0051732087,0.001633293,0.06506026,0.0033032496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026746377,0.0017678856,0.0023773343,0.008475004,0.003954329,0.004149878,0.008449062,0.0069632553,0.011611319],"category_scores_gemma":[0.06048456,0.0010320093,0.0056331544,0.0062295496,0.002276347,0.0020416374,0.0035552192,0.008662638,0.0050736615],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010324519,0.0001118303,0.0013419157,0.014447102,0.00024799662,0.00073472376,0.0010325667,0.0009939575,0.0005913629,0.009452669,0.6344698,0.3364728],"study_design_scores_gemma":[0.00018251041,0.0000515002,0.0028105797,0.03122765,0.00034348515,0.00086839654,0.00040245932,0.00044295695,0.0002920817,0.0042608976,0.9590304,0.000087133776],"about_ca_topic_score_codex":0.32135907,"about_ca_topic_score_gemma":0.41143703,"teacher_disagreement_score":0.9764583,"about_ca_system_score_codex":0.023541695,"about_ca_system_score_gemma":0.11784221,"threshold_uncertainty_score":0.6389771},"labels":[],"label_agreement":null},{"id":"W4410112845","doi":"10.1007/s13555-025-01420-3","title":"Correction: Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months","year":2025,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto; Lynde Centre for Dermatology","funders":"LEO Pharma; Sanofi; Eisai; Celgene; Eli Lilly and Company; Amgen","keywords":"Observational study; Psoriasis; Interim; Medicine; Interim analysis; Value (mathematics); Dermatology; Internal medicine; Clinical trial; Political science; Statistics; Mathematics","score_opus":0.0881417380056911,"score_gpt":0.3694065200282699,"score_spread":0.2812647820225788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410112845","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032272795,0.00095741346,0.0009888037,0.057542957,0.9120571,0.00010655737,0.025050098,0.0005591045,0.0024152047],"genre_scores_gemma":[0.042807348,0.0067777517,0.014128284,0.17089832,0.4939566,0.0017705203,0.036372866,0.00461627,0.22867207],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.98936874,0.0026251082,0.0022386455,0.0012330987,0.0037873946,0.00074707955],"domain_scores_gemma":[0.9041505,0.041943207,0.0057293386,0.006887475,0.038332824,0.0029566286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012313735,0.0031577116,0.0037042124,0.0041608843,0.001482304,0.0043325075,0.005266385,0.005544798,0.09312524],"category_scores_gemma":[0.21296306,0.0017135629,0.00384248,0.004716549,0.0016240097,0.0022239517,0.0014953306,0.011540023,0.03185035],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010433406,0.0000067673777,0.0001613589,0.00018243566,0.000053072214,0.0000778234,0.000008077706,0.000066429464,0.00001113267,0.0001991428,0.99645656,0.00267292],"study_design_scores_gemma":[0.0026691875,0.000119337594,0.00935453,0.0035247442,0.0008382579,0.0010628798,0.0001602491,0.0022025346,0.0007311052,0.0050045196,0.97412044,0.00021226115],"about_ca_topic_score_codex":0.049809303,"about_ca_topic_score_gemma":0.050488688,"teacher_disagreement_score":0.09312524,"about_ca_system_score_codex":0.00518321,"about_ca_system_score_gemma":0.010020858,"threshold_uncertainty_score":0.31153494},"labels":[],"label_agreement":null},{"id":"W4410386249","doi":"10.1007/s13555-025-01425-y","title":"Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023","year":2025,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly Canada; Eli Lilly and Company","keywords":"Alopecia areata; Atopic dermatitis; Dermatology; Medicine","score_opus":0.05614012639521138,"score_gpt":0.3888074622409804,"score_spread":0.332667335845769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410386249","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013834598,0.99648595,0.00014039854,0.00034591655,0.00013902805,0.0003150198,0.0007583254,0.000009065456,0.0004228486],"genre_scores_gemma":[0.02197477,0.97503585,0.0006724481,0.0008352765,0.00015054755,0.00056767854,0.0006237125,0.000009200422,0.00013052297],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98993194,0.0032142778,0.004478368,0.00062009494,0.0014607552,0.00029469217],"domain_scores_gemma":[0.9471671,0.036960203,0.010447392,0.00067062647,0.004294001,0.00046066698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010953165,0.001464649,0.007888994,0.013909473,0.00060473615,0.0032085595,0.0019016241,0.0019697759,0.0075407326],"category_scores_gemma":[0.049636293,0.000991906,0.009936216,0.012331493,0.000937324,0.0023801632,0.0017365599,0.0013963019,0.00061811844],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002624728,0.0000148223835,0.0007696604,0.9649403,0.012079307,0.00008819324,0.00010989788,0.000060822495,0.00012782271,0.00012504676,0.00090391043,0.020517686],"study_design_scores_gemma":[0.00034384182,0.00019438693,0.0035697592,0.8820259,0.1012587,0.00032112008,0.00021850382,0.000058648766,0.00014056942,0.00022452092,0.011614717,0.000029361418],"about_ca_topic_score_codex":0.005836977,"about_ca_topic_score_gemma":0.01831964,"teacher_disagreement_score":0.013909473,"about_ca_system_score_codex":0.003447444,"about_ca_system_score_gemma":0.011381082,"threshold_uncertainty_score":0.057926536},"labels":[],"label_agreement":null},{"id":"W4410417696","doi":"10.1007/s13555-025-01426-x","title":"Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 Trials","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Barrie Urology Group","funders":"Novartis Pharma; Incyte; Beth Israel Deaconess Medical Center; Sanofi; Novartis; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Hidradenitis suppurativa; Post-hoc analysis; Medicine; Secukinumab; Term (time); Post hoc; Sunburn; Dermatology; Internal medicine; Disease","score_opus":0.030757738874637695,"score_gpt":0.36117694443044535,"score_spread":0.33041920555580767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410417696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96243614,0.023980746,0.0018109523,0.0007197603,0.0009018442,0.0049478123,0.0027901577,0.00016354687,0.0022491256],"genre_scores_gemma":[0.9876952,0.0028590304,0.0012977745,0.0004695862,0.0003382741,0.004320205,0.0011993098,0.000041082338,0.0017795702],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99301565,0.005167528,0.00047339004,0.00047227915,0.00036003278,0.0005111423],"domain_scores_gemma":[0.9900193,0.006006121,0.0018396511,0.00074536644,0.0006666455,0.0007228102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013201971,0.0020597675,0.0058821924,0.00049907836,0.00044767713,0.0017767957,0.0010270332,0.001438197,0.0057914625],"category_scores_gemma":[0.009112169,0.00062197406,0.012538819,0.00059426157,0.0008901322,0.0011930793,0.000950807,0.002732057,0.000604722],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97407305,0.00080459326,0.0012551937,0.001272919,0.01494404,0.000033706972,0.00004600159,0.0004933935,0.0010841172,0.00004337767,0.00038894234,0.005560829],"study_design_scores_gemma":[0.74856806,0.17994913,0.028709797,0.00029422212,0.03628599,0.000114466064,0.000117640084,0.001696939,0.001484445,0.0004088763,0.002281185,0.0000892744],"about_ca_topic_score_codex":0.0006467359,"about_ca_topic_score_gemma":0.0014275598,"teacher_disagreement_score":0.013201971,"about_ca_system_score_codex":0.0008583492,"about_ca_system_score_gemma":0.001135131,"threshold_uncertainty_score":0.06981951},"labels":[],"label_agreement":null},{"id":"W4410443520","doi":"10.1007/s13555-025-01440-z","title":"Efficacy and Safety of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel: Post Hoc Analysis by Baseline Disease Severity","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Adapalene; Benzoyl peroxide; Post-hoc analysis; Post hoc; Clindamycin; Medicine; Phosphate; Dermatology; Baseline (sea); Acne; Internal medicine; Chemistry; Organic chemistry; Antibiotics; Political science","score_opus":0.005670551036702147,"score_gpt":0.26776364810348513,"score_spread":0.26209309706678297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410443520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940043,0.0017303812,0.00063324964,0.00010698262,0.0000924139,0.001027767,0.0012631813,0.000041378327,0.0011003924],"genre_scores_gemma":[0.9943817,0.0004792494,0.0010559396,0.00009401363,0.00006557472,0.0017846498,0.0005604137,0.00002365427,0.0015547684],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99701285,0.0014506732,0.00026872763,0.0005419759,0.00037152483,0.00035420057],"domain_scores_gemma":[0.9952336,0.0024108503,0.0011090942,0.0003650108,0.00044633393,0.0004352186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040053157,0.00075727276,0.0023259073,0.00040751425,0.0002417075,0.0007397841,0.0005209642,0.0006142562,0.0064820875],"category_scores_gemma":[0.003880294,0.00037041557,0.0024757925,0.0003502512,0.000422314,0.0008296892,0.00045126976,0.001477848,0.0004943068],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9407314,0.0063196453,0.0047677713,0.0006649553,0.0024310092,0.000025744122,0.00014843016,0.0004778464,0.016972395,0.00006384846,0.00061349757,0.02678342],"study_design_scores_gemma":[0.09557088,0.78957224,0.08289687,0.00015388906,0.007863481,0.00007503474,0.00018391712,0.0023708362,0.018172814,0.00029401897,0.002779995,0.0000660688],"about_ca_topic_score_codex":0.0005388781,"about_ca_topic_score_gemma":0.0009774226,"teacher_disagreement_score":0.0064820875,"about_ca_system_score_codex":0.0005746437,"about_ca_system_score_gemma":0.0010974491,"threshold_uncertainty_score":0.021684766},"labels":[],"label_agreement":null},{"id":"W4410850742","doi":"10.1007/s13555-025-01434-x","title":"Tildrakizumab Treatment Patterns in Adults With Moderate-to-Severe Plaque Psoriasis: A Retrospective Analysis From the Canadian Patient Support Program","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Brampton Civic Hospital; Nova Chemicals (Canada); Bayer (Canada); Probity Medical Research; Calgary Laboratory Services; SKiN Health; University of Calgary","funders":"Sun Pharma","keywords":"Medicine; Plaque psoriasis; Psoriasis; Retrospective cohort study; Dermatology; Internal medicine","score_opus":0.007483775893738951,"score_gpt":0.22781465538256276,"score_spread":0.22033087948882382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410850742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919247,0.0010245615,0.00007035602,0.00009683535,0.0000059568447,0.00009113155,0.005762249,0.000006502715,0.0010177853],"genre_scores_gemma":[0.9963676,0.00045433504,0.00011197246,0.00008956439,0.00000626554,0.000047512523,0.0028047524,0.0000028150653,0.000115199444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799144,0.0001320289,0.00021645377,0.00038889624,0.0009022082,0.000369013],"domain_scores_gemma":[0.9973888,0.00019803838,0.0010975047,0.00015455637,0.0007852329,0.0003759117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010465792,0.0003565127,0.00056721835,0.0016461052,0.0013612743,0.0008863203,0.0010174375,0.0004542027,0.0011249996],"category_scores_gemma":[0.0025566355,0.00036524617,0.00058972626,0.005644314,0.00045184203,0.00034370803,0.00065621897,0.0005840593,0.00014691435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008475551,0.000018498937,0.99817574,0.000033351036,0.000050702438,0.00003707779,0.00014159131,0.000022536371,0.000050878552,0.000016042704,0.00030977925,0.0010590208],"study_design_scores_gemma":[0.000007951475,0.000024573195,0.9991899,0.000019878566,0.000026773014,0.00007106768,0.0002412434,0.000082726,0.00001791404,0.0000034721857,0.00031020818,0.0000043417267],"about_ca_topic_score_codex":0.86130893,"about_ca_topic_score_gemma":0.875941,"teacher_disagreement_score":0.13869107,"about_ca_system_score_codex":0.0068790335,"about_ca_system_score_gemma":0.009884385,"threshold_uncertainty_score":0.27901566},"labels":[],"label_agreement":null},{"id":"W4410949005","doi":"10.1007/s13555-025-01443-w","title":"Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; University of Calgary","funders":"AbbVie","keywords":"Eczema Area and Severity Index; Medicine; Placebo; Dupilumab; Atopic dermatitis; Dermatology Life Quality Index; Clinical trial; Quality of life (healthcare); Internal medicine; Dermatology; Pathology","score_opus":0.052138522535357085,"score_gpt":0.34514272975325316,"score_spread":0.2930042072178961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410949005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886417,0.008054745,0.00037294894,0.00023411086,0.000113281305,0.00075022073,0.0004827296,0.00006007759,0.0012902601],"genre_scores_gemma":[0.99621093,0.0017244853,0.0005226461,0.00026307604,0.00007580882,0.00047284798,0.000351136,0.000005593671,0.000373477],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99925524,0.00040383893,0.00006663155,0.00009261379,0.00008852613,0.00009322292],"domain_scores_gemma":[0.9988901,0.00031787402,0.00039876037,0.000066631095,0.000060154798,0.00026645244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023713468,0.00082693226,0.0016381276,0.00039171902,0.00029926322,0.0007371798,0.0004667119,0.0006833489,0.0016655164],"category_scores_gemma":[0.0015371601,0.0003251558,0.0021270409,0.00041184828,0.0006323523,0.00076974573,0.00030966316,0.0020046302,0.00018392412],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.790378,0.021732956,0.0061110626,0.002862294,0.0042547835,0.00014626315,0.00021147069,0.0025634351,0.020229248,0.0002940564,0.0024599647,0.14875655],"study_design_scores_gemma":[0.43538168,0.52043015,0.028309053,0.00018299493,0.0032420515,0.00039748667,0.00010264577,0.002061183,0.007671781,0.0003834069,0.0017627974,0.0000747907],"about_ca_topic_score_codex":0.0004669286,"about_ca_topic_score_gemma":0.0019129226,"teacher_disagreement_score":0.0023713468,"about_ca_system_score_codex":0.0005499985,"about_ca_system_score_gemma":0.0007187212,"threshold_uncertainty_score":0.012540996},"labels":[],"label_agreement":null},{"id":"W4411000674","doi":"10.1007/s13555-025-01453-8","title":"Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; University of Calgary; Probity Medical Research; Health Sciences Centre; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Sanofi Genzyme; LEO Pharma; Galderma; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Dupilumab; Atopic dermatitis; Medicine; Retrospective cohort study; Multicenter study; Cohort; Dermatology; Internal medicine; Randomized controlled trial","score_opus":0.005650236608070343,"score_gpt":0.26809496436534785,"score_spread":0.2624447277572775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411000674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985447,0.00072294637,0.000070159964,0.000015519561,0.000004163257,0.000040406645,0.0004128974,0.000002096766,0.00018707395],"genre_scores_gemma":[0.99905246,0.0001413867,0.00008514955,0.000024685725,0.000012865458,0.000036613073,0.0005726645,0.0000017713328,0.0000724567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986778,0.00039481235,0.00018068061,0.000386756,0.00022406178,0.00013589424],"domain_scores_gemma":[0.99626654,0.00056961615,0.0021982598,0.00037080585,0.0002807322,0.00031411895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024328702,0.0004134976,0.00072032196,0.0005254491,0.00038873445,0.000913508,0.00043246406,0.0004759582,0.0011006068],"category_scores_gemma":[0.002724362,0.00026423734,0.0009274746,0.0007539231,0.0003323054,0.0006728541,0.00038084364,0.0006497908,0.000277748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007631685,0.0004026019,0.985157,0.000116550946,0.0006851683,0.00016274926,0.00013749464,0.00014950558,0.0007367223,0.000023063612,0.00017151562,0.004625936],"study_design_scores_gemma":[0.00042070478,0.0050680623,0.9910817,0.000038755534,0.0006285664,0.0010183738,0.00018307526,0.0003638609,0.00042955676,0.000022014448,0.00072590646,0.000019360506],"about_ca_topic_score_codex":0.0007222821,"about_ca_topic_score_gemma":0.00064372853,"teacher_disagreement_score":0.0024328702,"about_ca_system_score_codex":0.0004965857,"about_ca_system_score_gemma":0.0002685855,"threshold_uncertainty_score":0.012866378},"labels":[],"label_agreement":null},{"id":"W4411539937","doi":"10.1007/s13555-025-01452-9","title":"Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Dermira; Eli Lilly and Company","keywords":"Extension (predicate logic); Atopic dermatitis; Term (time); Dermatology; Medicine; Pediatrics; Computer science; Physics; Programming language","score_opus":0.007114266231606919,"score_gpt":0.254723067199235,"score_spread":0.24760880096762808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411539937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99737,0.0015099642,0.00013313674,0.00006661896,0.000018856534,0.00022858518,0.00021590183,0.000012381392,0.00044439395],"genre_scores_gemma":[0.9976876,0.0004621829,0.00031499745,0.00016631841,0.000054963493,0.00024871933,0.0005536036,0.0000031851457,0.0005085418],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99938107,0.00029079552,0.000054910386,0.00010126271,0.00007722852,0.0000947336],"domain_scores_gemma":[0.9984653,0.00034446258,0.00046339512,0.0001713976,0.00014270007,0.00041273053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029644957,0.000500619,0.001057894,0.00019230596,0.00032073463,0.0005800306,0.0003761049,0.0005828831,0.0016370892],"category_scores_gemma":[0.0011041673,0.00022946077,0.0017247054,0.00022454523,0.00030665856,0.00059350877,0.00039361947,0.0014395316,0.00028620064],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77272916,0.020436782,0.057890162,0.0009209405,0.0020338835,0.0002694706,0.00031870345,0.0009776388,0.021704918,0.00012258509,0.0013505601,0.121245205],"study_design_scores_gemma":[0.18994978,0.5987035,0.19964282,0.00010977166,0.0025076247,0.0004908871,0.000098653036,0.0009270963,0.0039928257,0.0001448418,0.0033856938,0.00004654243],"about_ca_topic_score_codex":0.00042817925,"about_ca_topic_score_gemma":0.0012503786,"teacher_disagreement_score":0.0029644957,"about_ca_system_score_codex":0.00040231488,"about_ca_system_score_gemma":0.00065412436,"threshold_uncertainty_score":0.015677929},"labels":[],"label_agreement":null},{"id":"W4411698955","doi":"10.1007/s13555-025-01469-0","title":"Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic Dermatitis","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trent University; Probity Medical Research; SKiN Health; Queen's University","funders":"AbbVie","keywords":"Atopic dermatitis; Quality of life (healthcare); Medicine; Disease; Dermatology; Internal medicine; Nursing","score_opus":0.01439431996463099,"score_gpt":0.30945580545963347,"score_spread":0.2950614854950025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411698955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99276406,0.0043113413,0.00033933355,0.00046318214,0.000029707997,0.0001250188,0.0003179912,0.000013883138,0.0016355535],"genre_scores_gemma":[0.9990006,0.00027636238,0.00030640306,0.00013009208,0.000021735073,0.00008792738,0.000111457804,0.0000014995384,0.00006377282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763155,0.0014970881,0.00021706666,0.00019806466,0.00025208236,0.00020405921],"domain_scores_gemma":[0.99691284,0.0015917841,0.0008982552,0.00013812621,0.00011938163,0.00033957715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038386271,0.00024474773,0.0010871425,0.00015095482,0.00021781404,0.0006784122,0.00019554526,0.00028763321,0.0019028826],"category_scores_gemma":[0.004205563,0.00009899627,0.0012576112,0.00026683864,0.00025401104,0.00042417095,0.00044228614,0.00083482417,0.00013222694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1793539,0.0067097824,0.39505145,0.002876514,0.0053785276,0.00011258582,0.00047654496,0.0059416327,0.005583199,0.0006269405,0.0036373488,0.39425156],"study_design_scores_gemma":[0.021292234,0.112389535,0.84602565,0.000500109,0.0053534773,0.0005677285,0.0005778415,0.0040829247,0.0034186984,0.0013126013,0.0044157766,0.00006343911],"about_ca_topic_score_codex":0.00032071414,"about_ca_topic_score_gemma":0.00066333474,"teacher_disagreement_score":0.0038386271,"about_ca_system_score_codex":0.0004209344,"about_ca_system_score_gemma":0.0006676409,"threshold_uncertainty_score":0.020300865},"labels":[],"label_agreement":null},{"id":"W4412395244","doi":"10.1007/s13555-025-01485-0","title":"Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trent University; Probity Medical Research; SKiN Health; Queen's University","funders":"AbbVie","keywords":"Atopic dermatitis; Measure (data warehouse); Medicine; Dermatology; Computer science; Data mining","score_opus":0.02678635831070938,"score_gpt":0.3347314174133577,"score_spread":0.30794505910264836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412395244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9460429,0.035689194,0.0036228278,0.0010105808,0.00014985373,0.005495578,0.0030924494,0.0001736069,0.0047228914],"genre_scores_gemma":[0.9857991,0.004035345,0.00433261,0.000733336,0.00010266457,0.0025930933,0.0018679214,0.000036093064,0.00049978134],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99564916,0.0028658465,0.0002597589,0.00028530078,0.0005746862,0.00036523567],"domain_scores_gemma":[0.9976667,0.0006811886,0.00090340606,0.00022180835,0.00020588592,0.00032107733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010391815,0.00092900917,0.0030370916,0.0005375151,0.00031679342,0.0020820918,0.0006560639,0.0007426717,0.0016195062],"category_scores_gemma":[0.004015452,0.00047653384,0.005698459,0.0006209896,0.00046049262,0.0008585291,0.00079188275,0.0026994466,0.00021964718],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60832787,0.01095191,0.049698163,0.007098594,0.02593525,0.0001727964,0.00046299043,0.00783285,0.021433368,0.0015297974,0.006603644,0.2599528],"study_design_scores_gemma":[0.39382845,0.2891703,0.2252635,0.0015367646,0.040260382,0.0009046864,0.0002469115,0.010200154,0.015834374,0.002747351,0.019731808,0.0002752814],"about_ca_topic_score_codex":0.0005259808,"about_ca_topic_score_gemma":0.0020871954,"teacher_disagreement_score":0.010391815,"about_ca_system_score_codex":0.0011585128,"about_ca_system_score_gemma":0.0019549,"threshold_uncertainty_score":0.054957807},"labels":[],"label_agreement":null},{"id":"W4412492282","doi":"10.1007/s13555-025-01463-6","title":"Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Alberta; University of Saskatchewan; EVERSANA (Canada); Western University; University of Toronto; Dalhousie University; Dermatrials Research; Probity Medical Research; McMaster University","funders":"LEO Pharma; Bausch Health; Astellas Pharma; Mylan; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Valeant Pharmaceuticals International; Janssen Canada; Sanofi; Amgen; Pfizer; Meiji Seika Pharma; Galderma; Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Psoriasis Area and Severity Index; Secukinumab; Internal medicine; Onset of action; Psoriasis; Confidence interval; Meta-analysis; Dermatology; Psoriatic arthritis","score_opus":0.031940586587068345,"score_gpt":0.2905279435827251,"score_spread":0.25858735699565677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412492282","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0057875714,0.9903319,0.0012626211,0.00029332514,0.00018282478,0.0005855455,0.0010878538,0.000051101248,0.00041735655],"genre_scores_gemma":[0.22869828,0.7602833,0.004064941,0.001391288,0.00033152112,0.0026577823,0.0019225647,0.000069111105,0.0005811814],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9877359,0.006318257,0.0028316977,0.0013843498,0.0013655545,0.00036420257],"domain_scores_gemma":[0.97406185,0.019067561,0.0040338826,0.00071089494,0.0017876405,0.00033818456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018153273,0.0027312073,0.01848891,0.0087585095,0.00054865784,0.003213437,0.0019959717,0.001923095,0.0043022144],"category_scores_gemma":[0.036645185,0.001344206,0.038145274,0.009514951,0.0006517603,0.002188319,0.002013772,0.0020052935,0.00039866642],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020695294,0.000025129773,0.0026162863,0.3210511,0.6628807,0.00010685793,0.00006255561,0.0008013592,0.00016261614,0.00017925672,0.0006446285,0.009400091],"study_design_scores_gemma":[0.00057297305,0.00013372902,0.0021193505,0.018569432,0.9766001,0.00006735446,0.000027085316,0.00027418692,0.00006806514,0.00024300489,0.0013045153,0.000020266163],"about_ca_topic_score_codex":0.0074318224,"about_ca_topic_score_gemma":0.015994724,"teacher_disagreement_score":0.01848891,"about_ca_system_score_codex":0.003201692,"about_ca_system_score_gemma":0.0041136,"threshold_uncertainty_score":0.096004784},"labels":[],"label_agreement":null},{"id":"W4412530626","doi":"10.1007/s13555-025-01478-z","title":"Correction: Complete/Near-Complete Itch Response Observed in Patients with Moderate-to-Severe Atopic Dermatitis Initiating Dupilumab: 3-Year, Real-World, Interim Data from the PROSE Registry","year":2025,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; University of Toronto","funders":"","keywords":"Dupilumab; Atopic dermatitis; Interim; Dermatology; Medicine; Interim analysis; Clinical trial; Internal medicine; History","score_opus":0.05136536911327145,"score_gpt":0.2977765509348031,"score_spread":0.24641118182153166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412530626","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008035245,0.001185898,0.00085409783,0.08978472,0.888959,0.000079542406,0.0140169915,0.00047436077,0.0038419175],"genre_scores_gemma":[0.07761292,0.012647056,0.011755848,0.19790506,0.49581456,0.0008413105,0.034043025,0.0031482135,0.16623202],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99379045,0.0012929746,0.0014518517,0.0008001555,0.0020769623,0.0005875742],"domain_scores_gemma":[0.95602816,0.015320522,0.004605248,0.002655146,0.019510942,0.0018799902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065377876,0.0018152705,0.0020109105,0.0031877903,0.0016613378,0.0036730815,0.0031120796,0.0043656183,0.03769666],"category_scores_gemma":[0.09436782,0.0010852794,0.0017347174,0.0028154857,0.0013396351,0.0017825442,0.0012464259,0.008308676,0.017063653],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064381726,0.0000073689334,0.0004944473,0.00014839965,0.00002528144,0.00030544648,0.000017610419,0.000044887383,0.000016503494,0.00027183298,0.9944705,0.004133189],"study_design_scores_gemma":[0.00048959145,0.000064457934,0.008765389,0.0019712404,0.00020743144,0.0028431662,0.00025339352,0.0007502137,0.0005115084,0.0018638524,0.9821552,0.00012470865],"about_ca_topic_score_codex":0.023934126,"about_ca_topic_score_gemma":0.024634484,"teacher_disagreement_score":0.03769666,"about_ca_system_score_codex":0.003260696,"about_ca_system_score_gemma":0.0058767465,"threshold_uncertainty_score":0.12610787},"labels":[],"label_agreement":null},{"id":"W4412703250","doi":"10.1007/s13555-025-01484-1","title":"Clinically Meaningful Improvements in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab who did not Achieve Clear or Almost Clear Skin at Week 16","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Genentech; LEO Pharma; Bausch Health; Glenmark Pharmaceuticals; Sanofi Genzyme; Incyte; CTI Biopharma; BioCryst; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Celldex Therapeutics; Amgen; Pfizer; Galderma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atopic dermatitis; Dermatology; Medicine","score_opus":0.012931610498249884,"score_gpt":0.2713952044670975,"score_spread":0.2584635939688476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412703250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99819237,0.0008538678,0.00008445186,0.00005074948,0.000018256262,0.00008482639,0.00021148582,0.0000054739494,0.00049859204],"genre_scores_gemma":[0.99891794,0.00025814702,0.0001978578,0.000115254225,0.000010917895,0.00008342419,0.00023439949,0.0000020094485,0.00018007479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99946934,0.00023827853,0.000043626445,0.000080928054,0.00008199602,0.00008593617],"domain_scores_gemma":[0.99934334,0.00025185905,0.00018558245,0.000031985917,0.000055439326,0.00013184224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011092632,0.00017125953,0.0008429234,0.000107189386,0.00013788887,0.00037668456,0.00012267365,0.00021805757,0.0011867932],"category_scores_gemma":[0.0011377145,0.000102103186,0.0009158275,0.00013561347,0.00017803027,0.00030123664,0.00015653693,0.00085669255,0.00011889404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2826114,0.014726054,0.44966632,0.002347666,0.004511481,0.0010375556,0.0009229227,0.0025287697,0.06310296,0.0006574401,0.004800496,0.17308699],"study_design_scores_gemma":[0.027798364,0.1779792,0.77406865,0.00031333696,0.0026088627,0.0012593805,0.0004302091,0.00238215,0.0068157827,0.0002808927,0.0060251784,0.00003811122],"about_ca_topic_score_codex":0.00064109,"about_ca_topic_score_gemma":0.002169857,"teacher_disagreement_score":0.0011867932,"about_ca_system_score_codex":0.0003233785,"about_ca_system_score_gemma":0.00054645276,"threshold_uncertainty_score":0.0058664083},"labels":[],"label_agreement":null},{"id":"W4413052347","doi":"10.1007/s13555-025-01498-9","title":"The Urticaria Voices Study: Physicians’ Perspectives on the Real-World Patient Burden, Treatments, and Outcomes in Chronic Spontaneous Urticaria","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharma; Asthma and Allergy Foundation of America","keywords":"Medicine; Omalizumab; Guideline; Quality of life (healthcare); Chronic urticaria; Family medicine; Cross-sectional study; Pediatrics; Internal medicine; Nursing; Immunoglobulin E","score_opus":0.008665839796341288,"score_gpt":0.2836571114187984,"score_spread":0.2749912716224571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413052347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986045,0.00021255299,0.00003593025,0.00047722526,0.000009309572,0.000022084872,0.00011679611,9.38322e-7,0.00052068784],"genre_scores_gemma":[0.99905354,0.0001648735,0.00009941917,0.0003362416,0.00003939358,0.000047192705,0.00013156942,0.0000012815124,0.00012640846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954749,0.0031742952,0.00027043914,0.00019876493,0.0005016043,0.00038001937],"domain_scores_gemma":[0.988054,0.004991644,0.0043477667,0.0002566644,0.0007959298,0.0015540073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053968243,0.00017224047,0.00029683765,0.00054206117,0.0009136168,0.001139465,0.00023165705,0.0007141886,0.0009110859],"category_scores_gemma":[0.0119026,0.00020932851,0.00031950715,0.0007140525,0.00056383817,0.0012468761,0.0014103975,0.000614984,0.00011085404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007785213,0.00091819576,0.9276484,0.00021200106,0.00011881991,0.0008555343,0.047716875,0.00009493841,0.0010434381,0.00015237728,0.0027051177,0.01775574],"study_design_scores_gemma":[0.0002468582,0.0009825106,0.92256415,0.00015531394,0.000063731044,0.0012358382,0.06902951,0.00035993126,0.00032155166,0.00010208707,0.004895581,0.000042957166],"about_ca_topic_score_codex":0.0047943685,"about_ca_topic_score_gemma":0.010603149,"teacher_disagreement_score":0.0053968243,"about_ca_system_score_codex":0.00069529144,"about_ca_system_score_gemma":0.0010317301,"threshold_uncertainty_score":0.028541505},"labels":[],"label_agreement":null},{"id":"W4413992604","doi":"10.1007/s13555-025-01503-1","title":"Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic Dermatitis","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada); University of British Columbia; EVERSANA (Canada); SKiN Health","funders":"Incyte","keywords":"Ruxolitinib; Atopic dermatitis; Medicine; Dermatology; Meta-analysis; Internal medicine; Myelofibrosis","score_opus":0.08300561932064904,"score_gpt":0.34513289262683955,"score_spread":0.2621272733061905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413992604","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07254429,0.9100213,0.006869518,0.0013817264,0.0011985702,0.0012142088,0.0036725723,0.00031850656,0.002779276],"genre_scores_gemma":[0.89548594,0.09158345,0.005632941,0.0015830807,0.000383964,0.001658806,0.002394072,0.00009631415,0.0011814546],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9832617,0.013001749,0.0012486613,0.0013710402,0.0008081562,0.00030862325],"domain_scores_gemma":[0.9838464,0.013035101,0.0015408713,0.0006868796,0.0006336545,0.00025703042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018815361,0.002932593,0.012028021,0.002896982,0.00043045924,0.002384178,0.0020425664,0.0020087785,0.0043773544],"category_scores_gemma":[0.031322405,0.0010907447,0.043126952,0.0027739424,0.00046826425,0.0013933815,0.001369658,0.00225773,0.00040219314],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011546491,0.000042366835,0.0032010206,0.028693998,0.9478349,0.000080025435,0.000026222557,0.0025771873,0.00018423403,0.00014726934,0.00050493435,0.00516132],"study_design_scores_gemma":[0.0027048031,0.0004368321,0.0027231942,0.0015596226,0.9898928,0.00004735585,0.000015882219,0.0014297932,0.00007196706,0.00041715102,0.0006826554,0.000017862549],"about_ca_topic_score_codex":0.008054163,"about_ca_topic_score_gemma":0.010566764,"teacher_disagreement_score":0.018815361,"about_ca_system_score_codex":0.0020336746,"about_ca_system_score_gemma":0.0015498652,"threshold_uncertainty_score":0.09950632},"labels":[],"label_agreement":null},{"id":"W4414371190","doi":"10.1007/s13555-025-01533-9","title":"Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health","keywords":"Narrative review; Psoriasis; Biologic Agents; Mechanism (biology); Observational study; Action (physics)","score_opus":0.015095661325495979,"score_gpt":0.25821738763741076,"score_spread":0.24312172631191478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414371190","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014494116,0.9962721,0.00024430844,0.00053193496,0.00017930176,0.00002209235,0.000027353355,0.0000052852865,0.0012682953],"genre_scores_gemma":[0.02340595,0.9738535,0.0006702461,0.0009378304,0.0002883289,0.000035239496,0.000053027885,0.0000043951195,0.00075135805],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99938405,0.00024470213,0.00012506291,0.00007921573,0.00013056108,0.000036408095],"domain_scores_gemma":[0.9985795,0.0009816565,0.0002747931,0.000025178093,0.00011356619,0.000025409152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013589833,0.00033291898,0.0010325847,0.00096050295,0.000183404,0.0015064871,0.00041440976,0.0007549954,0.00202191],"category_scores_gemma":[0.0025350414,0.0001683804,0.0011830628,0.00051987293,0.00029688916,0.00083326723,0.000364859,0.00086453493,0.00034116997],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007693149,0.00006155754,0.0011339893,0.101441324,0.0012657973,0.0012335613,0.0003647821,0.00044589498,0.004867086,0.0051851906,0.011089713,0.87214184],"study_design_scores_gemma":[0.0002860208,0.001853628,0.006921629,0.079221606,0.004890072,0.010348645,0.00052716414,0.00038250574,0.0052235685,0.0033171703,0.8869543,0.00007369465],"about_ca_topic_score_codex":0.00046008767,"about_ca_topic_score_gemma":0.0013992365,"teacher_disagreement_score":0.00202191,"about_ca_system_score_codex":0.0005194925,"about_ca_system_score_gemma":0.0010227696,"threshold_uncertainty_score":0.0071870685},"labels":[],"label_agreement":null},{"id":"W4414554196","doi":"10.1007/s13555-025-01534-8","title":"Physician-Reported Treatment Patterns in Moderate to Severe Chronic Hand Eczema: the RWEAL Multinational Medical Chart Review","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Contact Dermatitis and Allergies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Hotel Dieu Hospital","funders":"LEO Pharma","keywords":"Chart; MEDLINE; Chronic disease; Medical treatment","score_opus":0.017299568554015127,"score_gpt":0.31295557948642244,"score_spread":0.29565601093240734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414554196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92372775,0.03766813,0.0007819746,0.0009747714,0.00005829261,0.00068514503,0.029426279,0.00007034034,0.0066073434],"genre_scores_gemma":[0.9779498,0.008425731,0.0013717235,0.00035410596,0.00006195382,0.00038570305,0.010792826,0.000013098666,0.0006451329],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99479735,0.001980065,0.0013402381,0.00057360454,0.0011103507,0.0001982572],"domain_scores_gemma":[0.96231395,0.007960328,0.023351282,0.00092566304,0.004781559,0.00066725677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004855157,0.00015072599,0.0003542563,0.0055748476,0.00031268108,0.0007690598,0.0005011697,0.00028776898,0.0016289048],"category_scores_gemma":[0.013631487,0.0001602048,0.00033727306,0.0063803294,0.00029681105,0.00053079834,0.00061056175,0.00016683387,0.00025759422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008528234,0.000023099596,0.9832917,0.0007605773,0.00008697998,0.0001784424,0.00035349154,0.00004573554,0.00014585086,0.0000414947,0.0018873481,0.01309993],"study_design_scores_gemma":[0.000013838389,0.000047849404,0.99538225,0.00041531803,0.000060275175,0.0003598809,0.00031360795,0.00010772391,0.00009095674,0.0000076958795,0.003194399,0.000006172783],"about_ca_topic_score_codex":0.016016982,"about_ca_topic_score_gemma":0.019627867,"teacher_disagreement_score":0.016016982,"about_ca_system_score_codex":0.0011464385,"about_ca_system_score_gemma":0.0016553773,"threshold_uncertainty_score":0.031847537},"labels":[],"label_agreement":null},{"id":"W4414927188","doi":"10.1007/s13555-025-01557-1","title":"Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"Manchester Biomedical Research Centre; Allergan; LEO Pharma; National Institute for Health and Care Research; Incyte; Sun Pharma; Regeneron Pharmaceuticals; UCB; Celgene; Biogen; Valeant Pharmaceuticals International; Sanofi; Amgen; Meiji Seika Pharma; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Clinical trial; Post-hoc analysis; Psoriasis; Post hoc; Phases of clinical research","score_opus":0.04833259873561692,"score_gpt":0.38336368143340194,"score_spread":0.33503108269778503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414927188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91378146,0.029564569,0.01704408,0.0010956648,0.0019291056,0.011679586,0.017375218,0.0008299829,0.0067003635],"genre_scores_gemma":[0.9612246,0.0022537187,0.008620906,0.0012449655,0.0005267985,0.015043884,0.007789951,0.0005843249,0.0027109375],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.92610437,0.058284517,0.0044888277,0.00523864,0.003439072,0.002444471],"domain_scores_gemma":[0.9317414,0.049255103,0.007080666,0.00813251,0.0025506371,0.0012396711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06792486,0.0030622245,0.009644937,0.0016783783,0.00050775876,0.0028050148,0.0018560764,0.0017995216,0.005926365],"category_scores_gemma":[0.0514835,0.0010373342,0.020520024,0.0020759788,0.0012129194,0.002787945,0.0020861123,0.004607177,0.00064814533],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76481503,0.001133535,0.015216246,0.0040707802,0.17994046,0.0002693376,0.0002919731,0.005942518,0.004832461,0.0004231914,0.005648418,0.017416056],"study_design_scores_gemma":[0.29877394,0.16158788,0.17992696,0.0011665471,0.27914077,0.0009734622,0.00076563476,0.03802709,0.009827599,0.006008143,0.023196034,0.00060596765],"about_ca_topic_score_codex":0.0007695947,"about_ca_topic_score_gemma":0.0011260798,"teacher_disagreement_score":0.06792486,"about_ca_system_score_codex":0.0011502847,"about_ca_system_score_gemma":0.0022324424,"threshold_uncertainty_score":0.35922527},"labels":[],"label_agreement":null},{"id":"W4414973762","doi":"10.1007/s13555-025-01535-7","title":"Considerations for Treating Generalized Pustular Psoriasis (GPP): A Narrative Review","year":2025,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Centre de Recherche Dermatologique du Québec Métropolitain; Centre de Recherche Industrielle du Québec; Women's College Hospital; Hospital for Sick Children; Dermatrials Research; Health Sciences Centre; Ottawa Hospital; McGill University; University of Ottawa; Sunnybrook Health Science Centre; Quest University Canada; Queen's University; Probity Medical Research; University of British Columbia; McMaster University; SKiN Health; University of Calgary; Lynde Centre for Dermatology; University of Toronto","funders":"Boehringer Ingelheim","keywords":"Generalized pustular psoriasis; Psoriasis; Narrative review; Biologic Agents; Plaque psoriasis; Pathogenesis","score_opus":0.04927849051615285,"score_gpt":0.3358533445554728,"score_spread":0.2865748540393199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414973762","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033791952,0.998307,0.000074205265,0.00065129914,0.00036935328,0.000004526991,0.000009659522,0.0000047167264,0.0005455211],"genre_scores_gemma":[0.00031767428,0.9983872,0.00017467678,0.0005421191,0.000301308,0.0000063441826,0.000015426724,0.0000013296149,0.00025402263],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99965274,0.00008207592,0.00006948477,0.000056547357,0.00011532163,0.000023852292],"domain_scores_gemma":[0.9989986,0.00059646886,0.00014399536,0.000019335794,0.0001822822,0.000059363036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008952752,0.00085016823,0.0011460574,0.0025169046,0.00041781057,0.0014193193,0.0009487275,0.0014461151,0.004855408],"category_scores_gemma":[0.0021783859,0.0002622398,0.0007749319,0.001927906,0.0005288898,0.0018144983,0.0007839227,0.0022975784,0.0016621163],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059270733,0.000057902587,0.00012376948,0.056683987,0.00011997099,0.00039658978,0.00015722001,0.00032527803,0.0007173643,0.0059323977,0.08186732,0.8535589],"study_design_scores_gemma":[0.000014282162,0.000058368576,0.00032779295,0.02483617,0.00018539785,0.0022695814,0.00011378141,0.00005732047,0.00011949176,0.002346039,0.9696518,0.000020032958],"about_ca_topic_score_codex":0.0010597702,"about_ca_topic_score_gemma":0.0022544265,"teacher_disagreement_score":0.004855408,"about_ca_system_score_codex":0.00071169646,"about_ca_system_score_gemma":0.0016722797,"threshold_uncertainty_score":0.016242921},"labels":[],"label_agreement":null},{"id":"W4415133357","doi":"10.1007/s13555-025-01543-7","title":"Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Clinical trial; Alopecia areata; Phase (matter); Phases of clinical research; MEDLINE","score_opus":0.0657944768740517,"score_gpt":0.3830563487242735,"score_spread":0.3172618718502218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415133357","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06448939,0.003032757,0.013555899,0.0024844734,0.002091853,0.9034536,0.0031175148,0.0002740159,0.0075005568],"genre_scores_gemma":[0.11376021,0.00090203166,0.01833137,0.0037442518,0.0007383282,0.8592858,0.0008664426,0.000023487057,0.0023481036],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9847136,0.009139302,0.00079262914,0.0024683203,0.0017945727,0.0010915872],"domain_scores_gemma":[0.99319893,0.0017603728,0.0015655048,0.00082154234,0.00091092946,0.00174271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028575545,0.00399877,0.0032626463,0.0010518844,0.0018891636,0.0020471478,0.002676588,0.0041260114,0.014941568],"category_scores_gemma":[0.0126130665,0.0020433618,0.0018908546,0.00088367,0.004205212,0.00215291,0.0011464963,0.0048257723,0.0045507126],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85867023,0.034375045,0.0068455753,0.0071840766,0.0015905325,0.0004951416,0.000536492,0.0030276063,0.015973715,0.0095816655,0.00993436,0.051785666],"study_design_scores_gemma":[0.74507284,0.18357722,0.0075868373,0.00095836754,0.0014213013,0.00031502306,0.00013179696,0.0030986087,0.0036946756,0.006881186,0.04709628,0.00016582817],"about_ca_topic_score_codex":0.00036014704,"about_ca_topic_score_gemma":0.0010112262,"teacher_disagreement_score":0.028575545,"about_ca_system_score_codex":0.0014194829,"about_ca_system_score_gemma":0.007971812,"threshold_uncertainty_score":0.1511237},"labels":[],"label_agreement":null},{"id":"W4415261130","doi":"10.1007/s13555-025-01565-1","title":"Cost-Per-Responder Analysis for Tralokinumab and Dupilumab in Combination with Topical Corticosteroids in Patients with Moderate-To-Severe Atopic Dermatitis","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SKiN Health","funders":"LEO Pharma","keywords":"Dupilumab; Atopic dermatitis; MEDLINE; Monoclonal; Disease","score_opus":0.010955849818308397,"score_gpt":0.26775586455114536,"score_spread":0.256800014732837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415261130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835031,0.007634478,0.001145264,0.00048041545,0.000056811285,0.0005193215,0.005186998,0.00003645533,0.001437035],"genre_scores_gemma":[0.9948078,0.0005919959,0.0009052019,0.00015797265,0.00002916821,0.00022917295,0.0026726846,0.000011771992,0.00059427123],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99504846,0.0034536717,0.00021286079,0.0004563712,0.00039726996,0.00043146592],"domain_scores_gemma":[0.9943968,0.003820971,0.00090673874,0.00027701506,0.00030226543,0.00029623593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008162268,0.001111835,0.0027724958,0.0016959663,0.00023197709,0.0016289179,0.0012648152,0.0010041901,0.005665493],"category_scores_gemma":[0.008556595,0.0006327436,0.0143410135,0.0015657276,0.00044712468,0.0008290633,0.0010758835,0.0017679983,0.00033486323],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43568647,0.0025842234,0.21961248,0.0050981566,0.09101099,0.0011104669,0.00034236233,0.17737067,0.002595224,0.0032926938,0.0043039992,0.056992248],"study_design_scores_gemma":[0.061945114,0.059581306,0.5554589,0.0012313047,0.12783785,0.0020523646,0.0011409993,0.17574671,0.0026041293,0.0026208905,0.009377213,0.0004030582],"about_ca_topic_score_codex":0.01698402,"about_ca_topic_score_gemma":0.011624587,"teacher_disagreement_score":0.01698402,"about_ca_system_score_codex":0.005278359,"about_ca_system_score_gemma":0.0020691827,"threshold_uncertainty_score":0.043166757},"labels":[],"label_agreement":null},{"id":"W4415436310","doi":"10.1007/s13555-025-01555-3","title":"Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"melanin and skin pigmentation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"LEO Pharma; Bausch Health; Kyowa Hakko Kirin; Horizon Therapeutics; Incyte; Dermira; Celltrion; Valeant Pharmaceuticals International; Sanofi; Amgen; Meiji Seika Pharma; Pfizer; Concert Pharmaceuticals; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Ruxolitinib; Vitiligo; Clinical trial; Phase (matter); Phases of clinical research","score_opus":0.027316679752416022,"score_gpt":0.3794274668762527,"score_spread":0.35211078712383664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415436310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87841207,0.10035642,0.0044957106,0.0016383006,0.00021702041,0.003998869,0.0051064286,0.0003062134,0.0054689054],"genre_scores_gemma":[0.9772773,0.011619884,0.0028294057,0.0011272973,0.00025156434,0.0019610985,0.0038661165,0.00003662148,0.0010308194],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99665326,0.0020618443,0.0003067625,0.0003154846,0.00046786197,0.0001948072],"domain_scores_gemma":[0.9950656,0.0011342992,0.0023263216,0.00028820836,0.00070228096,0.0004834031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010896497,0.0006090469,0.0016540162,0.0006068037,0.00031348225,0.0014320299,0.0006520812,0.0007834261,0.0020139702],"category_scores_gemma":[0.005276366,0.00031139774,0.0027050597,0.00073143543,0.00025190916,0.0006640991,0.00042903607,0.001359597,0.0003569623],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2558259,0.004869117,0.069841266,0.008231145,0.030793902,0.00030035386,0.0003514843,0.0037195391,0.03597642,0.00042193042,0.009311143,0.58035785],"study_design_scores_gemma":[0.2254971,0.32047546,0.3729272,0.0016676377,0.0270934,0.00163888,0.00021492047,0.0048890505,0.0126744015,0.00074098277,0.032027386,0.00015354452],"about_ca_topic_score_codex":0.00041907624,"about_ca_topic_score_gemma":0.0015900075,"teacher_disagreement_score":0.010896497,"about_ca_system_score_codex":0.0009401046,"about_ca_system_score_gemma":0.0011375487,"threshold_uncertainty_score":0.057626903},"labels":[],"label_agreement":null},{"id":"W4415494179","doi":"10.1007/s13555-025-01562-4","title":"Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trent University; University of British Columbia; SKiN Health; Queen's University; Probity Medical Research; University of Toronto","funders":"LEO Pharma; Bausch Health; Sanofi Genzyme; Incyte; Castle Biosciences; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Helsinn; Celgene; Celltrion; Valeant Pharmaceuticals International; Sanofi; Amgen; Helsinn Therapeutics; Meiji Seika Pharma; Pfizer; Galderma; Ortho Dermatologics; Eli Lilly and Company","keywords":"Dermis; Clinical trial; Roflumilast; Plaque psoriasis; Phases of clinical research","score_opus":0.015043720830515493,"score_gpt":0.25846577537987603,"score_spread":0.24342205454936053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415494179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71381617,0.27230343,0.0022666396,0.0011334517,0.00041212473,0.0026109347,0.002434246,0.0002112421,0.004811736],"genre_scores_gemma":[0.9558176,0.037400234,0.0014727232,0.00090811995,0.00057654653,0.0013192224,0.0017422689,0.000036958758,0.00072626804],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.997449,0.0015106262,0.00031041843,0.00031593468,0.0002790806,0.00013490951],"domain_scores_gemma":[0.9971042,0.0011681248,0.0009492224,0.0001860831,0.0002754889,0.00031680858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007896459,0.0012450598,0.0043511465,0.00065788964,0.00028049137,0.0014712148,0.0005751547,0.00094560423,0.0018146848],"category_scores_gemma":[0.0042328695,0.00045813117,0.004777249,0.0011222718,0.00037645927,0.0007625929,0.00038789486,0.0011494199,0.000353382],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6567927,0.0039609945,0.025536291,0.008944168,0.06486916,0.00017204265,0.00022661798,0.0021903852,0.014553832,0.00016102772,0.0039054079,0.21868737],"study_design_scores_gemma":[0.6066043,0.15731914,0.13095695,0.0016248695,0.088722736,0.0007821536,0.00018545489,0.0017174737,0.0031618972,0.0005250034,0.008282235,0.00011786611],"about_ca_topic_score_codex":0.00064295233,"about_ca_topic_score_gemma":0.0020759632,"teacher_disagreement_score":0.007896459,"about_ca_system_score_codex":0.0007468264,"about_ca_system_score_gemma":0.001213151,"threshold_uncertainty_score":0.04176092},"labels":[],"label_agreement":null},{"id":"W4415729826","doi":"10.1007/s13555-025-01582-0","title":"A 6-Month, Prospective, Multi-arm Study for the Efficacy of Standardized Nutraceuticals to Improve Hair Fiber Thickness and Strength","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"","keywords":"Fiber; Nutraceutical; Materials testing","score_opus":0.014058727314546446,"score_gpt":0.33167289595468863,"score_spread":0.3176141686401422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415729826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99820244,0.00012662701,0.00015687056,0.000029803981,0.000019975318,0.0008498839,0.00023796492,0.000014698525,0.00036178858],"genre_scores_gemma":[0.9954164,0.00012938328,0.0006556972,0.00015705802,0.00005349468,0.0013456305,0.0005849206,0.0000060338753,0.0016513327],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99925643,0.00030069525,0.00006247808,0.00013372942,0.00011974276,0.00012698419],"domain_scores_gemma":[0.99832577,0.000242727,0.0003651685,0.00022100692,0.00020719173,0.00063821673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026682813,0.00089293625,0.0011828076,0.0004723823,0.00086601154,0.00051799975,0.00040974165,0.0010160736,0.0027272317],"category_scores_gemma":[0.0016076373,0.0005902315,0.0008476304,0.00032028882,0.00055682374,0.00071976514,0.00040241252,0.0013343951,0.0006749282],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6444283,0.18423297,0.12080117,0.00031929373,0.0013420607,0.00020627995,0.000726713,0.00046327332,0.018062629,0.000060597515,0.0009036752,0.028452914],"study_design_scores_gemma":[0.044114303,0.7125311,0.2401666,0.000024152047,0.00036794317,0.00007173008,0.0001406888,0.0003846218,0.0012760037,0.000051148167,0.0008441192,0.000027627837],"about_ca_topic_score_codex":0.0007811677,"about_ca_topic_score_gemma":0.0011612645,"teacher_disagreement_score":0.0027272317,"about_ca_system_score_codex":0.0003208224,"about_ca_system_score_gemma":0.00060053234,"threshold_uncertainty_score":0.01411134},"labels":[],"label_agreement":null},{"id":"W4416247285","doi":"10.1007/s13555-025-01592-y","title":"Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"LEO Pharma","keywords":"Dupilumab; Hand eczema; Atopic dermatitis; MEDLINE; Immunopathology","score_opus":0.024648016801837466,"score_gpt":0.3149663567128831,"score_spread":0.2903183399110456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416247285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854123,0.005857631,0.0031693806,0.00014407978,0.00028980387,0.0014583273,0.0013148981,0.000049220613,0.0023042741],"genre_scores_gemma":[0.99669635,0.00039164352,0.0013073815,0.0000932266,0.000046853056,0.00062544417,0.000461054,0.0000049696937,0.00037308922],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9909072,0.0069557005,0.0005387285,0.00064076285,0.000668889,0.0002886693],"domain_scores_gemma":[0.99320155,0.0043119933,0.0012364663,0.00064499327,0.0003519056,0.00025310816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00936395,0.0012407008,0.0025621343,0.0006292684,0.0002584131,0.0008303449,0.0009435428,0.0008524899,0.0050377813],"category_scores_gemma":[0.013535078,0.00043349428,0.004561292,0.0004780128,0.0005402381,0.00054725393,0.00082889746,0.0011344774,0.00027898315],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8929014,0.001342255,0.01763499,0.0024202126,0.043134537,0.00006358151,0.00013759694,0.003601652,0.002312786,0.00071119383,0.0005394915,0.035200264],"study_design_scores_gemma":[0.3867585,0.29608092,0.15134461,0.00064214563,0.12348882,0.00048197474,0.00025578964,0.020504627,0.00986815,0.0037551841,0.0066061052,0.0002132139],"about_ca_topic_score_codex":0.0011943983,"about_ca_topic_score_gemma":0.0011337402,"teacher_disagreement_score":0.00936395,"about_ca_system_score_codex":0.0008240616,"about_ca_system_score_gemma":0.00070908974,"threshold_uncertainty_score":0.049521863},"labels":[],"label_agreement":null},{"id":"W4416364435","doi":"10.1007/s13555-025-01589-7","title":"Burden, Treatment Patterns and Real-World Barriers to Prescribing Advanced Treatments in Adults with Atopic Dermatitis in Brazil and Colombia","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Formulary; Atopic dermatitis; Quality of life (healthcare); Disease; Health care; Quality (philosophy)","score_opus":0.006890003228127471,"score_gpt":0.2758173758415932,"score_spread":0.2689273726134657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416364435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577326,0.0012655212,0.00005152359,0.00032818905,0.000004762134,0.000022690223,0.00077733997,0.0000032733287,0.0017734637],"genre_scores_gemma":[0.99916697,0.0004746929,0.000070452516,0.000036619473,0.0000032100434,0.000006744263,0.00016821983,6.649205e-7,0.00007237729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99969625,0.0000757857,0.000043461543,0.000055104465,0.00006766359,0.000061687],"domain_scores_gemma":[0.99905103,0.00015995816,0.0005409516,0.000026705622,0.00010133194,0.00012005233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003169206,0.00013664919,0.00018704096,0.0006036691,0.00035805447,0.00060580135,0.00020500162,0.00017138547,0.0015033138],"category_scores_gemma":[0.0014783202,0.00011767892,0.00019008355,0.0007255424,0.0002331894,0.00022904197,0.00032522276,0.00020261858,0.00007504949],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041482086,0.000023716118,0.9915844,0.00009458821,0.000024990133,0.00013863474,0.0011613808,0.00003352802,0.00031577973,0.000047709404,0.00021862287,0.0063151075],"study_design_scores_gemma":[0.0000040012364,0.000020355601,0.9972422,0.000052797208,0.000010947292,0.00019087893,0.0017212953,0.00006414084,0.000032842487,0.000011344086,0.0006453611,0.0000038022072],"about_ca_topic_score_codex":0.17898113,"about_ca_topic_score_gemma":0.25016943,"teacher_disagreement_score":0.17898113,"about_ca_system_score_codex":0.001326568,"about_ca_system_score_gemma":0.0007558326,"threshold_uncertainty_score":0.35587865},"labels":[],"label_agreement":null},{"id":"W4416573257","doi":"10.1007/s13555-025-01573-1","title":"Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare Professionals","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Royal College of Physicians of Ireland; LEO Pharma; Galderma; AbbVie; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriasis; Health care; Multinational corporation; Clinical Practice; Health professionals; Infographic","score_opus":0.02146915936222471,"score_gpt":0.30855008643268034,"score_spread":0.2870809270704556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416573257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980831,0.00031973518,0.000038542763,0.00046437394,0.0000077771065,0.000014374771,0.00044932152,0.000001913,0.00062093657],"genre_scores_gemma":[0.9993199,0.00018147343,0.00004221265,0.00015913487,0.000008204715,0.000011383191,0.00022227869,7.040035e-7,0.000054630043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983834,0.0006055102,0.00024381495,0.00022924533,0.00032284867,0.00021504944],"domain_scores_gemma":[0.99449074,0.00083264534,0.0032596895,0.00020224148,0.00040600004,0.00080863043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001887237,0.00012397271,0.00025082662,0.0006815568,0.00041872024,0.0008207599,0.00033091436,0.0005688236,0.0011679211],"category_scores_gemma":[0.0063441438,0.000250649,0.00034468886,0.0013426566,0.0003732565,0.00082532514,0.0008634634,0.0008414829,0.00020706176],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000109924695,0.00001668703,0.9985274,0.000012569321,0.000011195965,0.000016442884,0.000366156,0.000008294649,0.000020937174,0.000006294855,0.000120942954,0.00088210526],"study_design_scores_gemma":[0.0000015599002,0.000030783616,0.99858105,0.000016569687,0.000005444244,0.00005961155,0.0011020175,0.000035085963,0.000007602314,0.0000071248623,0.000151266,0.0000017373721],"about_ca_topic_score_codex":0.018153975,"about_ca_topic_score_gemma":0.018195676,"teacher_disagreement_score":0.018153975,"about_ca_system_score_codex":0.00048017316,"about_ca_system_score_gemma":0.00058648834,"threshold_uncertainty_score":0.036096573},"labels":[],"label_agreement":null},{"id":"W4417103507","doi":"10.1007/s13555-025-01595-9","title":"Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"UCB Pharma","keywords":"MEDLINE; Population; Feature (linguistics); Component (thermodynamics)","score_opus":0.020032016934352907,"score_gpt":0.2725003341250734,"score_spread":0.2524683171907205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417103507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946517,0.0036024372,0.00014967243,0.000103335595,0.00002431601,0.00009245425,0.000526151,0.000013616676,0.000836343],"genre_scores_gemma":[0.99597675,0.0013012792,0.00044599807,0.00018509311,0.00006977255,0.00015513915,0.0013081619,0.000008424957,0.0005493294],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9980147,0.0012813745,0.0000895479,0.00016668963,0.00025999692,0.00018765169],"domain_scores_gemma":[0.99663216,0.0012947818,0.00080217957,0.0004543859,0.00023237804,0.0005840591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055781663,0.0004996622,0.0012623516,0.0002788563,0.00025655082,0.0006310624,0.00036967118,0.0006509037,0.0014903708],"category_scores_gemma":[0.0033603804,0.00025458616,0.00220689,0.00034908263,0.00046761567,0.0007121324,0.0006502102,0.0016708513,0.00027153827],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7792958,0.013747223,0.052057993,0.0009858132,0.005540575,0.00008218327,0.00040150565,0.0026841343,0.006632582,0.00029850972,0.0024429404,0.13583069],"study_design_scores_gemma":[0.13761096,0.35854515,0.48218638,0.00024289347,0.007594506,0.00029997117,0.00038888663,0.0029509307,0.0039549344,0.0009417616,0.005124947,0.0001586258],"about_ca_topic_score_codex":0.0005048626,"about_ca_topic_score_gemma":0.00072849845,"teacher_disagreement_score":0.0055781663,"about_ca_system_score_codex":0.0003347075,"about_ca_system_score_gemma":0.0004298245,"threshold_uncertainty_score":0.029500484},"labels":[],"label_agreement":null},{"id":"W4417103769","doi":"10.1007/s13555-025-01609-6","title":"A Post Hoc Analysis of Atopic Dermatitis of the Head and Neck and Other Body Regions from the Amlitelimab STREAM-AD Phase 2b Study","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; University of Toronto","funders":"Sanofi","keywords":"Post-hoc analysis; Head and neck; Atopic dermatitis; Post hoc; Head (geology)","score_opus":0.013489900040541701,"score_gpt":0.31094682926323164,"score_spread":0.29745692922268996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417103769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857405,0.002064594,0.0010769268,0.00029237536,0.00030492182,0.0025481656,0.004640256,0.000081349135,0.0032509537],"genre_scores_gemma":[0.98322046,0.00067465403,0.0018204745,0.0005905165,0.0002406792,0.002877759,0.005042561,0.00006700888,0.005465944],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9969097,0.0019192518,0.00014555719,0.00041582008,0.00027880043,0.00033094038],"domain_scores_gemma":[0.9970529,0.001577374,0.0003864651,0.00040518583,0.00025422176,0.00032383966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063057984,0.0012159275,0.0028881333,0.00035043943,0.00028431293,0.00086760515,0.0006500494,0.0007262114,0.007415498],"category_scores_gemma":[0.004074346,0.0003185992,0.0030866663,0.00033032746,0.00039545656,0.0005983054,0.00045908746,0.0017374702,0.00063469744],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95023465,0.00404507,0.007995338,0.0006560167,0.006989148,0.00015133209,0.00006806983,0.0011548515,0.007762707,0.00021238711,0.0046331915,0.016097162],"study_design_scores_gemma":[0.49507445,0.34504336,0.107207045,0.00011260917,0.022243155,0.00035246857,0.00016706297,0.008131105,0.0073634814,0.0007833543,0.013433558,0.00008828862],"about_ca_topic_score_codex":0.00075060606,"about_ca_topic_score_gemma":0.0014899189,"teacher_disagreement_score":0.007415498,"about_ca_system_score_codex":0.00045895338,"about_ca_system_score_gemma":0.0013373577,"threshold_uncertainty_score":0.03334868},"labels":[],"label_agreement":null},{"id":"W4417280112","doi":"10.1007/s13555-025-01612-x","title":"Exploring New Dimensions in Longitudinal Rosacea Management","year":2025,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Galderma","keywords":"Rosacea; Patient Empowerment; Quality of life (healthcare); Disease; Empowerment; Disease management; Health professionals; Health care","score_opus":0.15711213282398953,"score_gpt":0.3675673124102598,"score_spread":0.21045517958627027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417280112","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3605034,0.063201934,0.061427213,0.42098317,0.005829658,0.0023487953,0.0018278607,0.00048596677,0.08339201],"genre_scores_gemma":[0.8609683,0.02010215,0.08351852,0.02422844,0.0012978609,0.0034707722,0.0011775062,0.00016069302,0.0050758817],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.96798587,0.025333771,0.0014760604,0.0014329476,0.0024468515,0.0013244436],"domain_scores_gemma":[0.9297731,0.036590226,0.0080276625,0.004358876,0.011855312,0.00939483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06267336,0.00055690546,0.00079218386,0.002950288,0.005034809,0.008555369,0.0022936773,0.0018930301,0.005953024],"category_scores_gemma":[0.09379045,0.0005659134,0.0014204781,0.0029023106,0.0060616173,0.013408982,0.010675033,0.005178848,0.00074404984],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002683187,0.0007756991,0.24609704,0.002538534,0.00032359612,0.00073371077,0.17399472,0.0006530285,0.00041699625,0.08374152,0.03767629,0.45278057],"study_design_scores_gemma":[0.00017350946,0.0011685162,0.20764655,0.015071773,0.00057751714,0.0012991335,0.26517424,0.0028712058,0.00080892874,0.18950042,0.3153722,0.00033590614],"about_ca_topic_score_codex":0.009086703,"about_ca_topic_score_gemma":0.019012285,"teacher_disagreement_score":0.06267336,"about_ca_system_score_codex":0.009461666,"about_ca_system_score_gemma":0.024475664,"threshold_uncertainty_score":0.33145237},"labels":[],"label_agreement":null},{"id":"W4417289733","doi":"10.1007/s13555-025-01583-z","title":"Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Amgen","keywords":"Apremilast; Placebo; Palmoplantar pustulosis; Randomized controlled trial; Quality of life (healthcare); Clinical trial","score_opus":0.023753988291548504,"score_gpt":0.2986026229296635,"score_spread":0.274848634638115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417289733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6320829,0.2279281,0.006669605,0.021640373,0.005300514,0.063945584,0.014298257,0.0009666532,0.027168138],"genre_scores_gemma":[0.8142058,0.08235117,0.011954708,0.029464288,0.005790948,0.03592215,0.008819003,0.00015256357,0.011339217],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985185,0.0008807932,0.00019267513,0.00013052627,0.0001457411,0.00013172424],"domain_scores_gemma":[0.9982768,0.00052430865,0.00047301836,0.00008829021,0.00024920184,0.00038828878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053976947,0.00095635443,0.0021603464,0.00044844576,0.00066675316,0.001501559,0.00076962035,0.0023757943,0.0065357964],"category_scores_gemma":[0.0031532254,0.0004875935,0.0033451368,0.0006348118,0.0005215582,0.0007800266,0.0002854695,0.0020631962,0.0010810049],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74622303,0.009508582,0.0035870913,0.0232164,0.011608646,0.00044170202,0.0003330627,0.00067471544,0.01791852,0.000699917,0.017867964,0.1679204],"study_design_scores_gemma":[0.907193,0.07046635,0.0042269714,0.0011405201,0.0061347284,0.00015926316,0.0000664773,0.00027646098,0.0011316624,0.0003210218,0.008843646,0.00003996263],"about_ca_topic_score_codex":0.0008770628,"about_ca_topic_score_gemma":0.0027750717,"teacher_disagreement_score":0.0065357964,"about_ca_system_score_codex":0.0005915482,"about_ca_system_score_gemma":0.002760371,"threshold_uncertainty_score":0.028546095},"labels":[],"label_agreement":null},{"id":"W4417477681","doi":"10.1007/s13555-025-01618-5","title":"Tailoring Abrocitinib Treatment for Moderate-to-Severe Atopic Dermatitis to Patient Disease Course: A Narrative Review","year":2025,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"","keywords":"Dosing; Adverse effect; Narrative review; Atopic dermatitis; Randomized controlled trial; Quality of life (healthcare); Clinical trial; Disease","score_opus":0.036729150973519205,"score_gpt":0.3661624990328075,"score_spread":0.3294333480592883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417477681","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000096760334,0.99916065,0.000058371566,0.00016946474,0.00007696939,0.000009249076,0.000029130157,0.0000032253693,0.00039608148],"genre_scores_gemma":[0.0007104747,0.9987961,0.00010940426,0.00017140208,0.000060259892,0.000009366881,0.00003100967,0.0000010456466,0.000110862915],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99962795,0.00008920735,0.00009261212,0.00006664134,0.000102093916,0.00002143199],"domain_scores_gemma":[0.99876165,0.0008721332,0.00017093518,0.000017876502,0.00015073901,0.000026683685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092789583,0.00071545906,0.0014220576,0.0022337213,0.0002169733,0.0012023877,0.0008271284,0.00087573304,0.0047917184],"category_scores_gemma":[0.0027689727,0.00021337955,0.0011740247,0.0025706738,0.00025365214,0.0010243558,0.00054645876,0.0009879943,0.0008862072],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001287087,0.000046301164,0.00025028095,0.17665482,0.0005412385,0.000127748,0.00009956049,0.00031538552,0.0005378815,0.0020691063,0.020998364,0.7982307],"study_design_scores_gemma":[0.00009793159,0.00022723289,0.0021570001,0.14849147,0.0033814136,0.0020395392,0.00018406793,0.00024233862,0.0004540287,0.002427154,0.8402537,0.000044084176],"about_ca_topic_score_codex":0.0011026663,"about_ca_topic_score_gemma":0.0023297344,"teacher_disagreement_score":0.0047917184,"about_ca_system_score_codex":0.00057357154,"about_ca_system_score_gemma":0.0014997334,"threshold_uncertainty_score":0.016029835},"labels":[],"label_agreement":null},{"id":"W4417494321","doi":"10.1007/s13555-025-01619-4","title":"Clinical Implications of the Skin Microbiota in the Therapy of Cutaneous T Cell Lymphoma: A Scoping Review","year":2025,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; Sunnybrook Hospital; Richmond Hospital; University of Calgary","funders":"","keywords":"T cell; Dysbiosis; Cutaneous T-cell lymphoma; Cell; Microbiome; Mycosis fungoides; Immunotherapy","score_opus":0.06600939437309242,"score_gpt":0.438828839239316,"score_spread":0.37281944486622354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417494321","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000052701344,0.99929225,0.000051272866,0.0001524689,0.00009641345,0.000006901364,0.000019528565,0.0000026505775,0.00032579756],"genre_scores_gemma":[0.00036041063,0.9992298,0.00010850807,0.00010964891,0.000051257983,0.000009108562,0.000020853944,0.0000010111701,0.00010945375],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9995597,0.00012541913,0.0001247027,0.000054238033,0.00010722051,0.000028661438],"domain_scores_gemma":[0.99803334,0.001474515,0.0002026138,0.000030235828,0.00021302502,0.000046226214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012817101,0.0007560728,0.0020745618,0.0036475428,0.00036314514,0.0016043968,0.0008305839,0.0012414302,0.004984336],"category_scores_gemma":[0.0034952227,0.00028002937,0.0012914675,0.0034876263,0.0003977161,0.0013158144,0.0008675213,0.0011784609,0.0010294856],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084752945,0.000040669638,0.00015867614,0.15175386,0.00037295313,0.00013705141,0.00012939288,0.00025397324,0.00060473033,0.0021591028,0.014093204,0.83021164],"study_design_scores_gemma":[0.00003853633,0.00013396387,0.0010618401,0.19991662,0.0016833358,0.0010281098,0.00021910702,0.00011450869,0.0004348115,0.0020884052,0.7932498,0.000030928153],"about_ca_topic_score_codex":0.0016850276,"about_ca_topic_score_gemma":0.002788307,"teacher_disagreement_score":0.004984336,"about_ca_system_score_codex":0.00067310646,"about_ca_system_score_gemma":0.0024961554,"threshold_uncertainty_score":0.01667428},"labels":[],"label_agreement":null},{"id":"W4417525267","doi":"10.1007/s13555-025-01620-x","title":"Short-Term Efficacy of Lebrikizumab Versus Dupilumab in Combination with Topical Corticosteroids in Adults with Moderate-to-Severe Atopic Dermatitis: Matching-Adjusted Indirect Comparison","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"LEO Pharma; Sun Pharma; Castle Biosciences; Biogen; Celgene; Celldex Therapeutics; Mylan; Canadian Dermatology Foundation; Samsung; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Galderma; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Dupilumab; Atopic dermatitis; Monoclonal antibody; Clinical efficacy; Monoclonal","score_opus":0.015945744629677808,"score_gpt":0.28306203331305496,"score_spread":0.26711628868337717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417525267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9441686,0.037871063,0.0054630316,0.00045814025,0.00094532577,0.0034768085,0.0035330257,0.00012896887,0.003954913],"genre_scores_gemma":[0.99120367,0.0027917493,0.0022054017,0.00026748868,0.00017048614,0.0017150741,0.00085116836,0.0000104881365,0.0007845018],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9904203,0.0065807607,0.0009827369,0.00095306605,0.0007478768,0.00031525863],"domain_scores_gemma":[0.99351394,0.00419904,0.0014510658,0.00038068424,0.00022643764,0.00022881725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0086202575,0.0017586639,0.004943959,0.000898164,0.00027133254,0.0012400829,0.0011859299,0.0017513277,0.0054916725],"category_scores_gemma":[0.011905729,0.0007300614,0.009804561,0.0007385848,0.00057935267,0.0009913401,0.0009995627,0.0019267723,0.0003443346],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8734714,0.0009315694,0.009080433,0.0065563475,0.08195311,0.0000764745,0.000103074075,0.002785261,0.0008835466,0.00038627096,0.00042679423,0.023345774],"study_design_scores_gemma":[0.53864974,0.17399462,0.050815213,0.0013261747,0.20960772,0.00043231528,0.00020323423,0.015056218,0.0029453144,0.0030690394,0.0037279017,0.00017243973],"about_ca_topic_score_codex":0.0011983241,"about_ca_topic_score_gemma":0.0009782284,"teacher_disagreement_score":0.0086202575,"about_ca_system_score_codex":0.0008300794,"about_ca_system_score_gemma":0.0007383708,"threshold_uncertainty_score":0.04558885},"labels":[],"label_agreement":null}]}